sample	dbgap_dnaseq_sample	dbgap_subject_id	cohort	used_manuscript_analyses	manuscript_dnaseq	manuscript_rnaseq	manuscript_inhibitor	consensus_sex	inferred_sex	reportedRace	reportedEthnicity	inferred_ethnicity	centerID	CEBPA_Biallelic	consensusAMLFusions	ageAtDiagnosis	age_high	isRelapse	isDenovo	isTransformed	specificDxAtAcquisition_MDSMPN	nonAML_MDSMPN_specificDxAtAcquisition	priorMalignancyNonMyeloid	priorMalignancyType	cumulativeChemo	priorMalignancyRadiationTx	priorMDS	priorMDSMoreThanTwoMths	priorMDSMPN	priorMDSMPNMoreThanTwoMths	priorMPN	priorMPNMoreThanTwoMths	dxAtInclusion	specificDxAtInclusion	ELN2017	dxAtSpecimenAcquisition	specificDxAtAcquisition	ageAtSpecimenAcquisition	timeOfSampleCollectionRelativeToInclusion	specimenGroups	diseaseStageAtSpecimenCollection	specimenType	rnaSeq	exomeSeq	totalDrug	analysisRnaSeq	analysisExomeSeq	analysisDrug	cumulativeTreatmentTypeCount	cumulativeTreatmentTypes	cumulativeTreatmentRegimenCount	cumulativeTreatmentRegimens	cumulativeTreatmentStageCount	cumulativeTreatmentStages	responseToInductionTx	typeInductionTx	responseDurationToInductionTx	mostRecentTreatmentType	currentRegimen	currentStage	mostRecentTreatmentDuration	vitalStatus	overallSurvival	causeOfDeath	X..Basophils.in.PB	X..Blasts.in.BM	X..Blasts.in.PB	X..Eosinophils.in.PB	X..Immature.Granulocytes.in.PB	X..Lymphocytes.in.PB	X..Monocytes.in.PB	X..Neutrophils.in.PB	X..Nucleated.RBCs.in.PB	ALT	AST	albumin	creatinine	fabBlastMorphology	hematocrit	hemoglobin	karyotype	LDH	MCV	otherCytogenetics	plateletCount	platelet_high	surfaceAntigensImmunohistochemicalStains	CD7.Pos.	CD33	totalProtein	wbcCount	wbccount_High	FLT3.ITD	allelic_ratio	NPM1	RUNX1	ASXL1	TP53	variantSummary	HALLMARK.INFLAMMATORY.RESPONSE	HSC.Prog.like	Monocyte.like.y	cDC.like.y	Promono.like.y	Progenitor.like.y	HSC.like.y	Myeloid.like	GMP.like.y	UpInMDS_StrictCutoff	SF3B1_Mutation	SRSF2_Mutation	U2AF1_Mutation	ZRSR2_Mutation	Splicing_Mutation_either_or_SF3B1_SRSF2_U2AF1_ZRSR2	AML_MDS_wSplicingMachinery_Mutation	Found	IDH2	TET2	DNMT3A	SF3B1_Mut	platelet_high.1	Inv16_Pos	ASXL1_Mutated	TP53_Mutated	RUNX1_Mutated	FLT3_ITD_Mutated	wbccount_High.1	HighInflammation	High_AtypicalBcell	IL18R1_Expression	IL18RAP_Expression	IL1R1_Expression	IL2RB_Expression	IL4R_Expression	CXCL6_Expression	CLEC5A_Expression	IL18R1_high	IL18RAP_high	IL1R1_high	IL2RB_high	IL4R_high	CXCL6_high	CLEC5A_high																
BA2707R	BA2707D	2313	Both	no	no	no	no	Male	Male	White	NON-HISPANIC	White	1			68	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	y	Lung Cancer	y	y	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	72	1207	Relapse|Post-Chemotherapy	Relapse	Peripheral Blood	y	y	y	y	y	y	1	Standard Chemotherapy	3	"7+3 (Cytarabine, Idarubicin)|MiDAC|Decitabine"	3	Consolidation|Induction|Supportive/Palliative Care	Complete Response	Standard Chemotherapy	7	Standard Chemotherapy	Decitabine	Supportive/Palliative Care	9	Dead	1238	Dead-Disease	0			0	NA	14.9	0.8	2.5	0	NA	NA	NA	NA	NOS	22.7	7.6	"47,XY,del(9)(q22),+13[18]/48,idem,+mar[2]"	556	93.8	Missing ABL and ASS signal (84%)	32	TRUE	"partial CD7, CD11b, CD13, CD33, CD34, partial CD64, partial CD117, CD123, HLA-DR, and TdT-positive."	TRUE	TRUE	NA	47.2	TRUE	negative	0	negative	RUNX1 (p.A147Gfs*13; 42.3%)|RUNX1 (p.R162S; 46.5%)	ASXL1 (p.G646Wfs*12; 27.9%)		RUNX1 (p.A147fs*13 (1 bp insertion frameshift); MAF 35%)|RUNX1 (p.R162S; MAF 50%)|SRSF2 (p.P95R; MAF 44%)	0.622701277	0.77045207	0.603459927	0.869377608	0.669075722	2.775289026	0.38160187	1.3806252	0.625805542	-0.077223701		yes			yes		Found	FALSE	FALSE	FALSE	FALSE	TRUE	FALSE	TRUE	FALSE	TRUE	FALSE	TRUE	TRUE	TRUE	4.127338634	3.65036235	2.338146061	4.126543631	6.634346624	-2.151569342	1.287690856	yes	yes	no	yes	yes	no	no																
BA2667R	BA2667D	2286	Waves1+2	yes	yes	yes	yes	Male	Male	Unknown	UNKNOWN	White	1			74	TRUE	FALSE	FALSE	TRUE	FALSE	FALSE	n		n	n	n	n	y	y	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	74	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	0		0		0				NA	NONE	NONE	NONE	NA	Dead	126	Dead-Unknown	0	60		1	NA	26	18	24	NA	250	160	3.2	0.59	M2	22	7.1	"46,XY[20]"	399	87.4		107	TRUE	"partial CD7, CD13, CD33, CD34, CD38, CD58, CD117, CD123, TdT, and HLA-DR positive"	TRUE	TRUE	7	11.8	FALSE	negative	0	negative	RUNX1 (p.A142Gfs*4; 32.2%)			RUNX1 (p.A142Gfs*4; MAF 30% )|SRSF2 (p.P95L; MAF 48%)	0.634971373	0.83842716	0.772935629	0.973988972	0.779783838	2.798102934	0.32367247	1.449324946	0.796192269	0.166652689		yes			yes	yes	Found	FALSE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	TRUE	FALSE	3.149489649	4.798374704	0.958647032	5.938987264	5.222102663	-1.212051012	6.012542641	yes	yes	no	yes	no	no	yes																
BA2649R	BA2649D	2097	Waves1+2	yes	yes	yes	yes	Female	Female	White	NON-HISPANIC	White	1		PML-RARA	65	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	65	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	2	"ATRA (Tretinoin)|3+7 (Cytarabine, Daunorubicin)"	1	Induction	Unknown	Standard Chemotherapy	5	Standard Chemotherapy	"3+7 (Cytarabine, Daunorubicin)"	Induction	3	Dead	7	Dead-Other	0	72	57	0	NA	36	1	8	NA	24	33	2.9	0.6	M3	20.7	6.8	"46,X,der(X)add(X)(p22.1)add(X)(q22~24),add(7)(p15),der(15)t(15;17)(q22;q21),der(17)t(15;17)(q22;q21)inv(17)(q21q21)del(17)(q21)[17]/46,XX[3] (unusual PML-RARA translocation)"	398	90.2	"76% Unusual t(15;17), with the fusion signal on the derivative chromosome 15"	10	FALSE	"partial CD2, CD13, CD33, partial CD34, CD117, CD123, MPO-positive"	FALSE	TRUE	5.6	9.8	FALSE	positive	NA	negative				FLT3-ITD (MAF 40%)|SF3B1 (p.K66N; MAF 40%)|WT1 (rs16754; MAF 50%)	0.470929229	0.553590904	0.354564196	0.484965401	0.873425861	2.865491581	-0.053951276	1.195783386	1.118633946	0.123574659	yes				yes		Found	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	3.416598963	3.427494367	5.424173312	3.483257813	6.07014346	-3.580013984	6.443747639	yes	no	yes	no	yes	no	yes																
BA2592R	BA2592D	2070	Waves1+2	no	no	no	no	Female	Female			White	2			31	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	n		y	n	y	y	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	38	1496	Post-Chemotherapy|Post-Transplant|Residual Disease	Residual	Bone Marrow Aspirate	y	y	y	y	y	y	4	Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Other|Targeted Therapy - Kinase Inhibitor(s)	9	"Fludarabine, Melphalan|Dasatinib|7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)|Rituximab|Busulfan, Cyclophosphamide"	7	Allogeneic - Sibling|Hypomethylating/Low Dose Cytarabine|Consolidation|Salvage|Induction|Experimental|Re-induction	Complete Response	Standard Chemotherapy	-1	Targeted Therapy - Kinase Inhibitor(s)	Dasatinib	Experimental	24	Dead	2661	Dead-Unknown	NA	7	1	NA	NA	NA	NA	NA	NA	15	21	4.2	NA		31.9	11	"46,XX[20]"	NA	NA	nuc ish(DXZ1x2)[200]	45	TRUE		NA	NA	6.2	2.2	FALSE	negative	0	negative				BCOR (S259fs*10; MAF 15%)|CCND2 (P281R; MAF 19%)|FLT3-D835 (D835E; MAF 13%)|GATA2 (N297S; MAF 18%)|IKZF1 (Q44*; MAF 14%)|MLL2 (Y2907*; MAF 7%)|PTPN11 (E76V; MAF 17%)|PTPN11 (V45L; MAF 13%)|SETBP1 (H1100R; MAF 51%)|SF3B1 (K700E; MAF 18%)	0.718919702	0.775257883	0.663004696	0.584724195	0.779455134	2.963738682	0.26088293	1.289998759	0.962714704	0.377550026	yes				yes	yes	Found	FALSE	FALSE	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	TRUE	TRUE	3.299070264	5.215680434	2.462637097	6.452499093	4.817604546	-0.610774085	3.882506734	yes	yes	no	yes	no	yes	no																
BA2134R		2417	Waves1+2	no	no	no	no	Male	Male	White	NON-HISPANIC	White	1			72	TRUE	FALSE	FALSE	TRUE	FALSE	FALSE	n		y	n	n	n	y	y	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	72	8	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	n	y	y	n	y	1	Standard Chemotherapy	1	"3+7 (Cytarabine, Daunorubicin)"	1	Induction	Complete Response	Standard Chemotherapy	6	Standard Chemotherapy	"3+7 (Cytarabine, Daunorubicin)"	Induction	6	Dead	176	Dead-Unknown	0			1	NA	3	77	8	NA	57	27	3.5	0.61	M4	26.3	8.7	"46,XY,del(12)(p11.2p13)[15]/46,XY[5]"	324	92.8	84% 12p deletion	19	FALSE		NA	NA	7.2	56.5	TRUE	negative	0	negative		ASXL1 (p.A619fs*14; MAF 50%)		ASXL1 (p.A619fs*14; MAF 50%)|EZH2 (p.R583*; MAF 95%)|FLT3-D835|FLT3-D835 (MAF unavailable)|PTPN11 (p.D61H; MAF 15%)|RUNX1 ( p.P345?S356del; MAF 25%)|RUNX1 (p.P345?S356del; MAF 25%)|RUNX1 (p.V51; MAF 50%)|RUNX1 (p.V5I; MAF 50%)|TET2 (p.Y867H; MAF 50%)	0.79803251	0.674496977	0.907684502	1.050680323	0.821379962	2.652686374	0.276437538	1.542280096	0.864971181	0.22485713					no		Found	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	TRUE	FALSE	TRUE	FALSE	TRUE	TRUE	FALSE	2.775216721	4.122157445	4.977352049	2.891797274	6.453001016	-2.36650898	3.800759839	no	yes	yes	no	yes	no	no																
BA2162R	BA2162D	2220	Both	no	no	no	no	Male	Male	White	NON-HISPANIC	White	1			77	TRUE	FALSE	TRUE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	77	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	1	Standard Chemotherapy	1	"7+3 (Cytarabine, Idarubicin)"	1	Induction	Refractory	Standard Chemotherapy	7	Standard Chemotherapy	"7+3 (Cytarabine, Idarubicin)"	Induction	7	Dead	129	Dead-Disease	NA		47	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA		NA	NA	"46,XY,-7,+13,i(17)(q10)[20]"	NA	NA	"D7S486/ CEP 7: Ê92/100 cells (92%) had a 1 red/ 1 green signal pattern, indicating monosomy 7, consistent with the metaphase karyotype. | RARA: Ê79/100 cells (79%) had three signals, consistent with the isochromosome 17q observed in the metaphase karyotype and the presence of three copies of the long arm. ÊThere was no evidence for PML/RARA fusion. | TP53: Ê89/100 cells (89%) had a single signal, reflecting deletion and consistent with the isochromosome 17q observed in the metaphase karyotype."	NA	NA	"CD13, CD33, CD34, CD117, dim CD123, and HLA-DR-positive"	FALSE	TRUE	NA	25.3	TRUE	negative	0	negative		ASXL1 (p.W583*; 47.9%)		ASXL1 (p.W583*; MAF 50%)|ETV6 (p.N384*; MAF 40%)|FBXW7 (p.T196A; MAF 50%)|SRSF2 (p.P95H; MAF 70%)	0.703426192	0.931113871	0.813773972	0.82513836	0.817671192	2.77452187	0.521201271	1.477549255	0.961109162	0.29554315		yes			yes	yes	Found	FALSE	FALSE	FALSE	FALSE	NA	FALSE	TRUE	FALSE	FALSE	FALSE	TRUE	TRUE	FALSE	2.751194071	4.98230143	0.824641148	4.463019399	6.269279939	-0.610774085	5.761816992	no	yes	no	yes	yes	yes	yes																
BA3230R	BA3230D	2777	Waves3+4	yes	yes	yes	yes	Female	Female	White	NON-HISPANIC		1			71	TRUE	FALSE	TRUE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with maturation	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with maturation	71	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	1	Standard Chemotherapy	1	Decitabine	1	Induction	UNKNOWN	Standard Chemotherapy	-1	Standard Chemotherapy	Decitabine	Induction	-1	Dead	329	Dead-Disease	0.8	25	40	0	NA	4.7	1.6	38.9	1.3	13	49	2.4	0.68	M2	19.6	6.8	"46,XX,del(12)(p12p13)[23]"	NA	94.2	Normal	9	FALSE	"dim CD5, CD13, dim CD33, CD34, variable CD38, CD58, CD117, dim CD123 and HLA-DR positive"	FALSE	TRUE	4.5	68.85	TRUE	positive	0.694915254	negative		ASXL1 (p.E635Rfs*15; 22.0%)		CREBBP (W1745*; MAF ~50%)|FLT3-ITD (MAF ~50%)|SF3B1 (p.K666M; MAF ~50%)	0.572930229	0.770729276	0.779399979	0.558199606	1.011744808	2.736316857	0.131206718	1.319181584	1.071582001	0.358250831	yes				yes		Found	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	TRUE	FALSE	FALSE	TRUE	TRUE	FALSE	FALSE	5.816486103	6.170779131	6.347373671	0.919835107	5.938573569	-0.988728384	7.06807721	yes	yes	yes	no	no	no	yes																
BA2375R	BA2375D	2330	Waves1+2	yes	yes	yes	no	Male	Male	Black	NON-HISPANIC	Black	1			72	TRUE	FALSE	FALSE	TRUE	FALSE	FALSE	n		y	n	n	n	n	n	y	y	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	72	0	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Initial Diagnosis	Peripheral Blood	y	y	n	y	y	n	1	Standard Chemotherapy	1	Decitabine	1	Hypomethylating/Low Dose Cytarabine			NA	Standard Chemotherapy	Decitabine	Hypomethylating/Low Dose Cytarabine	-1	Dead	107	Dead-Disease	2.6		41	0	NA	15.3	9.3	28.8	0.6	36	31	3.8	1.66	M0	23.3	7.2	"46,XY,-7,+mar.ishder(7)del(7)(p11.2)del(7)(q11.2)(D7Z1+)[20]/45,XY,-7[2]/46,XY[3]"	398	82	"Two of twenty-five metaphase cells examined were monosomy 7, shown by  fluorescent in situ hybridization (FISH) in  a companion study  (GLC-13-06587) to be a true clone.  Twenty cells appeared to be missing a  chromosome 7 with an additional small marker."	42	FALSE	"CD13, dimCD19, partial CD33, partial CD34, CD38, CD58, dim cCD79a, CD117, and TdT positive."	TRUE	TRUE	6.6	12.44	FALSE	negative	0	negative	RUNX1 (p.R166G; MAF 22%)			CBL (p.L370del; MAF 63%)|JAK2 (p.V617F; MAF 43%)|RUNX1 (p.R166G; MAF 22%)|U2AF1 (p.Q157R; MAF 40%)	0.849795382	0.834135656	0.830256128	0.948504776	0.647785283	2.700039695	0.451272751	1.422124835	0.734390411	0.257517026			yes		yes	yes	Found	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	TRUE	TRUE	6.020771653	7.137564015	2.234588564	7.577242191	6.960916228	-1.837546925	3.843473655	yes	yes	no	yes	yes	no	no																
BA2377R	BA2377D	2385	Waves1+2	yes	yes	yes	yes	Male	Male			White	2		MLLT3-KMT2A	35	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with t(9;11)(p22;q23); MLLT3-MLL	Intermediate	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with t(9;11)(p22;q23); MLLT3-MLL	35	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	3	"7+3 (Cytarabine, Idarubicin)|HiDAC|Busulfan, Cyclophosphamide, Thymoglobulin"	3	Consolidation|Induction|Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	-1	Bone Marrow Transplant	"Busulfan, Cyclophosphamide, Thymoglobulin"	Allogeneic - Matched Unrelated Donor	-1	Alive	1156	Alive	NA	86		NA	NA	NA	NA	NA	NA	NA	NA	NA	NA		NA	NA	"46,XY,der(4)t(4;9;11)(p14;p22;q23),der(9)del(9)(p13p22)t(4;9;11),der(11)t(4;9;11)[19]/46,XY[1].isht(4;9;11)(5'MLL-,3'MLL+;5'MLL-,3'MLL-;5'MLL+,3'MLL-)[1] "	NA	NA	"nuc ish(ABL1,BCR)x2[200],(5'MLL,3'MLL)x2(5'MLL sep 3'MLLx1)[189/200],(PML,RARA)x2 [200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[198]"	NA	NA	"CD2(-), CD4(+), CD7(-), CD11b(+), CD13(partial +), CD14(-), CD15(+), CD16(-), CD33(+), CD34(-), CD36(partial +), CD45(+), CD56(variably +), CD64(+), CD117(partial +), CD79a(-), HLA-DR(+), MPO(-), Tdt(-)"	TRUE	TRUE	NA	NA	NA	positive	2.448275862	positive		ASXL1 (p.D943Qfs*6; 38.5%)		ASXL1 (D943fs*6; MAF 25%)|FLT3-D835 (BMA)|KMT2A (MLL-AF9 fusion)	0.566377116	0.336269174	0.403328659	0.836823033	0.708776936	2.526248508	0.191869164	1.157433974	0.582022282	-0.315260367					no		Found	FALSE	FALSE	FALSE	FALSE	NA	FALSE	TRUE	FALSE	FALSE	TRUE	NA	FALSE	TRUE	-0.305832616	1.54697322	5.630561549	2.683474124	6.481205729	-3.4062923	-1.21830795	no	no	yes	no	yes	no	no																
BA2387R	BA2387D	2454	Waves1+2	yes	yes	yes	yes	Female	Female	White	NON-HISPANIC	White	1			71	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	y	Thyroid Cancer	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute monoblastic and monocytic leukaemia 	Intermediate	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute monoblastic and monocytic leukaemia 	71	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	3	"7+3 (Cytarabine, Idarubicin)|MiDAC|Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation)"	3	Consolidation|Induction|Allogeneic - Mismatched Unrelated Donor	Complete Response	Standard Chemotherapy	6	Bone Marrow Transplant	"Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation)"	Allogeneic - Mismatched Unrelated Donor	-1	Dead	462	Dead-Treatment	0	95	88	0	0	6.7	5.1	0	0.1	20	20	2.6	0.62	M5	21.4	7	"46,XX,idic(7)(q11.2)[20]"	373	93.9		19	FALSE	"CD11b, CD13, CD33, partial CD34,      CD38, CD58, CD64, CD117, CD123, partial HLA-DR and cMPO positive"	FALSE	TRUE	5.8	78.71	TRUE	negative	0	negative				BCOR (p.T870fs*46 (2 bp deletion); MAF 50%)|IDH1 (p.R132C; MAF 50%)|MLL (PTD)|PTPN11 (p.S502L; MAF 50% )	0.311650749	0.735359379	-0.040725416	0.586280354	0.499710975	2.740541825	0.273770301	0.934327337	0.857214872	-0.383925074					no		Found	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	0.156429311	-0.043192785	-1.170291732	1.979028308	4.939975224	-1.57285324	-3.638332397	no	no	no	no	no	no	no																
BA2420R	BA2420D	2106	Waves1+2	yes	yes	yes	no	Male	Male	White	NON-HISPANIC	White	1			69	TRUE	FALSE	TRUE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with minimal differentiation	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with minimal differentiation	69	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	n	y	y	n	1	Standard Chemotherapy	3	"5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|MiDAC"	3	Consolidation|Induction|Re-induction	Refractory	Standard Chemotherapy	6	Standard Chemotherapy	MiDAC	Consolidation	63	Dead	470	Dead-Disease	0	80		0	0	78.5	15.1	6.4	2.9	21	15	3.1	1.01	M0	23.5	7.5	"47,XY,+8[2]/46,XY[18]"	NA	101.7	Consistent with karyotype	47	TRUE	"dim CD13, dimCD33, CD34, dim CD38, CD58, dimCD64, CD117, CD123, dim HLA-DR, TdT positive"	FALSE	TRUE	6.7	2.05	FALSE	negative	0	negative	RUNX1 (p.H242Afs*14; 24.5%)			MLL (PTD)|RUNX1 (p.H242fs*14; MAF 42% )|RUNX1 (p.N136K; MAF 30%)|U2AF1 (p.S34F; MAF 40%)	0.5460892	0.746567862	0.527521571	0.902210223	0.819372923	2.855030199	0.410021681	1.413531648	0.877742656	0.203370314			yes		yes		Found	FALSE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	2.156453828	3.178374621	2.524098871	5.643896541	5.769945422	-2.914937222	3.502344577	no	no	no	yes	no	no	no																
BA2080R	BA2080D	2135	Waves1+2	yes	yes	yes	yes	Male	Male			White	2	mono		77	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	y	Lung Cancer	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	"Acute myeloid leukaemia, NOS"	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	"Acute myeloid leukaemia, NOS"	78	0	Residual Disease|Post-Chemotherapy	Residual	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Targeted Therapy - Other	5	"7+3 (Cytarabine, Idarubicin)|Cytarabine|Bortezomib|Decitabine|Fludarabine, Cytarabine"	5	Hypomethylating/Low Dose Cytarabine|Salvage|Unknown|Induction|Experimental	Refractory	Standard Chemotherapy	6	Standard Chemotherapy	Decitabine	Hypomethylating/Low Dose Cytarabine	-1	Alive	344	Alive	NA	73	84	NA	NA	10	NA	6	NA	9	13	4.2	0.82		NA	NA	"46,XY[20]"	165	NA		NA	NA	"CD2(-), CD4(- to partial dim +), CD7(-), CD11b(-), CD13(+), CD14(-), CD15(few +), CD16(-), CD19(few +), CD33(variably +), CD34(variably +), CD36(-), CD38(variably +), CD45(variably +), CD56(-), CD64(-), CD117(+), HLA-DR (+), MPO(partial +), TdT(partial +)."	TRUE	TRUE	6.5	13.8	FALSE	negative	0	negative				ATM (S1993fs*23; MAF 44%)|CEBPA (L81fs*72; MAF 92%)|MUTYH (G382D; MAF 49%)|STAG2 (R1205*; MAF 92%)|TET2 (C1273S; MAF 46%)|TET2 (M823fs*1; MAF 47%)	0.501062162	0.704697288	0.618069604	0.64841193	0.844306429	2.922714874	0.26573571	1.207661734	0.989086936	0.197592842					no		Found	FALSE	TRUE	FALSE	FALSE	NA	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	TRUE	5.285747578	5.93293802	4.167156836	2.627466439	4.881845714	-1.697539521	4.689765802	yes	yes	yes	no	no	no	yes																
BA2354R	BA2354D	2050	Waves1+2	yes	yes	yes	yes	Male	Male	Asian	NON-HISPANIC	Asian	1		RUNX1-RUNX1T1	37	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with t(8;21)(q22;q22); RUNX1-RUNX1T1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with t(8;21)(q22;q22); RUNX1-RUNX1T1	37	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	4	"3+7 (Cytarabine, Daunorubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)|Etoposide, Mitoxantrone|Busulfan, Cyclophosphamide"	4	Salvage|Consolidation|Induction|Allogeneic - Matched Unrelated Donor	Refractory	Standard Chemotherapy	6	Bone Marrow Transplant	"Busulfan, Cyclophosphamide"	Allogeneic - Matched Unrelated Donor	0	Alive	1348	Alive	0.8			0	7.5	17.5	0	37.5	0.4	22	13	3	0.89	M2	15.8	5.5	"45,X,-Y,t(8;21)(q22;q22)[20]"	411	100.6	"RUNX1T1/RUNX1: Ê 94% of cells had the dual fusion signal pattern consistent with RUNX1T1/RUNX1 fusion and t(8;21), as seen on metaphase analysis."	42	TRUE	"dim CD7, CD13, dim CD33, CD34, CD38, CD56, dim partial      CD64, CD117, dim CD123, HLA-DR, MPO, dim TdT positive"	TRUE	TRUE	7	8.15	FALSE	negative	0	negative				EZH2 (p.F445fs*3; MAF 30% )|KIT (p.N822K (exon 17); MAF 5% )|KIT (p.Y418_D419insFL (exon 8); MAF 29%)|TET2 (p.G1160E; MAF 49% )	0.422869383	0.576471684	0.611809069	0.54646851	0.865578677	2.607159954	0.124094096	1.221642134	1.242724361	0.207418043					no		Found	FALSE	TRUE	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	4.805356331	5.253852829	3.956413745	3.204027111	6.208728417	-1.231423649	7.777132138	yes	yes	yes	no	yes	no	yes																
BA2044R	BA2044D	2267	Waves1+2	yes	yes	yes	no	Male	Male	White	NON-HISPANIC	White	1			57	TRUE	FALSE	TRUE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	57	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	n	y	y	n	2	Standard Chemotherapy|Bone Marrow Transplant	3	"7+3 (Cytarabine, Idarubicin)|HiDAC|Fludarabine, Melphalan, TBI"	3	Allogeneic - Sibling|Consolidation|Induction	Complete Response	Standard Chemotherapy	371	Bone Marrow Transplant	"Fludarabine, Melphalan, TBI"	Allogeneic - Sibling	-1	Dead	245	Dead-Treatment	0.3	50		0	0.6	32.6	14.7	51.8	0	82	52	3.4	0.78	M2	29.6	10.1	"46,XY,hsr(6)(p21p23)[17]/46,XY[5]"	160	93.7	Normal	91	TRUE	"CD13, CD33, CD34, CD38, CD58, CD117, CD123, and HLA-DR+"	FALSE	TRUE	7.5	3.53	FALSE	negative	0	negative	RUNX1 (p.Y377*; 11.5%)|RUNX1 (p.I114Afs*25; 33.0%)			RUNX1 (p.I114fs*25; MAF ~50% )|U2AF1 (p.S34F; MAF 43%)	0.621304757	0.584362823	0.767689292	0.985395571	0.892349499	2.773734209	0.134719784	1.433085761	0.933178335	0.315492035			yes		yes	yes	Found	FALSE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	TRUE	FALSE	3.963805754	4.120206457	3.969281028	5.016314662	6.739225147	-0.802256476	3.083662214	yes	yes	yes	yes	yes	yes	no																
BA2489R	BA2489D	2480	Waves1+2	yes	yes	yes	yes	Male	Male			Black	2			63	TRUE	FALSE	FALSE	TRUE	FALSE	FALSE	n		y	n	y	y	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	63	0	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	3	Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Other	3	"AG-221|Azacitidine|Fludarabine, Melphalan, TBI, ATG"	3	Hypomethylating/Low Dose Cytarabine|Experimental|Allogeneic - Child			NA	Bone Marrow Transplant	"Fludarabine, Melphalan, TBI, ATG"	Allogeneic - Child	-1	Alive	1156	Alive	0	20	0	0	NA	76	0	24	NA	18	16	4.1	1.24		24.9	8.3	"46,XY[20]"	148	100.4		72	FALSE		NA	NA	7.4	1.8	FALSE	negative	0	negative		ASXL1 (p.G646Wfs*12; 31.2%)		ASXL1 (G646fs*12; MAF 30%)|CIITA (Q320fs*41; MAF 51%)|CUX1 (P442fs*16; MAF 38%)|IDH2 (R140Q; MAF 46%)|SRSF2 (P95H; MAF 40%)|STAG2 (R614*; MAF 90%)	0.705378003	0.58247081	0.763167935	0.621591892	0.935200637	2.811609675	0.187327207	1.352622253	1.098991504	0.312819142		yes			yes	yes	Found	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	TRUE	TRUE	1.332427638	7.796635603	5.608414257	4.430629509	7.474165456	-1.995974726	5.606173771	no	yes	yes	yes	yes	no	yes																
BA2872R	BA2872D	2415	Waves1+2	yes	yes	yes	yes	Male	Male	White	NON-HISPANIC	White	1			65	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	y	Pancreatic adenocarcinoma	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	65	0	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	3	"3+7 (Cytarabine, Daunorubicin)|Decitabine|5+2 (Ara-C, Daunorubicin)"	3	Salvage|Induction|Re-induction	Refractory	Standard Chemotherapy	6	Standard Chemotherapy	Decitabine	Salvage	9	Dead	158	Dead-Disease	0	18	12	0.9	32	7.4	35.2	18.5	4.8	44	165	2.9	1.65	M2	20.1	6.7	"46,XY,i(17)(q10)[20]"	3923	81	"TP53/CEP17: 85% of cells were missing a signal for TP53, consistent with deletion due to the i(17) seen on metaphase analysis.  PML/RARA: 69% of cells had three signals for RARA (17q21), consistent with three copies of 17q due to the i(17) seen on metaphase analysis."	40	TRUE	"CD13, CD33, CD34, CD117, and HLA-DR positive"	FALSE	TRUE	5.7	161.89	TRUE	negative	0	negative				ASXL1 (p.R693fs*10; MAF 49% )|CREBBP (p.S893L; MAF 52% )|NRAS (p.G12D; MAF 46% )	0.675710494	0.421713102	0.845126676	0.835807591	0.971738409	2.672284105	0.08096482	1.490829944	1.012469844	0.51134402					no		Found	FALSE	FALSE	FALSE	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	FALSE	TRUE	TRUE	FALSE	3.827308739	6.048565377	3.76546798	2.400959234	6.734673352	1.842642149	7.237197009	yes	yes	yes	no	yes	yes	yes																
BA2629R	BA2629D	2486	Waves1+2	yes	yes	yes	yes	Male	Male	White	NON-HISPANIC	White	1			61	TRUE	FALSE	TRUE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with minimal differentiation	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with minimal differentiation	61	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	3	"5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|MiDAC"	3	Consolidation|Induction|Re-induction	Refractory	Standard Chemotherapy	6	Standard Chemotherapy	MiDAC	Consolidation	44	Dead	104	Dead-Treatment	0	80		0	0	45.5	0.8	0	0.3	14	18	2.4	0.73	M0	21.3	6.9	"46,XY,t(1;4)(q21;p14)[20]"	178	103.4	Normal	57	FALSE	"partial CD7, partial CD13, CD34, partial CD38,      partial CD117, dim CD123, HLA-DR and TDT positive"	TRUE	FALSE	7	13.68	FALSE	negative	0	negative	RUNX1 (p.R250Lfs*13; 50.0%)			BCOR (p.S571*; MAF 90% )|MLL (PTD)|ZRSR2 (p.C181F; MAF 88%)	0.34918862	0.876432082	0.077606234	0.726808097	0.286862189	2.859716924	0.586262935	0.822787028	0.612307719	-0.233499398				yes	yes		Found	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	2.041106692	1.371851629	-0.231575701	4.17562397	6.148462792	-2.969312096	-4.190401735	no	no	no	yes	yes	no	no																
BA2538R	BA2538D	2283	Waves1+2	yes	yes	yes	no	Male	Male			White	2			81	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	y	Colon Cancer	n	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	"Acute myeloid leukaemia, NOS"	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	"Acute myeloid leukaemia, NOS"	81	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	n	y	y	n	2	Supportive/Palliative Care|Targeted Therapy - Other	2	AG-221|Hydroxyurea	2	Experimental|Supportive/Palliative Care			NA	Targeted Therapy - Other	AG-221	Experimental	14	Dead	72	Dead-Disease	0		12	0	NA	69	5	12	NA	30	41	3.3	0.76		30.3	10.5	"46,XY[20]"	227	85.6	"nuc ish(RUNX1T1,RUNX1)x2[199],(ABL1,BCR)x2[200],(CCND1,IGH)x2[199]"	117	TRUE		NA	NA	8.8	33.1	TRUE	negative	0	negative	RUNX1 (p.Q213Rfs*24; 85.5%)	ASXL1 (p.G646Wfs*12; 25.0%)		"ASXL1 (Foundation, G646fs*12; MAF 33%)|FLT3 (Foundation, E596_Y597INSYEYDLPYDPRS; MAF 27%)|IDH2 (Foundation, R140Q; MAF 45%)|RUNX1 (Foundation, Q213fs24; MAF 82%)|SRSF2 (FOUNDATION, P95R; MAF 48%)"	0.576566213	0.882440657	0.576223915	0.762160512	0.621946769	2.852621112	0.639162303	1.151835481	0.68729646	0.123158691		yes			yes		Found	TRUE	FALSE	FALSE	FALSE	TRUE	FALSE	TRUE	FALSE	TRUE	FALSE	TRUE	FALSE	TRUE	2.39740781	3.902619235	2.548037457	4.599018015	6.836012105	0.336529519	2.514712869	no	yes	no	yes	yes	yes	no																
BA2153R	BA2153D	2301	Waves1+2	yes	yes	yes	no	Male	Male	White	NON-HISPANIC	White	1			70	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with minimal differentiation	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with minimal differentiation	70	15	Residual Disease|Post-Chemotherapy	Residual	Bone Marrow Aspirate	y	y	n	y	y	n	2	Standard Chemotherapy|Supportive/Palliative Care	4	"7+3 (Cytarabine, Idarubicin)|Azacitidine, Itacitinib|Azacitidine|Decitabine"	2	Salvage|Induction	Refractory	Standard Chemotherapy	6	Standard Chemotherapy	"Azacitidine, Itacitinib"	Salvage	449	Dead	1389	Dead-Disease	0	90	91	0	0	78.1	0.9	1.7	0	46	27	2	0.74	M0	24.4	8.1	"47,XY,+4[9]/46,XY[11] "	NA	103.8		23	TRUE	"CD7, CD13, CD33, CD34, CD38, CD56, CD117, CD123, HLA-DR and MPO+ (see Note) (Expression of the following antigens is dim and/or partial: ÊCD7, CD33, CD34, CD38, CD56, CD123, HLA-DR and MPO.) | Small clonal B cell population (<1% of total cells); CD19, CD20, and kappa+"	TRUE	TRUE	4.7	4.85	FALSE	negative	0	negative		ASXL1 (p.Q588*; MAF 43% )		ASXL1 (p.Q588*; MAF 43% )	0.412927808	0.927331636	0.307592121	0.383703029	0.441681611	2.857484794	0.632282139	0.888696731	0.609512138	-0.135716984					no		Found	FALSE	FALSE	FALSE	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	4.046331176	2.020939054	-0.334928321	3.856461801	4.983367855	-2.671580925	1.014003384	yes	no	no	yes	no	no	no																
BA2674R	BA2674D	2301	Waves1+2	no	no	no	no	Male	Male	White	NON-HISPANIC	White	1			70	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with minimal differentiation	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with minimal differentiation	71	281	Post-Chemotherapy|Relapse	Relapse	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Supportive/Palliative Care	4	"7+3 (Cytarabine, Idarubicin)|Azacitidine, Itacitinib|Azacitidine|Decitabine"	2	Salvage|Induction	Refractory	Standard Chemotherapy	6	Standard Chemotherapy	"Azacitidine, Itacitinib"	Salvage	449	Dead	1389	Dead-Disease	0	90		0	0	27.8	2.9	8.6	0.4	81	43	3.3	NA	M0	31.9	10.2	"47,XY,+4[2]/46,XY[18]"	235	94.7	"Two of twenty metaphase cells examined were abnormal, with trisomy 4, as seen previously."	91	TRUE	"partial CD7 (~35%), CD13, partial dim CD33, CD34, CD38, variable CD56, and CD117"	TRUE	TRUE	6.6	73.42	TRUE	negative	0	negative		ASXL1 (p.Q588*; MAF 49%)		ASXL1 (p.Q588*; MAF 49%)	0.499168959	0.912012613	0.568179403	0.457598265	0.513790329	2.837705819	0.576378861	1.146738308	0.627184083	-0.019378455					no		Found	FALSE	FALSE	FALSE	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	2.527421199	2.085728775	0.632666941	2.798042346	5.008304145	-0.988728384	2.141679992	no	no	no	no	no	no	no																
BA2520R	BA2520D	2400	Waves1+2	yes	yes	yes	yes	Male	Male			White	5			80	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	y	Mature B-Cell Neoplasm	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with minimal differentiation	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with minimal differentiation	80	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	3	Standard Chemotherapy|Targeted Therapy - Other|Targeted Therapy - Kinase Inhibitor(s)	3	"Cytarabine|Decitabine|PF-04449913 (Hedgehog Inhibitor), LDAC"	3	Consolidation|Salvage|Experimental			NA	Targeted Therapy - Kinase Inhibitor(s)	Decitabine	Salvage	-1	Dead	309	Dead-Disease	NA	80	86	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	M0	NA	NA	"46,XY,del(20)(q11.2q13.1)[15]/46,XY[5]"	NA	NA	Positive for deletion of 20q12 in 11.5% of 200 cells	4	FALSE	"positive for dim CD7, dim CD10, CD34, CD38, dim CD45, cCD79a, CD99, HLA-DR, TdT, dim PAX5"	TRUE	FALSE	NA	NA	NA	negative	0	negative	RUNX1 (p.R204*; 45.5%)|RUNX1 (p.S141*; 45.1%)	ASXL1 (p.D720Rfs*18; 14.1%)		ASXL1 (p.718_724del; MAF 50.3%)|RUNX1 (p.R177X; MAF 47%)|RUNX1 (p.S114X; MAF 44.8%)|SRSF2 (p.P95H; MAF 45.1%)	0.49230989	0.7274974	0.420327423	0.659048806	0.551893151	2.834468292	0.358700458	1.029540803	0.70732814	-0.089185417		yes			yes		Found	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	TRUE	FALSE	TRUE	FALSE	NA	FALSE	TRUE	3.732809492	4.074801989	1.124399465	6.747855302	4.956449885	-2.760852267	1.34489747	yes	yes	no	yes	no	no	no																
BA2479R		2362	Waves1+2	yes	no	yes	no	Female	Female			White	5			71	TRUE	FALSE	TRUE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	71	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	n	n	y	n	n	1	Standard Chemotherapy	1	"Venetoclax (ABT-199), Azacitidine"	1	Induction	Complete Response	Standard Chemotherapy	115	Standard Chemotherapy	"Venetoclax (ABT-199), Azacitidine"	Induction	115	Alive	1044	Alive	NA	65		NA	NA	NA	NA	NA	NA	NA	NA	NA	NA		NA	NA	"46,XX[20]"	NA	NA		96	TRUE	"positive for CD33, CD13, CD117, and myeloperoxidase; negative for CD34 and HLA-DR"	FALSE	TRUE	NA	1.6	FALSE	negative	0	positive				ASXL1 (p.A1312V; MAF 33.6%)|IDH1 (p.A1312V; MAF 32.1%)|NPM1 (p.L258fs; MAF 31.1%)	0.732410104	0.375607688	0.671194037	0.636560085	0.368818488	2.56709333	0.117356043	1.197842468	0.280667063	0.129958991					no		Found	TRUE	FALSE	FALSE	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	TRUE	TRUE	5.133332979	6.44756726	2.277454383	8.643556921	7.605103304	0.030874783	-0.268163697	yes	yes	no	yes	yes	yes	no																
BA2844R	BA2844D	2275	Waves1+2	yes	yes	yes	yes	Male	Male	Unknown		HispNative	2	N/A		61	TRUE	FALSE	TRUE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	"Acute myeloid leukaemia, NOS"	Intermediate	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	"Acute myeloid leukaemia, NOS"	61	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	3	"7+3 (Cytarabine, Idarubicin)|HiDAC|Azacitidine"	3	Hypomethylating/Low Dose Cytarabine|Consolidation|Induction	Complete Response	Standard Chemotherapy	-1	Standard Chemotherapy	Azacitidine	Hypomethylating/Low Dose Cytarabine	-1	Alive	195	Alive	0	64	47.4	1.7	NA	23.3	27.6	0	NA	29	26	3.7	1.01		32.9	10.3	"46,XY[20]"	578	99.7	"nuc ish(D5S2064,D5S630,EGR1)x2[199],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1, RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]"	20	TRUE	"CD2(-), CD7(partial +), CD11b(partial +), CD13(+), CD14(-), CD15(partial +), CD16(-), CD19(few appear very dim +), CD25(-), CD33(variably +), CD34(variably +), CD36(subset +), CD38(+), CD45 (variably +), CD56(+), CD64(partial +), CD117(+), CD123(-), HLA-DR(+), MPO(+), TdT(-). (73% population of medium to large sized cells)"	TRUE	TRUE	7.2	20.8	FALSE	negative	0	negative				ASXL1 (G967DEL; MAF 45%)|CEBPA (A111FS*56; MAF 48%)|GATA2 (A318V; MAf 37%)|GATA2 (L321F; MAF 7%)|NRAS (G13V; MAF 37%)	0.530002494	0.589031413	0.521186058	0.9312305	0.741550764	2.848778819	0.115340016	1.330484303	0.932334887	-0.003903447					no		Found	FALSE	FALSE	FALSE	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	TRUE	2.862515491	2.221876593	1.028884744	3.413989372	4.333803972	-1.363856605	5.702197684	yes	no	no	no	no	no	yes																
BA2836R	BA2836D	2242	Waves1+2	yes	yes	yes	yes	Male	Male			White	2			59	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	59	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	1	Standard Chemotherapy	2	"7+3 (Cytarabine, Idarubicin)|HiDAC"	2	Consolidation|Induction	Complete Response	Standard Chemotherapy	6	Standard Chemotherapy	HiDAC	Consolidation	107	Dead	430	Dead-Unknown	0	35	27.4	0	NA	36.8	6.6	29.2	NA	13	25	2.9	1.4		23.6	7.6	"46,XY[20]"	383	NA	"nuc ish(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200], (5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]"	35	TRUE	"CD2(-), CD7(-), CD11b(-), CD13(+), CD14(-), CD15(- to partial dim +), CD16(-), CD25(-), CD33(+ to slightly bright +), CD34(partial +), CD36(equivocal), CD38(slightly dim and variable), CD45(dim +), CD56(-), CD64(-), CD117(+), CD123(+), HLA-DR(+), MPO(+), TdT(-)."	TRUE	TRUE	6	3.6	FALSE	negative	0	positive				CEBPA (H224fs*97; MAF 7%)|CEBPA (Y181*; MAF 15%)|IDH2 (R140Q; MAF 35%)|NPM1 (W288fs*10+; MAF 26%)|POT1 (splice site 1164-1G>A; MAF 48%)|SRSF2 (P95R; MAF 37%)	0.64528824	0.705130205	0.730720658	0.804391599	0.91650951	2.80249899	0.311723346	1.401282126	0.862324556	0.156931642		yes			yes		Found	TRUE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	TRUE	TRUE	2.84794513	3.988974495	1.408184558	4.704530812	5.351555208	0.170321229	3.596599359	no	yes	no	yes	no	yes	no																
BA2714R	BA2714D	2366	Waves1+2	yes	yes	yes	yes	Male	Male	White	NON-HISPANIC	White	1			60	TRUE	FALSE	TRUE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	60	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	1	Standard Chemotherapy	3	"FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine|SWOG S1203 (7+3 +/- Vorinostat)"	3	Salvage|Induction|Re-induction	Complete Response	Standard Chemotherapy	167	Standard Chemotherapy	Azacitidine	Salvage	6	Dead	870	Dead-Disease	0	90	61	1	4	47	10	1	0.1	30	26	2.4	1.17	M4	14	4.6	"46,XY[20]"	612	104.5	Normal	80	TRUE	"dim CD4, dim CD7, dim CD11b, CD13, CD33, variable CD34, CD38, CD58, variable CD64, CD117, CD123, dim HLA-DR, MPO, and dim TdT"	TRUE	TRUE	5.8	70.84	TRUE	negative	0	positive				FLT3-V491L (p.V491L; MAF 51%)|NPM1 (p.W288fs*12; MAF 50%)|SF3B1 (p.K666Q; MAF 47%)|WT1 (p.Y395fs*51; MAF 49%)	0.628516903	0.673467819	0.662694306	0.819282729	0.851230684	2.825109369	0.105169136	1.460719423	0.823171366	-0.047065286	yes				yes		Found	FALSE	FALSE	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	TRUE	TRUE	FALSE	1.488141969	1.018229942	-0.155093445	3.117239626	6.229043006	-1.982860036	1.532974469	no	no	no	no	yes	no	no																
BA3317R	BA3317D	2366	Waves3+4	no	no	no	no	Male	Male	White	NON-HISPANIC		1			60	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	62	769	Post-Chemotherapy|Relapse	Relapse	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	3	"FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine|SWOG S1203 (7+3 +/- Vorinostat)"	3	Salvage|Induction|Re-induction	Complete Response	Standard Chemotherapy	167	Standard Chemotherapy	Azacitidine	Salvage	6	Dead	870	Dead-Disease	0	80	45	1.8	0	49.6	0	3.5	0.9	31	20	3	0.85	M4	26.2	9.3	"46,XY,t(3;4)(p21;q21)[20]"	261	99.6	Normal	44	TRUE	"CD13, CD34, dim CD33, CD38, CD58, CD71, CD117, CD123, partial TdT, and partial MPO+ "	TRUE	TRUE	6.1	3.42	FALSE	negative	0	positive				FLT3 (p.N841T; MAF 43%)|NPM1 (p.W288fs*12; MAF 41%)|SF3B1 (p.K666Q; MAF 48%)|WT1 (p.Y395fs*51; MAF 44%)	0.336926047	0.805451534	0.113127322	0.509418602	0.673316422	2.928551488	0.195958063	0.831917487	0.968710477	-0.227397597	yes				yes		Found	FALSE	FALSE	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	1.130716438	1.087265128	-0.416155586	3.594713283	3.842193862	-0.638748848	0.364990869	no	no	no	no	no	yes	no																
BA2440R	BA2440D	2263	Waves1+2	yes	yes	yes	yes	Male	Male			White	5			76	TRUE	FALSE	TRUE	FALSE	FALSE	FALSE	n		n	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	76	1	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	0		0		0				NA	NONE	NONE	NONE	NA	Alive	31	Alive	NA	20		NA	NA	NA	NA	NA	NA	NA	NA	NA	NA		NA	NA	"41~42,XY,del(3)(p13p21),add(4)(q21),add(5)(q11.2),-7,-10,add(12)(p11.2),-15,add(15)(q21),add(17)(p11.2),-19,-20,-22,+2mar[cp6]/42~43,sl,+21[cp5]/42,sl,i(21)(q10)[cp2]/43~44,sl,+add(7)(p11)[cp2]/43~46,sl,+add(7)(p11),+21[cp4]/81~87<4n>,slx2[cp2]"	NA	NA	"Loss of chromosome 5q31 sequences (73.5%)|Loss of chromosome 7 sequences (monosomy 7) (61.5%)|Gain of 21q22 (AML1) sequences (11.5%)|Polysomy for 8, 20q (7.5%), 11q, 15q, 16q and 17q sequences"	91	TRUE		NA	NA	NA	5.6	FALSE	negative	0	negative				ASXL1 (p.E1102D; MAF 31.1%)|DNMT3A (p.F543C; MAF 35.7%)	0.80755386	0.617626223	0.792538525	0.814118637	0.979208709	2.75904934	0.151377766	1.492253808	0.950030131	0.445423165					no		Found	FALSE	FALSE	TRUE	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	TRUE	TRUE	2.747269925	4.767096327	3.716097572	4.551297836	6.345033334	2.057901585	4.889545346	no	yes	yes	yes	yes	yes	yes																
BA2410R	BA2410D	2495	Waves1+2	yes	yes	yes	no	Female	Female			White	2			57	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	57	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	n	y	y	n	1	Standard Chemotherapy	1	"7+3 (Cytarabine, Idarubicin) plus Crenolanib"	1	Induction	Complete Response i	Standard Chemotherapy	-1	Standard Chemotherapy	"7+3 (Cytarabine, Idarubicin) plus Crenolanib"	Induction	-1	Dead	81	Dead-Treatment	NA	55	47	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA		NA	NA	"46,XX[20]"	NA	NA	Normal	NA	NA	"It reveals 0.23% CD34 (+) myeloid blasts with the following immunophenotype: CD2(-), CD7(-), CD13(+), CD15(-/few +), CD33 (bright +), CD36(few +), CD38(partial +), CD45(+), CD64(-), CD117(+), HLA-DR(-), MPO (partial +). (A limited/targeted immunophenotypic analysis could be performed on this paucicellular specimen.) | CD2(-), CD4(partial dim +), CD7(-), CD11b(-), CD13(variably +), CD15(-/few +), CD33(bright +), CD34(-), CD36(- /few +), CD38(+), CD45(+), CD56(-), CD64(few +), CD117(+), and HLA-DR(-) (There is also a 16% population of medium-sized cells with the following immunophenotype)"	TRUE	TRUE	NA	26.5	TRUE	positive	NA	positive				ASXL1 (E981G; MAF 49%)|DNMT3A (F290fs*24; MAF 40%)|FLT3-ITD (MAF 18%)|JAK2 (N322I; MAF 51%)|NPM1 (W288fs*10+; MAF 38%)	0.501041864	0.825425063	0.491362696	0.519249417	0.879682851	2.992672791	0.24364764	1.136172081	0.838587862	0.00110078					no		Found	FALSE	FALSE	TRUE	FALSE	NA	FALSE	TRUE	FALSE	FALSE	TRUE	TRUE	FALSE	TRUE	1.67574341	3.09979908	2.38904504	4.106337586	5.216385714	2.061119916	4.464478356	no	no	no	yes	no	yes	yes																
BA2986R	BA2986D	2110	Waves1+2	yes	yes	yes	no	Female	Female	White	NON-HISPANIC	White	1			48	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	"Acute myeloid leukaemia, NOS"	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	"Acute myeloid leukaemia, NOS"	56	0	Residual Disease|Post-Chemotherapy|Post-DLI|Post-Transplant	Residual	Bone Marrow Aspirate	y	y	n	y	y	n	3	DLI|Standard Chemotherapy|Bone Marrow Transplant	7	"7+3 (Cytarabine, Idarubicin)|HiDAC|Donor Lymphocyte Infusion|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)|Cytarabine, Mitoxantrone|Busulfan, Cyclophosphamide"	5	Allogeneic - Sibling|Consolidation|Unknown|Induction|Re-induction	Refractory	Standard Chemotherapy	6	Standard Chemotherapy	"MEC (Cytarabine, Etoposide, Mitoxantrone)"	Re-induction	5	Dead	3069	Dead-Disease	0	62	5	0	0	83.2	1.8	0	0	28	21	2.5	0.8		24.1	8.3	"46,XX,t(1;11)(q44;q13),del(6)(p23)[9]/46,idem,t(17;20)(q25;q11.2)[11]"	290	94.5	"All probe results were within normal laboratory limits.      *Note: while it was not disrupted, MLL (11q23) was observed on the end of      the derivative chromosome 1 on available metaphase cells, reflecting the      t(1;11)."	53	TRUE	"dim CD2, CD13, CD33, CD34, CD38, CD117, dim CD123, dim      HLA-DR, and TdT positive"	FALSE	TRUE	6.5	1.46	FALSE	negative	0	negative				BCOR (p.A1262S; MAF 45% )|DNMT3A (p.R882H; MAF 15% )|GATA1 (c.-12C>T; MAF 35%)	0.572024108	0.72805843	0.31411252	0.755517382	0.60580828	2.918676813	0.340319481	1.194735972	0.761374732	-0.231494184					no		Found	FALSE	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	4.791024581	6.6047618	0.450991498	8.270316657	4.964400321	-3.144296937	0.78292856	yes	yes	no	yes	no	no	no																
BA2622R	BA2622D	2453	Waves1+2	yes	yes	yes	no	Male	Male	White	NON-HISPANIC	White	1			76	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	y	Basal Cell Carcinoma	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	76	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	n	y	y	n	1	Standard Chemotherapy	3	CPX-351 (Liposomal Cytarabine + Daunorubicin)|Decitabine|Incyte trial (azacitidine and JAK 1 inhibitor)	2	Consolidation|Induction	Complete Response	Standard Chemotherapy	35	Standard Chemotherapy	Incyte trial (azacitidine and JAK 1 inhibitor)	Induction	77	Dead	520	Dead-Unknown	0	50	5	2	0.2	52.2	37.1	8.5	0	18	16	3.7	1.45	M0	22.3	7.6	"47,XY,+8[3]/46,XY[17]"	NA	118.6	5% trisomy 8	104	TRUE	"#1 Immunophenotype: CD13, CD34, CD38, dim CD45, CD58, CD117, HLA-DR and TdT positive | #2 Immunophenotype: dim CD4, partial CD13, dim CD34, CD38, CD58, CD123, HLA-DR, and partial TdT positive"	FALSE	FALSE	7.7	4.48	FALSE	negative	0	negative	RUNX1 (p.A338Rfs*256; 73.3%)	ASXL1 (p.G646Wfs*12; 20.0%)		CBL (p.Y371H; MAF 43%)|EZH2 (p.K30fs*8; MAF 48%)|RUNX1 (p.A338fs*; MAF 41%)|SF3B1 (p.H662Q; MAF 28%)	0.755388239	0.649675146	0.821213988	0.98362282	0.482415046	2.645722906	0.335563217	1.511929615	0.584217639	0.010273172	yes				yes	yes	Found	FALSE	FALSE	FALSE	TRUE	TRUE	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	TRUE	TRUE	4.074385753	4.27835541	3.877403932	7.240537792	6.312990183	-3.689319128	1.957630753	yes	yes	yes	yes	yes	no	no																
BA2970R	BA2970D	2327	Waves1+2	yes	yes	yes	yes	Male	Male	Black	NON-HISPANIC	Black	2			63	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	n		n	n	n	n	n	n	y	y	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	63	0	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Supportive/Palliative Care	2	Ruxolitinib|Hydroxyurea	1	Supportive/Palliative Care			NA	Supportive/Palliative Care	Hydroxyurea	Supportive/Palliative Care	103	Dead	8	Dead-Disease	1	9	15.4	2.9	NA	20.2	16.3	42.3	NA	NA	NA	NA	0.6		22.7	7	"46,XY[20]"	1086	NA	"nuc ish(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[199], (5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]"	126	TRUE	"CD34(+), CD7(partial +), CD13(+), CD33(+), CD38(partial +), CD45(moderately +), CD56 (+), CD117(+), HLA-DR(variably +), other myeloid and lymphoid antigens(-)."	TRUE	TRUE	NA	73.4	TRUE	positive	9	positive		ASXL1 (p.W898*; 42.1%)		ASXL1 (Foundation; W898*; MAF 47%)|KRAS (Foundation; A59T mutation; MAF 47%)|KRAS (Foundation; G13C; MAF 3%)|SUZ12 (Foundation; W617*; MAF 49%)	0.780282338	0.78587969	0.755449965	0.721561079	0.955568228	2.829812289	0.341382061	1.3625522	1.012044725	0.333940006					no		Found	FALSE	FALSE	FALSE	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	TRUE	TRUE	TRUE	TRUE	2.536142514	7.455713454	5.079761292	3.176785506	5.268147981	1.476380914	7.100069657	no	yes	yes	no	no	yes	yes																
BA2052R	BA2052D	2412	Waves1+2	yes	yes	yes	yes	Male	Male	Unknown		White	2			71	TRUE	FALSE	TRUE	FALSE	FALSE	FALSE	n		n	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	"Acute myeloid leukaemia, NOS"	Intermediate	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	"Acute myeloid leukaemia, NOS"	71	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Supportive/Palliative Care	1	Azacitidine	1	Hypomethylating/Low Dose Cytarabine			NA	Supportive/Palliative Care	Azacitidine	Hypomethylating/Low Dose Cytarabine	-1	Dead	288	Dead-Unknown	0.9	34		2.8	NA	NA	NA	NA	NA	28	27	4.2	1.18		29.3	9.8	"46,XY,inv(4)(p14p16.1)[3]/46,XY[16]"	194	NA	"nuc ish(D5S2064,D5S630,EGR1)x4[32/200],(D7Z1,D7S522)x4[17/200],(D8Z2, D20S108)x4[27/200],(RUNX1T1,RUNX1)x4[32/200],(5'MLL,3'MLL)x4(5'MLL con 3'MLLx4)[21/200],(PML,RARA)x4 [34/200],(5'CBFB,3'CBFB)x4(5'CBFB con 3'CBFBx4)[35/200]"	73	TRUE	"CD2 (-), CD7(few +), CD11b(-), CD13(partial dim +), CD14(-), CD15(partial dim +), CD16(-), CD22(partial dim +), CD33(-), CD34(bright +), CD36(-), CD38(moderately bright +), CD45(partial +), CD56(-), CD64(-), CD117(partial +), HLADR(+) (32% population of medium to large cells)"	TRUE	TRUE	7.1	NA	NA	negative	0	negative				"BCOR (Foundation; Q1337*; MAF 56%)|CTCF (Foundation; R49H; MAF 19%)|RUNX1 (Foundation; loss, splice site 477_508+22>GGG; MAF 50%)|SRSF2 (Foundation; R94_S101del;MAF 39%)|TET2 (Foundation; splice site 3409+2T>G; MAF 51%)"	0.736746152	0.815015398	0.725451141	0.624822193	0.906702909	2.86846862	0.48353972	1.297231689	1.026122999	0.3370516		yes			yes		Found	FALSE	TRUE	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	TRUE	FALSE	NA	TRUE	TRUE	3.12161169	4.845625219	4.035420656	4.943441779	6.563268979	-1.93006375	4.045158301	yes	yes	yes	yes	yes	no	no																
BA2510R	BA2510D	2073	Waves1+2	yes	yes	yes	no	Male	Male			White	5		KMT2A_re	65	TRUE	FALSE	TRUE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	65	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	n	y	y	n	3	Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Other	3	"7+3 (Cytarabine, Idarubicin)|Venetoclax (ABT-199), Azacitidine|Fludarabine, Cyclophosphamide, TBI "	3	Experimental|Re-induction|Double Umbilical Cord Blood Transplant (DUCBT)			NA	Bone Marrow Transplant	"Fludarabine, Cyclophosphamide, TBI "	Double Umbilical Cord Blood Transplant (DUCBT)	-1	Dead	210	Dead-Disease	NA	95	62	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA		NA	NA	"48,XY,+8,der(11)t(11;?)(q23;?),+21[19]/46,XY[1]"	NA	NA	Gain of 8q22 and 21q22 (88%)	33	FALSE	"positive for CD11b, CD13, CD33, CD38, dim CD45, dim CD56, CD64, and HLA-DR"	FALSE	TRUE	NA	19.8	FALSE	negative	0	negative		ASXL1 (p.W960*; 48.8%)		ASXL1 (p.W960X; MAF 29.4%)|PTPN11 (p.E76V; MAF 29.5%)	0.428577289	0.485985975	0.207229426	1.023418638	0.792038356	2.713189298	-0.016079107	1.202432934	0.645901847	-0.254674548					no		Found	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	TRUE	0.880316656	1.895537678	0.041398241	3.22332801	4.819388543	-2.528601933	-0.233793723	no	no	no	no	no	no	no																
BA2804R	BA2804D	2101	Waves1+2	yes	yes	yes	yes	Male	Male			White	5	mono		87	TRUE	FALSE	FALSE	TRUE	FALSE	FALSE	n		y	n	n	n	n	n	y	y	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute monoblastic and monocytic leukaemia 	Intermediate	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute monoblastic and monocytic leukaemia 	87	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Targeted Therapy - Other	2	AG-120|Decitabine	2	Hypomethylating/Low Dose Cytarabine|Experimental			NA	Targeted Therapy - Other	AG-120	Experimental	-1	Dead	249	Dead-Disease	NA	60	39	NA	NA	NA	2	NA	NA	NA	NA	NA	NA	M5	NA	NA	"47,XY,+21[3]/46,XY[9]"	NA	NA	9.5% gain 21q22	43	TRUE	"A distinct blastic population, expressing CD7, CD13, CD15, CD33, CD34, CD38, dim CD45, CD64, MPO, and HLA-DR | A large monocytic population, positive for CD11b, CD13, CD14, CD15, CD33, CD38, CD45, CD64, HLA-DR and MPO"	TRUE	TRUE	NA	139.9	TRUE	negative	0	negative				ASXL1 (p.G642fs; MAF 31.6%)|CEBPA (p.A66fs; MAF 37.3%)|CEBPA (p.Q162fs; MAF 50.3%)|IDH1 (p.R132C; MAF 48.7%)|TP53 (p.N107D; MAF 97.6%)	0.541634488	0.436271696	0.797864156	0.570758738	1.041578155	2.605098275	-0.002201984	1.38583482	1.12096811	0.217208382					no		Found	TRUE	FALSE	FALSE	FALSE	TRUE	FALSE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	TRUE	4.076001538	5.97482137	3.378445713	2.180034982	5.836403806	0.695918604	7.839857484	yes	yes	yes	no	no	yes	yes																
BA2670R	BA2670D	2456	Waves1+2	yes	yes	yes	yes	Female	Female	White		White	2			72	TRUE	FALSE	FALSE	TRUE	FALSE	FALSE	n		y	n	y	y	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	73	0	Residual Disease|Post-Chemotherapy	Residual	Peripheral Blood	y	y	y	y	y	y	2	Standard Chemotherapy|Other	4	"Lenalidomide|Azacitidine|Decitabine|Clofarabine, Cytarabine"	2	Hypomethylating/Low Dose Cytarabine|Maintenance			NA	Other	"Clofarabine, Cytarabine"	Hypomethylating/Low Dose Cytarabine	-1	Dead	465	Dead-Disease	0		25	0	NA	2	54	18	NA	41	34	3.6	0.58		27.5	8.8	"46,XX,+1,der(1;21)(q10;q10)[6]/46,XX[14]"	NA	NA	"nuc ish(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200]"	NA	NA		NA	NA	6.2	58.2	TRUE	negative	0	negative				RUNX1 (PB)|SF3B1 (PB)	1.066673618	0.79576505	0.890183192	0.936628083	0.703124793	2.675124883	0.392349169	1.527782545	0.733093132	0.112952446	yes				yes	yes	Found	FALSE	FALSE	FALSE	TRUE	NA	FALSE	FALSE	FALSE	TRUE	FALSE	TRUE	TRUE	TRUE	4.558465291	4.905695821	6.006804942	5.245407749	6.879120863	1.602315747	5.529127847	yes	yes	yes	yes	yes	yes	yes																
BA2589R	BA2589D	2064	Waves1+2	yes	yes	yes	yes	Female	Female			HispNative	5			42	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myelomonocytic leukaemia	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myelomonocytic leukaemia	42	0	Post-Chemotherapy|Residual Disease	Residual	Peripheral Blood	y	y	y	y	y	y	2	Standard Chemotherapy|Targeted Therapy - Other	3	"7+3 (Cytarabine, Idarubicin)|AG-221|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)"	3	Salvage|Induction|Experimental	Refractory	Standard Chemotherapy	-1	Targeted Therapy - Other	AG-221	Experimental	-1	Dead	448	Dead-Disease	NA	50	51	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA		NA	NA	"46,XX[20]"	NA	NA	Normal	256	TRUE	"positive for CD13, CD34, CD38, dim CD45, CD117, HLA-DR, and MPO"	FALSE	FALSE	NA	10.7	FALSE	negative	0	negative				ASXL1 (p.G652S; MAF 41.3%)|ASXL1 (p.S1231F; MAF 50.4%)|DNMT3A (p.S307fs; MAF 45.6%)|IDH1 (c.C315T; p.G105G; MAF 46.6%)|IDH2 (p.R140Q; MAF 43.8%)|SRSF2 (p.P95H; MAF 42.2%)	0.983780749	0.802690577	0.706372162	0.926662775	0.861100664	2.771197962	0.451211544	1.345588244	0.948742145	0.161094086		yes			yes		Found	TRUE	FALSE	TRUE	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	TRUE	TRUE	4.068863171	5.346914821	5.469904883	6.332354356	7.030483189	2.360639815	6.346913297	yes	yes	yes	yes	yes	yes	yes																
BA2198R	BA2198D	2338	Waves1+2	yes	no	yes	no	Male	Male			White	3			61	TRUE	FALSE	TRUE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with maturation	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with maturation	61	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	n	y	y	n	1	Standard Chemotherapy	1	"7+3 (Cytarabine, Idarubicin)"	1	Induction	Refractory	Standard Chemotherapy	-1	Standard Chemotherapy	"7+3 (Cytarabine, Idarubicin)"	Induction	-1	Dead	42	Dead-Disease	NA	84	91	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	M2	NA	NA	"46,XY[20]"	NA	NA	Normal	NA	NA	"partial  weak CD4 (20% positive), CD13, partial weak CD11b (60%  positive), partial weak CD15 (20% positive), CD34, CD117,  myeloperoxidase, and partial HLA-DR (60% positive)"	FALSE	FALSE	NA	25	TRUE	negative	0	negative	RUNX1 (p.R166Q; 46.0%)|RUNX1 (p.R162K; 44.5%)	ASXL1 (p.E635Rfs*15; 10.5%)		ASXL1 (p.Glu635Argfs*15; MAF 9%)|CSF3R (p.Tyr779*; MAF 5.4%)|IDH2 (p.Arg140Gln; 37.7%)|PHF6 (p.Arg319*; MAF 88.6%)|RUNX1 (p.Arg162Lys; MAF 43%)|RUNX1 (p.Arg166Gln; MAF 35.3%)|SMC1A (p.Arg790Gln; 9.2%)|U2AF1 (p.Gln157Pro; MAF 51.3%)	0.526611045	0.7878846	0.489871572	0.711212838	0.497634961	2.816225689	0.497469535	1.249231901	0.805741976	-0.069630813			yes		yes		Found	TRUE	FALSE	FALSE	FALSE	NA	FALSE	TRUE	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	1.502892052	1.817833197	1.945891382	3.925347124	6.243148638	-3.43132344	2.976790876	no	no	no	yes	yes	no	no																
BA2066R	BA2066D	2066	Waves1+2	yes	yes	yes	yes	Female	Female	White	NON-HISPANIC	White	1		KMT2A_re	62	TRUE	FALSE	TRUE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	62	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	3	Standard Chemotherapy|Bone Marrow Transplant|Other	4	"3+7 (Cytarabine, Daunorubicin)|MiDAC|Hydroxyurea|Fludarabine, Melphalan, TBI, ATG"	4	Hypomethylating/Low Dose Cytarabine|Consolidation|Induction|Allogeneic - Child	Complete Response	Standard Chemotherapy	7	Bone Marrow Transplant	"Fludarabine, Melphalan, TBI, ATG"	Allogeneic - Child	-1	Dead	317	Dead-Other	0	95	70	0	0	9.5	23.3	0	0.1	54	57	3.3	0.78	M5	27.4	9.1	"46,XX,t(1;11)(p36.1;q23),add(9)(p22)[13]/46,sl,del(2)(p21p23),del(20)(q11.2-13.1)[4]/46,sl,add(12)(p11.2)[2]"	861	93.2	"MLL: 85%  The t(1;11) with these breakpoints in not common, but has been associated with monoblastic leukemia"	26	FALSE	"CD4, partial CD11b, CD15, CD33, CD38, moderate CD45, partial CD56, CD64, CD123, partial CD117, and HLA-DR"	FALSE	TRUE	6.8	87.72	TRUE	negative	0	negative		ASXL1 (p.R693*; 19.8%)		ASXL1 (p.R693*; MAF 19%)|BCOR (p.S209L (possibly a benign germline polymorphism); MAF 48%)|FLT3 (p.A680V; MAF 17%)|FLT3 (p.I836delI (in-frame deletion of one amino acid in TK domain); MAF 11%)|NRAS (p.G12S; MAF 19%)	0.539698832	0.523717665	0.520811853	0.745857205	0.744653405	2.638524271	0.086453168	1.442381318	0.491556963	-0.240664672					no		Found	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	0.078289048	1.051640088	0.533230431	3.114422883	5.963452628	-3.328538012	1.205444399	no	no	no	no	no	no	no																
BA2229R	BA2229D	2240	Waves1+2	yes	yes	yes	yes	Female	Female			White	5			61	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	n		y	n	y	y	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	61	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	2	"Cyclophosphamide, Fludarabine, TBI|7+3 (Cytarabine, Idarubicin) plus Sorafenib"	2	Induction|Double Umbilical Cord Blood Transplant (DUCBT)	Complete Response	Standard Chemotherapy	-1	Bone Marrow Transplant	"Cyclophosphamide, Fludarabine, TBI"	Double Umbilical Cord Blood Transplant (DUCBT)	-1	Alive	884	Alive	NA	40	28	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA		NA	NA	"46,XX,del(5)(q31q33),der(21)(qter->q22::p11.2->qter),del(21)(q22)[19] "	NA	NA	"65% Loss 5q31; 14.5% Gain of 8 centromere, trisomy; Trisomy for 21q22  (40.5%), and trisomy for 8q22 and 21q22 (7.0%)"	26	TRUE	"positive CD13, CD34, dim CD45, CD117 and HLA-DR"	FALSE	FALSE	NA	4.8	FALSE	negative	0	negative				BCOR (p.1189_1192del; MAF 33.1%)|NRAS (p.G12D; MAF 10%)|SRSF2 (p.P95H; MAF 34.4%)	0.866567153	0.825422943	0.558716395	0.706969317	0.314208537	2.811597937	0.647413124	1.113591981	0.600281805	-0.101554221		yes			yes	yes	Found	FALSE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	TRUE	TRUE	4.510748273	5.070596193	4.937870074	6.585715882	7.633935323	1.085955021	2.318122323	yes	yes	yes	yes	yes	yes	no																
BA2905R	BA2905D	2019	Waves1+2	yes	yes	yes	no	Male	Male			White	5	N/A		77	TRUE	FALSE	FALSE	TRUE	FALSE	FALSE	n		y	n	y	y	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Intermediate	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	77	0	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Initial Diagnosis	Peripheral Blood	y	y	n	y	y	n	2	Standard Chemotherapy|Targeted Therapy - Other	3	AG-221|Azacitidine|Decitabine	3	Hypomethylating/Low Dose Cytarabine|Experimental|Maintenance			NA	Targeted Therapy - Other	AG-221	Experimental	-1	Dead	38	Dead-Disease	NA	70	72	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA		NA	NA	"47,XY,+11[8]/46,XY[12]"	NA	NA	35% gain of 11q23	174	TRUE	"CD34, CD117, HLA-DR, CD13, and CD33. A subset of the myeloblasts showed aberrant co-expression of CD34 and myeloperoxidase.  A subset of the myeloblasts showed aberrant expression of CD56."	FALSE	TRUE	NA	33.1	TRUE	negative	0	negative				ASXL1 (p.G642fs; MAF 32.1%)|CEBPA (p.K90fs; MAF 39.1%)|EZH2 (p.F246fx; MAF 91.4%)|IDH2 (p.R140Q; MAF 49.2%)|RUNX1 (p.L29S; MAF 52.9%)|STAG2 (p.D884fs; MAF 89.8%)|TET2 (p.P1723S; MAF 48.4%)|TET2 (p.Y867H; MAF 50.3% )	0.622080612	0.758643007	0.588028563	0.543896098	0.651029255	2.925741322	0.41447345	1.119966745	0.924904944	0.012781632					no		Found	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	TRUE	FALSE	TRUE	FALSE	TRUE	TRUE	TRUE	2.412118063	6.262496751	3.166388755	3.39561115	5.581951198	0.692902997	4.782928817	no	yes	yes	no	no	yes	yes																
BA2976R	BA2976D	2494	Waves1+2	yes	yes	yes	yes	Male	Male	White	NON-HISPANIC	White	1			85	TRUE	FALSE	FALSE	TRUE	FALSE	FALSE	n		y	n	n	n	y	y	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Intermediate	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	85	0	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	1	Azacitidine	1	Maintenance			NA	Standard Chemotherapy	Azacitidine	Maintenance	232	Dead	80	Dead-Disease	0	36		0	8.7	20.2	27.2	20.2	1.6	24	23	3.4	0.88	M4	31.5	9.6	"46,XY,del(12)(p11.2p13)[20]"	200	95.7	"ETV6: 84% of cells were missing a signal for ETV6 (12p13), consistent with the deletion seen on metaphase analysis. "	46	FALSE	"CD34, CD117, dim CD123, CD33, dim HLA-DR, CD13, and CD58. (Blasts) | CD64, CD11b, CD33, CD15, dim HLA-DR, CD13, dim CD71, and CD58. (Monoblasts/promonocytes.)"	TRUE	TRUE	7	40.53	TRUE	negative	0	negative				NRAS (p.Q61R; MAF 30%)|U2AF1 (p.S34F ; MAF 50%)	0.809027947	0.745028376	0.856569146	0.699949748	0.87787166	2.689622507	0.226431273	1.480206298	0.924885993	0.409721358			yes		yes	yes	Found	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	TRUE	TRUE	TRUE	4.515790051	5.991126785	4.417142448	4.135534194	6.903606205	1.740441011	7.137564015	yes	yes	yes	yes	yes	yes	yes																
BA2035R	BA2035D	2424	Waves1+2	yes	yes	yes	yes	Male	Male	White	NON-HISPANIC	White	1			61	TRUE	FALSE	TRUE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML without maturation	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML without maturation	61	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	3	Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Kinase Inhibitor(s)	5	"Fludarabine, Melphalan|3+7 (Cytarabine, Daunorubicin)|MiDAC|Midostaurin|Hydroxyurea"	5	Allogeneic - Sibling|Hypomethylating/Low Dose Cytarabine|Consolidation|Induction|Maintenance	Complete Response	Standard Chemotherapy	6	Targeted Therapy - Kinase Inhibitor(s)	Midostaurin	Maintenance	284	Alive	2182	Alive	0	92	98	0	0.8	2.6	0	0	0.1	35	23	3.2	0.86	M1	19.9	6.8		330	106.4	Normal	49	TRUE	"dim CD33, CD34, CD38, dim CD45, CD117, and MPO"	FALSE	TRUE	8	84.96	TRUE	positive	NA	negative				DNMT3A (p.R882H; MAF ~50%)|FLT3-ITD (MAF 40%)|IDH1 (p.R132S; MAF ~50%)|SRSF2 (p.P95L; MAF ~40% )	0.209848184	0.975317125	-0.068099829	0.343044736	0.286423182	2.959279775	0.535005897	0.657697505	0.60270415	-0.366575271		yes			yes		Found	TRUE	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	TRUE	TRUE	FALSE	FALSE	0.7723449	1.561191974	-0.097429914	3.281164924	3.024285183	-0.78853803	-0.871720723	no	no	no	no	no	yes	no																
BA2760R	BA2760D	2524	Waves1+2	yes	yes	yes	no	Female	Female			White	5			54	TRUE	FALSE	TRUE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	54	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	n	y	y	n	1	Standard Chemotherapy	1	"7+3 (Cytarabine, Idarubicin) plus Sorafenib"	1	Induction	Complete Response	Standard Chemotherapy	19	Standard Chemotherapy	"7+3 (Cytarabine, Idarubicin) plus Sorafenib"	Induction	19	Dead	36	Dead-Treatment	NA	75		NA	NA	NA	39	NA	NA	NA	NA	NA	NA		NA	NA	"50,XX,+8,+10,+12,+21[20]"	NA	NA	- Gain of chromosome 8 in 55% of cells - Gain of 8q22 (ETO) sequence in 77.8% of cells; 21q22 (AML1) gain in 12% and loss in 77.8% cells	9	TRUE	"CD11b, CD13, CD14 (subset), CD33, CD34 (subset), CD38, CD45, CD64 (subset), HLA-DR and MPO"	FALSE	TRUE	NA	37.2	TRUE	negative	0	negative	RUNX1 (p.D198N; 35.5%)			EZH2 (p.D146H; MAF 51.6%)|RUNX1 (p.D171N; MAF 19.8%)	0.898955034	0.640674767	0.849634656	0.955767177	0.84150926	2.633063469	0.352274896	1.509964618	0.982242434	0.225114259					no		Found	FALSE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	TRUE	FALSE	TRUE	TRUE	TRUE	6.852067908	6.777758501	5.073052837	4.184392873	6.043172961	-2.151569342	6.077366518	yes	yes	yes	yes	no	no	yes																
BA2201R	BA2201D	2291	Waves1+2	yes	yes	yes	yes	Male	Male	White	NON-HISPANIC	White	1			68	TRUE	FALSE	TRUE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	FavorableOrIntermediate	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	68	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	3	"HiDAC|3+7 (Cytarabine, Daunorubicin)|Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation)"	3	Consolidation|Induction|Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	23	Bone Marrow Transplant	"Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation)"	Allogeneic - Matched Unrelated Donor	-1	Dead	861	Dead-Other	0.9	86		0	0	2.6	20.8	0.9	0.2	20	28	2.9	1.49	M5	33	10.8	"46,XY[20]"	1211	95.9	Normal	83	TRUE	"Variable CD13, variable CD14, CD33, variable CD64, CD117, CD123, and partial HLA-DR positive"	FALSE	TRUE	7.2	134.36	TRUE	positive	NA	positive				FLT3-ITD (MAF 91%)|IKZF1 (p.Q156H; MAF 45%)|NPM1 (p.W288fs*; MAF 49%)|SF3B1 (p.K666Q; MAF 50%)	0.606173375	0.569983342	0.748421145	0.724710748	0.995123241	2.602794433	-0.035425063	1.487549058	0.840391162	0.009242182	yes				yes		Found	FALSE	FALSE	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	TRUE	TRUE	TRUE	FALSE	0.623156646	1.307417208	0.138726037	2.520079577	6.369828867	-0.697873876	4.802496495	no	no	no	no	yes	yes	yes																
BA2113R	BA2113D	2088	Waves1+2	yes	yes	yes	yes	Female	Female	White	NON-HISPANIC	White	1			63	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	63	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	1	Decitabine	1	Induction	Unknown	Standard Chemotherapy	9	Standard Chemotherapy	Decitabine	Induction	9	Dead	25	Dead-Disease	1.8	41		0.9	0	79.6	0.9	14.2	0	21	19	2.7	0.98	M2	27.7	9.4	"45~46,XX,add(1)(q42),del(5)(q31q35),del(6)(q13),del(9)(q13q34),del(17)(p13),i(21)(q10)[cp12]/46~47,idem,+mar[cp6]/46,XX[2]"	404	88.5	"EGR1 (5q31): 73% of cells were missing a signal for EGR1 (5q31), consistent with the deletion seen on metaphase analysis.  TP53 (17p13.1): 71% of cells were missing a signal for TP53 (17p13.1), consistent with the deletion seen on metaphase analysis.  RUNX1 (21q22): 77% of cells had three signals fo"	6	FALSE	"CD13, dimCD33, CD34, CD38, CD58, partial CD64, CD117, CD123, and HLA-DR positive."	FALSE	TRUE	7.6	1.61	FALSE	negative	0	negative			TP53 (p.R248Q; 53.3%)	TP53 (p.R248Q; MAF 56%)|U2AF1 (p.Q157P; MAF 41%)	0.580979316	0.662405415	0.557571932	0.716008896	0.800779222	2.846780004	0.306508175	1.37173575	0.865752855	0.191882647			yes		yes	yes	Found	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	2.127913771	2.974501064	2.022587049	5.186215225	6.028194684	-2.335407551	4.002469856	no	no	no	yes	no	no	no																
BA2955R	BA2955D	2039	Waves1+2	yes	yes	yes	yes	Female	Female	White	NON-HISPANIC	White	1			66	TRUE	FALSE	TRUE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute monoblastic and monocytic leukaemia 	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute monoblastic and monocytic leukaemia 	66	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	3	Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Kinase Inhibitor(s)	4	"3+7 (Cytarabine, Daunorubicin), Bortezomib|MiDAC|Fludarabine, Cytarabine|Ibrutinib"	4	Allogeneic - Sibling|Consolidation|Induction|Maintenance	Refractory	Standard Chemotherapy	6	Targeted Therapy - Kinase Inhibitor(s)	Ibrutinib	Maintenance	382	Alive	2175	Alive	0	60	52	0	0.9	29.8	54.4	1.8	0.5	23	19	2.5	0.84	M5	24.2	7.7	"47,XX,+6[6]/46,XX[19]"	453	104.8	"IGH/MAF: 74/100 cells (74%) had variant abnormal 0-1 red/ 1-4 green/ 2-7 yellow signal patterns reflecting IGH/MAF fusion. The majority of cells (56%) were 0 red/ 1 green/ 3 yellow. IGH: 68/100 (68%) cells scored had signal patterns consistent with IGH rearrangement and the 14;16 translocation,above | CDKN2C/CKS1B: 61/100 cells (61%) had 3-6 CKS1B (1q21) signals and 2 CDKN2C signals, reflecting gain of 1q. | The IGH/CCND1 and IGH/FGFR3 probe sets had extra IGH signals reflecting IGH involvement in the 14;16 "	92	TRUE	"dimCD4, CD11b, CD13, dimCD14, CD33, CD56, CD58, CD64, dimCD123 and HLA-DR positive; Minor subset of blasts with immunophenotype: CD13, CD33, CD34, CD58, CD117, dimCD123, HLA-DR and MPO positive."	FALSE	TRUE	7.4	14.94	FALSE	positive	NA	negative	RUNX1 (p.P240Qfs*22; 40.0%)			"BCOR (p.G1659E MAF ~10%,)|FLT3-ITD (MAF 38%)|NRAS (p.Q61R MAF ~5%)|RUNX1 (p.P240fs*22; MAF 37%)|RUNX1 (splice site [at invariant AG (G>A) splice acceptor site at end of Intron 6];  MAF 36% ))"	0.733367642	0.561936871	0.682170856	1.08581199	0.509252674	2.482737184	0.254560483	1.502928991	0.581488198	-0.063206191					no		Found	FALSE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	TRUE	TRUE	FALSE	TRUE	TRUE	4.528023663	2.374829896	5.331375564	5.135490459	6.512059957	-2.767649574	2.702852354	yes	no	yes	yes	yes	no	no																
BA2089R	BA2089D	2080	Waves1+2	yes	yes	yes	yes	Male	Male	White	NON-HISPANIC	White	1			68	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	n		y	n	y	y	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	68	0	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Initial Diagnosis	Leukapheresis	y	y	y	y	y	y	1	Standard Chemotherapy	2	"3+7 (Cytarabine, Daunorubicin)|Azacitidine"	2	Induction|Maintenance	Refractory	Standard Chemotherapy	7	Standard Chemotherapy	"3+7 (Cytarabine, Daunorubicin)"	Induction	7	Dead	122	Dead-Unknown	0		83	0	0.8	8.1	9.8	1.6	0.7	29	137	3.3	2.67	M5	35.5	11.4	"46,XY[20]"	3615	92.4	normal	104	TRUE		NA	NA	6.4	140.18	TRUE	negative	0	negative		ASXL1 (p.G645Wfs*12; 60.0%)		ASXL1 (p.G645fs*12; MAF 52%)|IDH1 (p.R132L; MAF 47%)|KRAS (p.G12A; MAF 36%)|MLL (Partial tandem duplication )|SRSF2 (p.P95H; MAF 49%)	0.688649056	0.354180994	0.847682144	0.623817251	0.764914353	2.246347269	0.071266547	1.530836411	0.938388383	0.096653105		yes			yes	yes	Found	TRUE	FALSE	FALSE	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	FALSE	TRUE	TRUE	FALSE	1.543050372	2.197478723	2.638243536	3.05091544	6.230337807	-3.763766929	7.020524979	no	no	no	no	yes	no	yes																
BA2224R	BA2224D	2202	Waves1+2	yes	yes	yes	no	Male	Male	White	NON-HISPANIC	White	1			62	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	n		y	n	y	n	n	n	y	y	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	62	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	n	y	y	n	1	Standard Chemotherapy	2	Decitabine|Hydroxyurea	2	Induction|Re-induction	Complete Response i	Standard Chemotherapy	-1	Standard Chemotherapy	Hydroxyurea	Re-induction	263	Dead	424	Dead-Disease	0	21	2.5	1.7	0	68.3	1.7	25	0	22	9	3.2	0.81	M2	20.6	6.8	"46,XY,del(5)(q22q35),del(12)(q24.1q24.1),add(17)(p11.2)[19]/46,XY[1]"	NA	100.5	EGR1 (73.5%) ;  TP53: (85.5%)	174	TRUE	"CD7, CD34, CD117, HLA-DR, CD13, CD33, dim CD123, variable CD15 and subset MPO"	TRUE	TRUE	5.8	3.74	FALSE	negative	0	negative			TP53 (p.G266V; 65.7%)	JAK2 (p.V617F; MAF 1.5%)|SF3B1 (p.G742D; MAF 35%)|TP53 (p.G266V; MAF 55%)	0.622442946	0.773539222	0.67147729	0.689543016	0.909079442	2.894224202	0.394024546	1.370986366	0.925665277	0.369900566	yes				yes	yes	Found	FALSE	FALSE	FALSE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	TRUE	TRUE	5.060341068	6.274267782	3.12161169	7.243011976	6.38934322	-0.845075814	5.311827986	yes	yes	yes	yes	yes	yes	yes																
BA2046R	BA2046D	2265	Waves1+2	yes	yes	yes	no	Male	Male			White	2			61	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	"Acute myeloid leukaemia, NOS"	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	"Acute myeloid leukaemia, NOS"	61	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	n	y	y	n	1	Standard Chemotherapy	2	"7+3 (Cytarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)"	2	Induction|Re-induction	Complete Response	Standard Chemotherapy	-1	Standard Chemotherapy	"MEC (Cytarabine, Etoposide, Mitoxantrone)"	Re-induction	-1	Alive	496	Alive	0	45	48	2	NA	69	4	2	NA	12	15	3.8	NA		22.7	7.6	"46,XY[19]"	NA	NA	"nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1, RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[199]"	27	FALSE	"CD2(-), CD4(-), CD7(subset +), CD11b(-), CD13(+), CD14(-), CD15(partial dim +), CD16(-), CD33(-), CD34(+), CD36(-), CD38(variably +), CD45(moderately +), CD56(-), CD64(-), CD117(+), HLA-DR(+)."	TRUE	TRUE	6.8	1.39	FALSE	negative	0	negative	RUNX1 (N260fs*223+; MAF 26%)			IDH1 (R132C; MAF 42%)|NF1 (N935H; MAF 49%)|RUNX1 (N260fs*223+; MAF 26%)|SRSF2 (P95L; MAF 38%)	0.482140548	0.763326486	0.405727409	0.712339772	0.551554087	2.868711771	0.434198578	1.072470326	0.716557324	0.104721454		yes			yes		Found	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	TRUE	1.746092473	3.653113355	0.500949085	5.806944625	5.574126984	-1.199077939	0.92389842	no	yes	no	yes	no	no	no																
BA2972R	BA2972D	2111	Waves1+2	yes	yes	yes	yes	Male	Male	White	NON-HISPANIC	White	1	bi		40	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated CEBPA	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated CEBPA	40	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	3	"HiDAC|3+7 (Cytarabine, Daunorubicin)|Treo/Flu/TBI (Treosulfan, Fludarabine, Total Body Irradiation)"	3	Consolidation|Induction|Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	6	Bone Marrow Transplant	"Treo/Flu/TBI (Treosulfan, Fludarabine, Total Body Irradiation)"	Allogeneic - Matched Unrelated Donor	-1	Alive	2163	Alive	0	80	27.8	0	0	62.6	4.4	5.2	0	26	22	3.9	0.78	M1	37.6	13.2	"46,XY[20]"	NA	91.7	normal	66	FALSE	"dim CD7, CD13, CD33, CD34, CD38, partial CD56 (25%), CD58, dim CD64, CD117, dim CD123, HLA-DR, and MPO+."	TRUE	TRUE	7.4	2.68	FALSE	negative	0	negative				CEBPA (p.K313_V314insK; MAF 39%)|CEBPA (p.S28fs*81; MAF 28%)|ZRSR2 (p.R378W; VAF 100%)	0.508458302	0.689539597	0.464444547	0.787929664	0.715896824	2.857821692	0.055151782	1.245532494	1.026007492	-0.036787201				yes	yes		Found	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	TRUE	3.618031116	3.11268959	-0.161688881	4.651209228	4.591168879	-1.801268356	4.441539749	yes	no	no	yes	no	no	yes																
BA2426R	BA2426D	2511	Waves1+2	yes	yes	yes	no	Male	Male			White	5		CBFB-MYH11	62	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	y	Non-Hodgkins Lymphoma	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	62	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	n	y	y	n	1	Standard Chemotherapy	1	"7+3 (Cytarabine, Idarubicin)"	1	Induction	Complete Response	Standard Chemotherapy	-1	Standard Chemotherapy	"7+3 (Cytarabine, Idarubicin)"	Induction	-1	Alive	26	Alive	NA	50	20	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA		NA	NA	"46,XY,inv(16)(p13.1q22)[20]"	NA	NA	positive for rearrangement of CBFB in 60.5% of cells.	32	FALSE	"positive for CD13, CD33, HLA-DR, CD34, and CD117, with partial aberrant expression of CD7. (Peripheral blood) | positive for CD34, CD117, HLA-DR, CD13, and CD33 (Marrow)"	TRUE	TRUE	NA	52.8	TRUE	negative	0	negative				EZH2 (p.D146H; MAF 50%)	0.689177016	0.752568491	0.717556381	1.022854361	0.858934886	2.706575876	0.361925356	1.516046859	1.051229711	0.011058247					no		Found	FALSE	FALSE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	TRUE	TRUE	TRUE	2.051615298	1.575369363	2.376965905	3.419127662	5.879656655	-2.32040487	5.384709273	no	no	no	no	no	no	yes																
BA3004R	BA3004D	2420	Waves1+2	yes	yes	yes	yes	Female	Female	White	NON-HISPANIC	White	1			76	TRUE	FALSE	TRUE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	76	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	2	"5+2 (Cytarabine, Idarubicin)|Decitabine"	2	Induction|Re-induction	Refractory	Standard Chemotherapy	8	Standard Chemotherapy	"5+2 (Cytarabine, Idarubicin)"	Re-induction	4	Dead	26	Dead-Disease	0	95	54	0	0.9	16.8	3.5	24.8	1.1	23	22	3.5	1.33	M1	31.5	10.3	"46,XX[22]"	244	92.6	Normal	29	FALSE	"dimCD13, CD33, CD45, CD56, dimCD117 and MPO positive"	FALSE	TRUE	7	27.17	TRUE	positive	NA	positive				ASXL1 (p.G966delG; MAF 50%)|DNMT3A (p.R736H; MAF 45%)|FLT3-ITD (MAF 20%)|NPM1 (p.W288fs*12; MAF 35%)	0.53342152	0.68412956	0.634766532	0.463268063	0.813202076	2.917543472	0.354685833	1.29964288	0.875861093	0.165157184					no		Found	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	TRUE	TRUE	FALSE	FALSE	1.761844554	5.344339074	2.989978183	6.116335963	5.717556877	-1.789188955	2.712388767	no	yes	yes	yes	no	no	no																
BA3010R	BA3010D	2478	Waves1+2	yes	yes	yes	yes	Male	Male	White	NON-HISPANIC	White	6			71	TRUE	FALSE	FALSE	TRUE	FALSE	FALSE	y	Non-Hodgkins Lymphoma	y	n	y	y	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	71	0	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	1	Standard Chemotherapy	3	Vidaza|Rituximab|Decitabine	2	Consolidation|Maintenance			NA	Standard Chemotherapy	Decitabine	Maintenance	86	Dead	51	Dead-Disease	NA	20	10	1	NA	22	48	16	NA	6	33	3.7	1.57		26	8.1	"46,XY[20]"	NA	91.9		13	FALSE	"Positive for CD34, CD117, HLADR, CD33, CD13 but negative for CD14, CD64, CD11b, CD19, and CD3 (Peripheral Immunophenotyping) | The blasts are positive for CD34 and CD117 (Bone marrow Immunophenotyping)"	FALSE	TRUE	7	44.8	TRUE	negative	0	negative	RUNX1 (p.R320*; 40.9%)	ASXL1 (p.G646Wfs*12; 39.4%)		BCOR (p.A603pfs*66; MAF55%)|KRAS (p.G12V; MAF 49%)|RUNX1 (pR320*; MAF 47%)|SRSF2 (p.P95H; MAF 49%)|STAG2 (p.Y636*; MAF 96%)	0.579481893	0.681723599	0.71228376	0.942795562	0.903282993	2.606646722	0.240007026	1.494451399	1.060330618	0.278243635		yes			yes	yes	Found	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	TRUE	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	3.231321844	4.877972568	4.107911311	4.032176665	6.078619914	-1.883287015	6.23576327	yes	yes	yes	yes	yes	no	yes																
BA2394R	BA2394D	2381	Waves1+2	yes	yes	yes	yes	Male	Female;Male			White	3			73	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	y	Lung Cancer	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	73	0	Residual Disease|Post-Chemotherapy	Residual	Peripheral Blood	y	y	y	y	y	y	1	Standard Chemotherapy	1	Azacitidine	1	Hypomethylating/Low Dose Cytarabine			NA	Standard Chemotherapy	Azacitidine	Hypomethylating/Low Dose Cytarabine	7	Dead	36	Dead-Disease	NA		79	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA		NA	NA	"45,X,-Y[20]"	NA	NA	Normal	NA	NA		NA	NA	NA	19.64	FALSE	negative	0	negative	RUNX1 (c.319C>G; MAF 73.9%)	ASXL1 (c.1940dup; MAF 37.9%)		ASXL1 (c.1940dup; MAF 37.9%)|BCORL1 (c.3496dup: MAF 7.5%)|RUNX1 (c.319C>G; MAF 73.9%)|TET2 (c.3803+1G>A; MAF 39.3%)	0.651723676	0.872786554	0.801722147	0.75330968	0.623727913	2.739874931	0.581424331	1.425880158	0.615363004	-0.009458828					no		Found	FALSE	TRUE	FALSE	FALSE	NA	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	TRUE	FALSE	4.337147741	2.350741185	1.30967693	3.424053486	7.54733362	-1.797092471	2.08727892	yes	no	no	no	yes	no	no																
BA2109R	BA2109D	2251	Waves1+2	yes	yes	yes	yes	Female	Female	White	NON-HISPANIC	White	1			52	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myelomonocytic leukaemia	MissingKaryo	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myelomonocytic leukaemia	52	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	1	Standard Chemotherapy	2	"7+3 (Cytarabine, Idarubicin)|HiDAC"	2	Consolidation|Induction	Complete Response	Standard Chemotherapy	8	Standard Chemotherapy	HiDAC	Consolidation	81	Dead	585	Dead-Disease	0			30	13	9	21	19	0.1	54	50	2.2	0.84	M4	18.8	6.5		NA	98.9		21	TRUE		NA	NA	6.5	65.58	TRUE	negative	0	negative				NOTCH1 (p.K2181R ; MAF 50%)|SRSF2 (p.P95H ; MAF 50%)	0.862974227	0.407641546	0.893404641	0.79051564	1.012559769	2.352943823	0.029768581	1.515941507	1.120763107	0.302812815		yes			yes		Found	FALSE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	TRUE	TRUE	TRUE	4.414961877	6.561707	5.278283722	2.71568991	6.678377848	0.824641148	6.810861641	yes	yes	yes	no	yes	yes	yes																
BA2132R	BA2132D	2140	Waves1+2	yes	yes	yes	yes	Female	Female			White	6			70	TRUE	FALSE	TRUE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	"Acute myeloid leukaemia, NOS"	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	"Acute myeloid leukaemia, NOS"	70	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	1	Standard Chemotherapy	1	Azacitidine	1	Induction	Unknown	Standard Chemotherapy	37	Standard Chemotherapy	Azacitidine	Induction	37	Alive	37	Alive	NA	90	17	NA	NA	20	18	2	NA	24	26	3.8	0.76		25	8.2	"46,XX,del(5)(q22q35)[20]"	NA	87.7	Positive for 5q deletion in 91% of cells.	35	TRUE	"POSITIVE FOR CD34, HLA-DR, CD117 AND CD33, AND NEGATIVE FOR MPO, TdT, CD13, CD19, CD20 AND CD10. (Bone Marrow Immunophenotyping)"	FALSE	TRUE	6.2	7.7	FALSE	positive	0.333333333	negative				FLT3-ITD|MLL |U2AF1 (p.S34F; MAF 35%)	0.680999683	0.85949647	0.724025569	0.969192779	0.752934944	2.926286887	0.340833761	1.427681567	0.730548739	-0.019559419			yes		yes		Found	FALSE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	TRUE	FALSE	TRUE	TRUE	3.986494596	4.397367075	4.566214579	5.587977067	5.542826655	1.343606903	4.174488059	yes	yes	yes	yes	no	yes	no																
BA2846R	BA2846D	2004	Waves1+2	yes	yes	yes	no	Male	Male	White	NON-HISPANIC	White	1			75	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	y	Rectal Cancer	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	75	0	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Initial Diagnosis	Bone Marrow Aspirate	y	y	n	y	y	n	1	Supportive/Palliative Care	2	Hydroxyurea|Decitabine	1	Supportive/Palliative Care			NA	Supportive/Palliative Care	Decitabine	Supportive/Palliative Care	4	Dead	17	Dead-Disease	0	90	90	0	0	5.1	0.8	0.9	1	23	51	2.9	0.97	M1	25.3	8.5	"46,XY[20]"	728	91.3	Normal	28	FALSE	"CD33, dim CD38, variable CD56, CD58, dim CD64, CD117, CD123, and MPO positive."	FALSE	TRUE	6.6	62.87	TRUE	negative	0	positive				IDH2 (p.R140Q; MAF 47%)|NPM1 (p.W288fs*12 (4 nt insertion with frameshift); MAF 17%)|SRSF2 (p.P95L; MAF 37%)	0.43069121	0.650445038	0.517751175	0.643923556	0.817785057	2.874510075	0.208553456	1.273292278	0.777498942	-0.124997296		yes			yes		Found	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	1.470181328	2.21458395	-0.342203265	3.965479708	4.683098974	0.839553071	0.011641161	no	no	no	yes	no	yes	no																
BA2885R	BA2885D	2139	Waves1+2	yes	yes	yes	yes	Female	Female	White	NON-HISPANIC	White	1			81	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	y	Skin cancer	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	81	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	1	Azacitidine	1	Induction	Unknown	Standard Chemotherapy	6	Standard Chemotherapy	Azacitidine	Induction	6	Dead	14	Dead-Disease	0	90	70	0	0.8	6.1	72.2	12.2	0.4	62	50	2.9	4.22	M5	22.8	7.3	"46,XX[20]"	262	90.8	Normal	29	TRUE	"CD11b, variable CD13, variable CD14, CD33, CD56, CD64, dim CD123 and dim HLA-DR positive"	FALSE	TRUE	5.8	97.26	TRUE	negative	0	positive		ASXL1 (p.G645Vfs*58; 16.7%)		ASXL1 (p.W796fs*22; MAF 48%)|NPM1 (p.W288fs*12; MAF 40%)|TET2 (p.S825fs*1; MAF 49%)	0.74453358	0.216067496	0.865696291	0.738239031	1.109124687	2.259350834	-0.170486313	1.534846787	0.831175001	0.158779907					no		Found	FALSE	TRUE	FALSE	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	FALSE	TRUE	TRUE	FALSE	3.177838623	3.842193862	2.925454618	1.972594566	6.839193485	-0.346863898	4.241980745	yes	yes	yes	no	yes	yes	no																
BA3322R	BA3322D	2009	Waves3+4	no	no	no	no	Male	Male	White	NON-HISPANIC		1			62	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML without maturation	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML without maturation	63	487	Post-Chemotherapy	Remission	Bone Marrow Aspirate	y	y	n	y	y	n	1	Standard Chemotherapy	3	"5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|Azacitidine"	2	Induction|Re-induction	Refractory	Standard Chemotherapy	7	Standard Chemotherapy	Azacitidine	Re-induction	-1	Dead	581	Dead-Unknown	1.1	2		0.4	0.7	55.7	4.3	37.8	1.1	31	18	3.5	NA	M1	36.6	12.2	" 46,XY[20)"	NA	90.4		240	TRUE	"CD5, CD19, CD20 and dim surface kappa light chain + "	FALSE	FALSE	7.4	2.8	FALSE	negative	0	negative	RUNX1 (p.E223*; MAF 1%)	ASXL1 (p.S1028*; MAF 14%)		ASXL1 (p.S1028*; MAF 14%)|BCOR (p.Y1350*; MAF 6%)|FBXW7 (p.T15_G16insP; MAF 49%)|FLT3|RUNX1 (p.E223*; MAF 1%)	0.697063323	0.343570193	0.746239609	0.681823902	0.792600099	2.383993219	-0.032358435	1.389802352	0.950770171	0.472522618					no		Found	FALSE	FALSE	FALSE	FALSE	TRUE	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	TRUE	TRUE	5.100726813	6.694658781	3.519358737	8.362662152	7.118172349	-2.183717161	5.194507623	yes	yes	yes	yes	yes	no	yes																
BA2174R	BA2174D	2341	Waves1+2	yes	yes	yes	yes	Female	Female	White	NON-HISPANIC	Asian	1			46	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	y	Anaplastic Astrocytoma	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	46	0	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	7	"7+3 (Cytarabine, Idarubicin)|HAM (Cytarabine, Mitoxantrone)|Azacitidine|Hydroxyurea|Decitabine|ME (Etoposide, Mitoxantrone)|Fludarabine, Melphalan, ATG"	4	Consolidation|Induction|Re-induction|Double Umbilical Cord Blood Transplant (DUCBT)	Refractory	Standard Chemotherapy	1	Bone Marrow Transplant	"Fludarabine, Melphalan, ATG"	Double Umbilical Cord Blood Transplant (DUCBT)	-1	Dead	637	Dead-Disease	0.9	25	16	1.7	4.3	6.1	32.2	48.7	0.2	14	15	3.1	0.64		32	9.5	"46,XX,del(3)(p25),add(6)(p22),t(10;12)(p15;q13)[5]/46,XX[18]"	440	80.6	Normal	92	TRUE	"Immunophenotype: CD13, CD34, CD38, CD58, CD117, CD123, HLA-DR and TdT-positive; small subset of blasts also express CD19, CD22, and CD79a"	TRUE	FALSE	6.8	42.57	TRUE	negative	0	negative				DNMT3A (p.I824V; VAF 50%)|GATA1 (p.S412R; MAF 60%)|NRAS (p.G13R; MAF 50%)|RUNX1 (p.T196I ; MAF 50%)|U2AF1 (p.I24T; MAF 5%)	0.760881421	0.707509197	0.842091223	1.001913113	0.905891315	2.726342893	0.213518255	1.509529501	0.998152115	0.401352219			yes		yes		Found	FALSE	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	FALSE	TRUE	FALSE	TRUE	TRUE	TRUE	4.650152755	6.12052955	4.579773911	3.406263516	6.88614747	-1.273558253	7.54856624	yes	yes	yes	no	yes	no	yes																
BA2311R	BA2311D	2222	Waves1+2	yes	yes	yes	yes	Female	Female		HISPANIC	HispNative	2			53	TRUE	FALSE	TRUE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myelomonocytic leukaemia	Intermediate	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myelomonocytic leukaemia	53	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	3	Standard Chemotherapy|Bone Marrow Transplant|Supportive/Palliative Care	4	"7+3 (Cytarabine, Idarubicin)|HiDAC|Cyclophosphamide|Fludarabine, Cyclophosphamide, TBI "	4	Consolidation|Induction|Allogeneic - Child|Maintenance	Complete Response	Standard Chemotherapy	-1	Supportive/Palliative Care	Cyclophosphamide	Maintenance	1	Alive	653	Alive	0	20	8	0	NA	37	20	30	NA	18	23	3.3	0.86	M4	20	6.2	"46,XX[20]"	426	105.3	"nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1, RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]"	38	FALSE	"CD34(+), CD13(dim +), CD15(partial +), CD33(dim to partial +), CD34(+), CD38(variably +), CD45(dim +), CD56(-), CD64 (small subset +), CD117(+), HLA-DR(partial +), other myeloid and lymphoid antigens(-)."	FALSE	TRUE	7	6.63	FALSE	negative	0	negative				IDH2 (R140Q; MAF 51.0%)|KMT2A (Foundation; MLL-PTD exons 2-10)|PAX5 (V26G; MAF 1.0%)|SRSF2 (R94_S101DEL; MAF 40.0%)	0.786976771	0.477876386	0.876596886	1.060073253	0.864784417	2.559663685	0.10453615	1.536915272	0.785263779	0.311179713		yes			yes		Found	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	TRUE	FALSE	4.032569117	5.486858128	3.368217022	4.413131336	6.972507264	-1.098384096	5.877330099	yes	yes	yes	yes	yes	no	yes																
BA2821R	BA2821D	2145	Waves1+2	yes	yes	yes	yes	Female	Female	White	NON-HISPANIC	White	1			37	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	"Acute myeloid leukaemia, NOS"	Intermediate	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	"Acute myeloid leukaemia, NOS"	37	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	4	"HiDAC|3+7 (Cytarabine, Daunorubicin)|Azacitidine|Hydroxyurea"	4	Hypomethylating/Low Dose Cytarabine|Consolidation|Induction|Re-induction	Refractory	Standard Chemotherapy	8	Standard Chemotherapy	Azacitidine	Consolidation	-1	Dead	542	Dead-Disease	1.7	95	74	2.5	0.8	13.6	14.4	10.2	0.4	23	14	3.1	0.46	M0/M1	27.9	9.2	"46,XX[20]"	NA	89.4	Normal	49	TRUE	"variable CD11b, CD13, dim CD19, dim CD33, CD34, variable CD64, CD117, CD123, and HLA-DR"	FALSE	TRUE	7	26.57	TRUE	negative	0	negative				ASXL1 (p.A1312V; MAF 50%)|KRAS (p.K117N; MAF 48%)|WT1 (p.L378P; MAF 48%)|WT1 (p.R380fs*69 (1 bp deletion with frameshift); MAF 48%)	0.456051412	0.790737721	0.657224507	0.819257374	0.859107958	2.919975022	0.070614821	1.329765869	0.904150488	0.048723036					no		Found	FALSE	FALSE	FALSE	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	1.538021511	2.279702339	1.713581132	1.618024569	5.214325428	-3.932857166	5.325945105	no	no	no	no	no	no	yes																
BA2233R	BA2233D	2316	Waves1+2	yes	yes	yes	yes	Male	Male	White		White	4			72	TRUE	FALSE	TRUE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	72	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	2	CPX-351 (Liposomal Cytarabine + Daunorubicin)|Hydroxyurea	1	Induction	Complete Response	Standard Chemotherapy	-1	Standard Chemotherapy	CPX-351 (Liposomal Cytarabine + Daunorubicin)	Induction	-1	Alive	95	Alive	NA	97	96	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	M1	NA	NA	"46,XY[5]"	NA	NA	"D5S721, EGR1 Êdel(5q)/monosomy 5, D7Z1, D7S522  del(7q)/monosomy 7, D8Z2 trisomy #8, D20S108, 20qter del(20q)   "	NA	NA	"CD117, MPO,CD38(PARTIAL), CD33(DIM) AND NOT EXPRESSING CD34 AND HLA-DR"	FALSE	TRUE	NA	125.9	TRUE	negative	0	positive				"FLT3 (p.D839G; MAF~45%)|IDH2 (p.R140L; MAF ~50%)|MLL2 (p.V2338I; MAF ~50%)|NPM1 (p.W288fs*12;MAF ~35%)|SRSF2 (p.P95H, MAF~55%)"	0.273197102	0.654577131	0.302874651	0.379510965	0.796482234	2.970911069	0.274784385	1.011536116	0.725288983	-0.238959063		yes			yes		Found	TRUE	FALSE	FALSE	FALSE	NA	FALSE	FALSE	FALSE	FALSE	FALSE	TRUE	FALSE	TRUE	1.617109534	2.273772977	-0.899929858	3.731965881	4.141343766	-1.039441945	0.332971491	no	no	no	no	no	no	no																
BA2880R	BA2880D	2568	Waves1+2	yes	yes	yes	yes	Male	Male	White	NON-HISPANIC	White	5			85	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	y	Not specified	n	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Myeloid sarcoma	Intermediate	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Myeloid sarcoma	85	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	0		0		0				NA	NONE	NONE	NONE	NA	Alive	34	Alive	1.5	2		24	NA	11.5	8	55	NA	4	8	3.7	1.2		48.8	16.1	"46,XY[20]"	NA	NA	Normal	141	TRUE		NA	NA	6.3	11.4	FALSE	negative	0	negative				EZH2 (c.436G>C; p.D146H)|TET2 (c.5182G>T; p.E1728X)	0.698381349	0.389520442	0.854602318	0.768492429	0.973208684	2.450090653	-0.1098574	1.467793709	1.052174796	0.567269398					no		Found	FALSE	TRUE	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	TRUE	TRUE	5.634367702	7.299680564	5.272497823	5.194136031	7.438268726	1.854032931	7.356734551	yes	yes	yes	yes	yes	yes	yes																
BA2133R	BA2133D	2383	Waves1+2	no	no	no	no	Female	Female	White		White	6			73	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	y	Breast Cancer	y	n	n	n	n	n	y	y	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	73	0	Post-Chemotherapy	Remission	Peripheral Blood	y	y	y	y	y	y	2	Standard Chemotherapy|Targeted Therapy - Other	4	Ruxolitinib|AG-221|Cytarabine|Azacitidine	4	Induction|Experimental|Maintenance|Supportive/Palliative Care	Complete Response	Standard Chemotherapy	90	Standard Chemotherapy	Cytarabine	Supportive/Palliative Care	8	Dead	560	Dead-Unknown	NA			0.5	NA	39.2	7.5	52.5	NA	10	21	4.5	0.87		34.1	10.9		NA	92.4		6	FALSE		NA	NA	7.6	3.8	FALSE	negative	0	positive				IDH2 (p.R140Q; MAF 32%)|JAK2 (p.V617F; MAF 30%)|NPM1 (p.W288Cfs*12; MAF 35%)|SRSF2 (p.R94dup; MAF 31%)|WT1 (p.R440Tfs*14; MAF 29%)	0.872616375	0.419738918	0.83236604	0.807658445	0.675730658	2.284856923	0.097166875	1.45889893	0.578811085	0.13947715		yes			yes		Found	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	TRUE	TRUE	5.397803331	9.247041739	2.786952278	5.998072506	8.023245235	1.192150153	4.414601973	yes	yes	yes	yes	yes	yes	yes																
BA2212R	BA2212D	2035	Waves1+2	yes	yes	yes	yes	Male	Male	Asian		Asian	2			75	TRUE	FALSE	FALSE	TRUE	FALSE	FALSE	n		y	n	y	y	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	75	0	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	3	"Vidaza|Decitabine|Fludarabine, Cytarabine"	2	Salvage|Supportive/Palliative Care			NA	Standard Chemotherapy	"Fludarabine, Cytarabine"	Salvage	-1	Dead	159	Dead-Disease	0	27	2	0	NA	60.2	8.4	29.4	NA	12	15	4.8	0.98		30.7	9.3	"46,XY,t(1;12)(p32;p13)[3]/46,XY[17]"	215	NA	"nuc ish(D5S2064,D5S630,EGR1)x2[197],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[194],(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[199],(PML,RARA)x2[199],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[198]"	121	TRUE	"CD2(-), CD4(-),CD7(-), CD10(partial +), CD11b(-), CD13(dim +), CD14(-), CD38(variably +/small subset -), CD45(dim to moderately +), CD56(-), CD64(-), CD117(variably +), HLA-DR(variably +). | Population #2 (0.48% of total events) comprises small cells with the following immunophenotype: CD5(- to partial dim +),CD10(-), CD19(slighty bright +), CD20(bright +), CD38(-), CD45(+), kappa(-), lambda(dim +)."	TRUE	FALSE	7.5	3.09	FALSE	negative	0	negative		ASXL1 (p.G646Wfs*12; 39.3%)		ASXL1 (G646fs*12; MAF 37.0%)|BCOR (S1608*; MAF 3.0%)|KRAS (G12R; MAF 5.0%)|STAG2 (Q932fs*6; MAF 91.0%)|SUZ12 (E601fs*10; MAF 38.0%)|TET2 (C127fs*92; MAF 6.0%)|TET2 (S1870*; MAF 45.0%)	0.589081697	0.777629973	0.650253986	0.74818657	0.939217388	2.862062161	0.319494327	1.328608693	1.054760472	0.401776687					no		Found	FALSE	TRUE	FALSE	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	TRUE	-0.054271382	5.085166296	4.37379318	3.634576735	4.359065242	-1.987265845	6.025763653	no	yes	yes	no	no	no	yes																
BA2685R	BA2685D	2266	Waves1+2	yes	yes	yes	no	Male	Male			White	6			67	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	y	Not specified	y	n	y	y	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	67	0	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Initial Diagnosis	Bone Marrow Aspirate	y	y	n	y	y	n	1	Standard Chemotherapy	4	"Vidaza|Cytarabine|3+7 (Cytarabine, Daunorubicin)|Decitabine"	4	Consolidation|Salvage|Induction|Supportive/Palliative Care	Complete Response	Standard Chemotherapy	8	Standard Chemotherapy	Decitabine	Salvage	83	Dead	230	Dead-Unknown	NA	60		NA	NA	NA	0	NA	NA	NA	NA	NA	NA		NA	NA	"46, XY, del (3) (q12q21) [2]/47, idem, +8[11]/47, idem, der (15) t (1;15) (q21;p11.2) [7]"	NA	NA	Trisomy 8 is detected in 28% of cells.	NA	NA	"Positive for CD34, CD117, HLADR, CD33, CD13 and Negative for CD11b and CD64 (Bone Marrow Immunophenotyping)"	FALSE	TRUE	NA	NA	NA	negative	0	negative		ASXL1 (p.G646Wfs*12; 28.0%)		BCOR (p.KB39Qfs*5; MAF 45%)|KIT (p.T916A; MAF 50%)|NRAS (p.G12A; MAF 24%)|SRSF2 (p.P95R; MAF 40%)	0.52871349	0.741996527	0.519364384	0.459212535	0.853548795	2.718059447	0.250382708	1.156842183	1.073007987	0.315752824		yes			yes	yes	Found	FALSE	FALSE	FALSE	FALSE	NA	FALSE	TRUE	FALSE	FALSE	FALSE	NA	FALSE	TRUE	1.142242428	5.268147981	3.555177543	4.757286868	5.284347448	-0.452652967	5.519507027	no	yes	yes	yes	no	yes	yes																
BA2273R	BA2273D	2544	Waves1+2	yes	yes	yes	no	Male	Male			White	6			67	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	n		y	n	n	n	n	n	y	y	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	"Acute myeloid leukaemia, NOS"	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	"Acute myeloid leukaemia, NOS"	67	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	n	y	y	n	1	Standard Chemotherapy	2	"Cytarabine|3+7 (Cytarabine, Daunorubicin)"	2	Consolidation|Induction	Complete Response	Standard Chemotherapy	7	Standard Chemotherapy	Cytarabine	Consolidation	35	Dead	165	Dead-Unknown	NA	80	10	2	NA	68	4	8	NA	8	10	3.9	0.85		21.2	7.2	"46,XY[20]"	NA	110.4	The translocations commonly seen in AML are not detected. Loss of RARA and CBFB genes are detected in 14-39% of cells.	84	FALSE	"These are positive for CD34, CD117, HLADR, CD33, CD13, CD14 and CD11b. (Bone Marrow Immunophenotyping)"	FALSE	TRUE	5.9	0.9	FALSE	negative	0	negative			TP53 (p.Y220C; 42.0%)	BCOR (MAF 49%)|IDH1 (p.R132C MAF 12%)|JAK2 (p.V617F; MAF 43%)|MLL |NF1 (MAF 18%)|TP53 (p.Y220C; MAF 35%)	0.603377612	0.818015712	0.496764667	0.602271025	0.717172358	2.945516031	0.329426284	1.140528526	0.941215274	0.189181834					no		Found	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	TRUE	TRUE	2.360639815	2.685933155	3.915315683	4.815490798	4.53948778	-4.259329304	1.547916899	no	no	yes	yes	no	no	no																
BA2659R	BA2659D	2057	Waves1+2	yes	yes	yes	yes	Male	Male	White	NON-HISPANIC	White	1	mono		86	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	86	0	Residual Disease	Residual	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Targeted Therapy - Other	3	AG-221|Azacitidine|Hydroxyurea	3	Hypomethylating/Low Dose Cytarabine|Consolidation|Experimental			NA	Standard Chemotherapy	Hydroxyurea	Consolidation	55	Dead	596	Dead-Disease	0	23		0	0.8	8.6	19	59.5	0	16	15	3.4	1.52		27.8	9	"47,XY,+8[20]"	398	97.5	"(FISH) was performed with a chromosome 8 probe, listed below. 95/100 (95%) interphase cells scored had three signals, consistent with trisomy 8 and the metaphase karyotype. "	299	TRUE	"dimCD7, CD13, dimCD14, dimCD20, CD33, CD34, CD117, CD123, dim HLA-DR and MPO positive"	TRUE	TRUE	7.6	10	FALSE	negative	0	negative				BCOR (p.S1139*; MAF 80%)|CEBPA (p.R343fs*79; MAF 40%)|DNMT3A (p.E285*; MAF 45%)|DNMT3A (p.G707fs*72; MAF 45%)|IDH2 (p.R140Q; MAF 40%)|SRSF2 (p.P95H; MAF 40%)	0.711824864	0.727555373	0.840517711	0.761532928	0.949208212	2.821030358	0.163756462	1.494984452	1.133564985	0.436054668		yes			yes	yes	Found	TRUE	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	TRUE	TRUE	1.236826765	6.12729526	4.349464211	4.250005997	6.66836925	1.701306886	6.872750383	no	yes	yes	yes	yes	yes	yes																
BA2124R	BA2124D	2310	Waves1+2	yes	yes	yes	yes	Male	Male			White	3			67	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	y	Skin cancer	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	67	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	2	"7+3 (Cytarabine, Idarubicin)|IDAC"	2	Consolidation|Induction	Complete Response	Standard Chemotherapy	-1	Standard Chemotherapy	IDAC	Consolidation	-1	Alive	579	Alive	NA	71.5	56	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA		NA	NA	"46,XY[20]"	NA	NA	Normal	NA	NA	"CD33, CD38, CD56, CD117, and myeloperoxidase"	FALSE	TRUE	NA	16.24	FALSE	negative	0	positive				NPM1 (p.Trp288fs; MAF 16.4%)|TET2 (p.Leu1081fs; MAF 42.3%)|TET2 (p.Leu1780fs; MAF 46.3%)|ZRSR2 (p.Arg126*; MAF 97.7%)	0.262758871	0.430654503	0.500013387	0.264159369	0.981984125	2.878906987	-0.0586875	1.215297684	0.935165789	0.056264684				yes	yes		Found	FALSE	TRUE	FALSE	FALSE	NA	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	1.403935493	2.882795628	0.600021705	2.611627168	4.185154904	0.246524714	1.210297225	no	no	no	no	no	yes	no																
BA2746R	BA2746D	2522	Waves1+2	yes	yes	yes	yes	Female	Female		HISPANIC	HispNative	5			56	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	56	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	4	"7+3 (Cytarabine, Idarubicin)|HiDAC|GCLAC (GCSF, Clofarabine & Cytarabine)|Fludarabine, Cyclophosphamide, Thiotepa, TBI"	4	Consolidation|Salvage|Induction|Double Umbilical Cord Blood Transplant (DUCBT)	Complete Response	Standard Chemotherapy	27	Standard Chemotherapy	"GCLAC (GCSF, Clofarabine & Cytarabine)"	Salvage	-1	Dead	323	Dead-Disease	0	1.5	2	0	NA	23	57	13	NA	67	33	3	1.87		29	9.5	"46,XX[19]"	NA	NA	Normal	28	FALSE	"Positive (\Approximately 55% of assayed cells are an abnormal population of immature monocytic cells (consistent with monoblasts and promonocytes). Approximately 30% of assayed cells are mature monocytes. Both the immature and mature monocytic cells show uniform aberrant expression of CD56. A small population of myeloblasts (CD117+/CD34neg) is present, accounting for less than 5% of assayed cells.)\\"	FALSE	FALSE	7.5	58.7	TRUE	"positive\"""""	NA	NA	NA	NA	NA		Not_HSC_Like		Promono_Like	cDC_Like	0.738604804	n	0.738604804	0.457231821	0.876222948	1.013392825	0.111111111	positive				ASXL1 (c.1954G>A; p.G652S)|DNMT3A (c.2644C>T; p.R882C)|FLT3 (c.2503G>T; p.D835Y)|FLT3-ITD (FLT3-ITD 21 bp insertion)|NPM1 (c.859_860insTCTG; p.W288fs)					no		Found	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	TRUE	TRUE	TRUE	TRUE	2.101386714	2.772192643	2.622837124	3.943512255	6.506985455	-0.894523655	5.456367319	no											2.526480338	-0.016161458	1.562163126	0.868451453	n	0.096665804
BA2798R	BA2798D	2395	Waves1+2	yes	yes	yes	no	Male	Male	White		White	6	N/A		71	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	n		y	n	n	n	n	n	y	y	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	"Acute myeloid leukaemia, NOS"	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	"Acute myeloid leukaemia, NOS"	71	0	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Initial Diagnosis	Bone Marrow Aspirate	y	y	n	y	y	n	2	Standard Chemotherapy|Targeted Therapy - Other	5	"AG-120|KB004|Lenalidomide|Venetoclax (ABT-199), Azacitidine|Decitabine"	4	Salvage|Induction|Experimental|Maintenance	Refractory	Standard Chemotherapy	32	Standard Chemotherapy	"Venetoclax (ABT-199), Azacitidine"	Salvage	77	Dead	548	Dead-Unknown	NA	75	26	2	NA	15	8	43	NA	118	53	3.8	1.26		22.9	7.7	"46,XY,del(7)(q32),add(13)(p11.2)[15]"	NA	81.8	"This test has detected 7q deletion and an abnormal chromosome 13 in all 15 metaphase cells analyzed. 7q deletion is the most cp,,om abnormality in MDS and other types of myeloid malignancies."	24	TRUE	"These are positive for CD34, CD117, HLADR, CD33 and CD13 (Bone Mrrow Immunophenotyping)"	FALSE	TRUE	8.7	5	FALSE	negative	0	negative	RUNX1 (p.G408Vfs*193; 34.8%)	ASXL1 (p.Q428*; 43.9%)		ASXL1 (p.Q428*; MAF 44%)|CEBPA (p.A4S; MAF 47%)|IDH1 (p.R132C; MAF 45%)|JAK2 (p.V617F; MAF 57%)|MLL |RUNX1 (p.G406Vfs*193; MAF 39%)|TET2 (p.R1366S; MAF 40%)	0.647899325	0.820739623	0.655211118	0.711356431	0.800440571	2.76351504	0.436051092	1.263600665	1.017181447	0.099061139					no		Found	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	TRUE	TRUE	2.4904206	4.371994177	2.569227321	5.165316956	6.043172961	-0.349152177	4.540203293	no	yes	no	yes	no	yes	yes																
BA2801R	BA2801D	2146	Waves1+2	no	no	no	no	Male	Male		NON-HISPANIC	White	6			72	TRUE	FALSE	FALSE	FALSE	TRUE	FALSE	y	Lung Cancer	y	n	y	n	n	n	n	n	MYELODYSPLASTIC SYNDROMES	"Myelodysplastic syndrome, unclassifiable"	NonAML	MYELODYSPLASTIC SYNDROMES	"Myelodysplastic syndrome, unclassifiable"	73	0	Residual Disease		Peripheral Blood	y	y	y	y	y	y	1	Standard Chemotherapy	1	Vidaza	1	Supportive/Palliative Care			NA	Standard Chemotherapy	Vidaza	Supportive/Palliative Care	268	Dead	292	Dead-Unknown	NA		4	1	NA	13	5	23	NA	13	57	2.5	1.83		25	8.2		NA	105.9		32	TRUE		NA	NA	5.8	66.7	TRUE	negative	NA	negative	RUNX1 (p.S322Nfs*277; 44.4%)	ASXL1 (p.R693*; 38.7%)		"ASXL1 (p.R693* MAF 48%)|EZH2 (p.1131T, MAF 71%)|EZH2 (p.C565R MAF 27%)|JAK2 (p.V617F, MAF 26%)|KRAS (p.Q61P, MAF 13%)|RUNX1 (p.S322Nfs*277, MAF 42%)|TET2 (p.Q1813*, MAF 51%)|TET2 (p.Q866Rfs*14, MAF 39%)|ZRSR2 (p.R295*, MAF 97%)"	0.740005187	0.583133064	0.816492537	0.556530681	1.007854164	2.484681033	0.106748821	1.391061163	1.175808986	0.408500169				yes	yes		Found	FALSE	TRUE	FALSE	FALSE	TRUE	FALSE	TRUE	FALSE	TRUE	FALSE	TRUE	TRUE	FALSE	7.165478419	7.406090488	6.051098104	-0.720294248	6.92625028	1.26748234	6.203141395	yes	yes	yes	no	yes	yes	yes																
BA3030R	BA3030D	2046	Waves1+2	no	no	no	no	Female	Female	Unknown	UNKNOWN	White	1			70	FALSE	FALSE	FALSE	FALSE	TRUE	FALSE	n		n	n	n	n	y	n	n	n	MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASMS	"Atypical chronic myeloid leukaemia, BCR-ABL1 negative"	NonAML	MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASMS	"Atypical chronic myeloid leukaemia, BCR-ABL1 negative"	70	0	Unknown		Bone Marrow Aspirate	y	y	y	y	y	y	1	Targeted Therapy - Kinase Inhibitor(s)	1	Hydroxyurea	1	Induction	Unknown	Targeted Therapy - Kinase Inhibitor(s)	-1	Targeted Therapy - Kinase Inhibitor(s)	Hydroxyurea	Induction	-1	Dead	33	Dead-Disease	1.6	13	6.8	0.8	0	5.7	2.5	72.1	5.7	24	36	2.9	0.95		29.1	8.9	"46,XX[20]"	953	105.1	Normal	208	TRUE	"CD13, CD33, CD34, partial CD117, CD123, HLA-DR"	FALSE	TRUE	6.7	109.77	TRUE	positive	0.428571429	negative				FLT3-ITD (MAF 45%)|IKZF1 (p.N159S ; MAF 45%)|SF3B1 (p.K666N ; MAF 45%)	0.617247039	0.798706073	0.712467287	0.626252214	0.887845732	2.781318441	0.194935304	1.277720393	1.063362925	0.454337541	yes				yes		Found	FALSE	FALSE	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	TRUE	TRUE	TRUE	FALSE	5.106296016	7.021254246	1.914616164	2.908910573	7.060209939	2.151148373	7.054988955	yes	yes	no	no	yes	yes	yes																
BA2528R	BA2528D	2531	Waves1+2	yes	yes	yes	no	Male	Male	Declined	NON-HISPANIC	White	1			75	TRUE	FALSE	TRUE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with maturation	Intermediate	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with maturation	75	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	n	y	y	n	1	Standard Chemotherapy	2	"7+3 (Cytarabine, Idarubicin)|Azacitidine"	3	Induction|Frontline|Maintenance	Refractory	Standard Chemotherapy	7	Standard Chemotherapy	Azacitidine	Maintenance	-1	Alive	1936	Alive	0	23	rare	1	NA	51	11.2	36.8	NA	23	16	3.4	0.55	M2	27.1	9.1	"46,XY[19]"	178	88	Normal	28	FALSE	"CD13, CD33, CD34, CD38, CD117, CD123, dim HLA-DR, TdT, and MPO positive"	FALSE	TRUE	6.4	1	FALSE	negative	0	negative				DNMT3A (p.R882H; MAF 41%)|SF3B1 (p.K700E; MAF 43%)	0.58000844	0.658019646	0.701858261	0.585146988	0.916861573	2.773947564	0.107371614	1.367663234	1.014653876	0.37878597	yes				yes		Found	FALSE	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	TRUE	2.207866474	5.251435933	1.863751888	5.930389564	6.06971778	-1.160989408	6.804250513	no	yes	no	yes	yes	no	yes																
BA2306R		2085	Waves1+2	yes	no	yes	yes	Male	Male	Black		AdmixedBlack	6		RUNX1-RUNX1T1	50	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with t(8;21)(q22;q22); RUNX1-RUNX1T1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with t(8;21)(q22;q22); RUNX1-RUNX1T1	50	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	n	y	y	n	y	1	Standard Chemotherapy	2	"HiDAC|3+7 (Cytarabine, Daunorubicin)"	2	Consolidation|Induction	Refractory	Standard Chemotherapy	20	Standard Chemotherapy	HiDAC	Consolidation	182	Alive	424	Alive	NA	70	91	0	NA	7	2	0	NA	23	25	2.4	0.66		26.6	8.7	"46,XY,t(8;21)(q22;q22)[20]"	NA	94.7		28	TRUE		NA	NA	6.3	71.1	TRUE	negative	0	negative				"ASXL1 (p.P581R, MAF 46%)|PDGFRB (p.D111N, MAF 52%)|SMC1A (p.R586Q, MAF 96%)"	0.395638552	0.56075566	0.544003667	0.653345744	0.815133235	2.5283462	0.062940338	1.407797176	1.261448996	-0.08289433					no		Found	FALSE	FALSE	FALSE	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	1.341422887	0.777022585	1.144899545	1.891315265	5.53793534	-1.082918838	8.247178934	no	no	no	no	no	no	yes																
BA2842R	BA2842D	2085	Waves1+2	no	no	no	no	Male	Male	Black		Black	6		RUNX1-RUNX1T1	50	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with t(8;21)(q22;q22); RUNX1-RUNX1T1	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with t(8;21)(q22;q22); RUNX1-RUNX1T1	50	21	Residual Disease	Residual	Peripheral Blood	y	y	y	y	y	y	1	Standard Chemotherapy	2	"HiDAC|3+7 (Cytarabine, Daunorubicin)"	2	Consolidation|Induction	Refractory	Standard Chemotherapy	20	Standard Chemotherapy	HiDAC	Consolidation	182	Alive	424	Alive	NA	8	0	0	NA	12	29	54	NA	19	9	2.3	0.51		22.8	7.5	"46,XY,t(8;21)(q22;q22)[20]"	NA	88.7	RUNX1/RUNX1T1 fusion positive in 6.5% of cells	224	TRUE		NA	NA	5.1	6.8	FALSE	negative	0	negative				"ASXL1 (p.P581R, MAF 46%)|PDGFRB (p.D111N, MAF 52%)|SMC1A (p.R586Q, MAF 96%)"	0.925291573	0.479784543	0.89863887	0.883917521	0.885239709	2.367847497	0.152694685	1.548878011	0.891356672	0.347339151					no		Found	FALSE	FALSE	FALSE	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	TRUE	TRUE	4.452819975	6.099369759	4.777012625	5.239657954	7.140703761	-0.224671623	5.843531338	yes	yes	yes	yes	yes	yes	yes																
BA2442R	BA2442D	2549	Waves1+2	yes	yes	yes	yes	Female	Female			White	3			66	TRUE	FALSE	TRUE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	"Acute myeloid leukaemia, NOS"	Intermediate	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	"Acute myeloid leukaemia, NOS"	66	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	1	Standard Chemotherapy	1	"7+3 (Cytarabine, Idarubicin)"	1	Induction	UNKNOWN	Standard Chemotherapy	6	Standard Chemotherapy	"7+3 (Cytarabine, Idarubicin)"	Induction	6	Dead	13	Dead-Treatment	NA		16	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA		NA	NA	"47,XX,+8[18]"	NA	NA	Normal	NA	NA	"Large population of CD117 pos myeloblasts, representing 80% of leukocytes, consistent w/ AML."	FALSE	FALSE	NA	129.5	TRUE	positive	0.428571429	negative				FLT3-ITD (p.Tyr591_Val592ins16; MAF 10%)|WT1 (p.Val379fs; MAF 13%)|ZRSR2 (p.Arg415Trp; MAF 48.9%)	0.425854012	0.919774253	0.536069108	0.81704054	0.837546121	2.8815301	0.368368129	1.338412202	0.939760694	0.073752314				yes	yes		Found	FALSE	FALSE	FALSE	FALSE	NA	FALSE	FALSE	FALSE	FALSE	TRUE	TRUE	FALSE	FALSE	3.222269335	2.920787546	3.120495315	1.794969448	5.750230366	-0.848175605	4.574417205	yes	no	yes	no	no	yes	yes																
BA2663R	BA2663D	2519	Waves1+2	no	no	no	no	Male	Male			White	7			67	TRUE	FALSE	FALSE	FALSE	TRUE	FALSE	n		y	n	n	n	y	y	n	n	MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASMS	Chronic myelomonocytic leukaemia	NonAML	MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASMS	Chronic myelomonocytic leukaemia	66	0	Residual Disease		Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	2	Cytarabine|Decitabine	2	Induction|Supportive/Palliative Care	UNKNOWN	Standard Chemotherapy	-1	Standard Chemotherapy	Cytarabine	Induction	-1	Alive	304	Alive	NA	17	7	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA		NA	NA		NA	NA	Trisomy 8	NA	NA		NA	NA	NA	NA	NA	negative	0	negative	RUNX1 (p.R166*; 44.9%)			ASXL1|EZH2|PTPN11|RUNX1|STAG2	0.89096588	0.358083841	0.921287478	0.949570177	0.948363021	2.310095959	0.046730483	1.561324392	0.909190213	0.425832887					no		Found	FALSE	FALSE	FALSE	FALSE	NA	FALSE	TRUE	FALSE	TRUE	FALSE	NA	TRUE	TRUE	5.031864213	7.071035687	5.18332908	4.446279887	7.032670382	1.914616164	7.374848472	yes	yes	yes	yes	yes	yes	yes																
BA2989R	BA2989D	2332	Waves1+2	yes	yes	yes	yes	Male	Male	White		HispNative	2			70	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	71	0	Post-Chemotherapy|Residual Disease	Residual	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	2	Azacitidine|Decitabine	1	Hypomethylating/Low Dose Cytarabine			NA	Standard Chemotherapy	Azacitidine	Hypomethylating/Low Dose Cytarabine	98	Alive	305	Alive	0	44	31	2	NA	46	0	14	NA	41	18	3.7	0.91		21.6	7.1	"47,XY,+21[19]/46,XY[1]"	91	NA	"nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],"	35	TRUE	"CD2(-), CD4(dim +), CD7(-), CD10(-), CD11b(-), CD13(bright +), CD14(-), CD15(partial +), CD16(-), CD22(-), CD19(partial +), CD33(partial +), CD34(+), CD36(-), CD38(bright and variably +), CD45(+), CD56(-), CD64(-), CD79a(-), CD117(+), HLA-DR(predominantly + and variable), TdT(partial +), and MPO(-) | In addition, there is a 0.92% population of CD117(bright +)/CD34(-)/CD45(dim +)/CD33(- to dim +) small cells with low orthogonal light scatter. The exact identity of these cells is uncertain"	TRUE	TRUE	7.7	5.05	FALSE	positive	0.086956522	negative	RUNX1 (p.I366Vfs*231; 65.5%)			BCOR (Foundation; R1480*; MAFs: 88%)|BCORL1 (Foundation; P304fs*117; MAFs: 72%)|FLT3-ITD|NF1 (Foundation; I679fs*21; MAFs: 5%)|NF1 (Foundation; V2649fs*31 (subclonal); MAFs: 12%)|PHF6 (Foundation; R225*; MAFs: 87%)|PTPN11 (Foundation; A72T; MAFs: 8%)|RUNX1 (Foundation; I366fs*114+; MAFs: 57%)|TET2 (Foundation; Q742*; MAFs: 41%)	0.763895841	0.814298429	0.597519072	0.606103828	0.900964202	2.685165978	0.458256327	1.327886565	1.080357603	0.070883091					no		Found	FALSE	TRUE	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	TRUE	TRUE	FALSE	TRUE	TRUE	3.281164924	3.225997109	1.148665991	4.960565492	6.654599047	-2.69590525	6.736374381	yes	no	no	yes	yes	no	yes																
BA2721R	BA2721D	2556	Waves1+2	yes	yes	yes	yes	Female	Female	White	NON-HISPANIC	White	1			69	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	y	Breast Cancer	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with maturation	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with maturation	69	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	3	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)|Targeted Therapy - Other	8	"7+3 (Cytarabine, Idarubicin)|Sorafenib|MEC (Cytarabine, Etoposide, Mitoxantrone)|MiDAC|IMGN779 (Immunogen Trial)|Fludarabine, Cyclophosphamide, Thiotepa, TBI|ALRN-6924|Azacitidine, Midostaurin, Ponatinib"	4	Salvage|Induction|Experimental|Re-induction	Refractory	Standard Chemotherapy	6	Targeted Therapy - Other	IMGN779 (Immunogen Trial)	Salvage	-1	Dead	565	Dead-Disease	1.8		40	0.9	8.8	10.5	9.6	26.3	2.8	27	22	3.4	0.64	M2	23.5	7.1	"46,XX[20]"	399	103.5	normal	12	FALSE	"CD13, CD34, CD58, CD117, partial MPO and HLA-DR +"	FALSE	FALSE	6.5	61.22	TRUE	positive	1	negative	RUNX1 (p.A187T; MAF 42%)			CREBBP (p.S893L; MAF 41%)|FLT3-ITD (MAF 47%)|RUNX1 (p.A187T; MAF 42%)|SF3B1 (p.K700E; MAF 51%)|TET2 (p.K751fs*61; MAF 44%)	0.701489432	0.867113796	0.8247919	0.951181856	0.862173474	2.765759366	0.307902612	1.481057125	0.850344298	0.367009854	yes				yes		Found	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	TRUE	TRUE	TRUE	TRUE	FALSE	5.171688369	5.820000639	4.753808985	5.173810012	6.439296181	-0.659685538	7.037793486	yes	yes	yes	yes	yes	yes	yes																
BA2728R	BA2728D	2094	Waves1+2	yes	yes	yes	no	Female	Female	White	NON-HISPANIC	White	1		GATA2-MECOM	58	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	y	Basal Cell Carcinoma|Squamous cell carcinoma	y	n	y	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1	58	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	n	y	y	n	2	Standard Chemotherapy|Bone Marrow Transplant	3	"Azacitidine|SWOG S0919 (Ida/Ara+Pravastatin) |Busulfan, Cyclophosphamide"	3	Allogeneic - Sibling|Induction|Maintenance	Complete Response	Standard Chemotherapy	70	Standard Chemotherapy	Azacitidine	Maintenance	102	Alive	1911	Alive	0	21	0	0	2.3	41.7	25.9	30.1	0.1	NA	NA	NA	NA	M2	35.1	11	"46,XX,t(3;3)(q21;q26)[20]"	NA	107	"98/100 (98%) interphase cells scored had a 1 red/ 1 green/ 2 yellow signal pattern, interphase cells scored had a 1 red/ 1 green/ 2 yellow signal pattern, consistent with RPN1/MECOM fusion. Two metaphases showed a fusion signal on one derivative 3 and red, yellow and green signals on the other deriv"	360	TRUE	"variable CD11b, CD13, dim CD33, CD34, CD58, CD117, CD123"	FALSE	TRUE	NA	13.83	FALSE	negative	0	negative				NRAS (p.G12D; MAF 47%)|SF3B1 (p.K666N; MAF 47%)	0.853362192	0.675810549	0.874432173	0.720318211	0.81412926	2.539220037	0.180771067	1.497995973	0.830500345	0.426148363	yes				yes		Found	FALSE	FALSE	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	TRUE	FALSE	4.927710471	5.743185276	1.499693009	4.759714994	6.310689736	-0.997814662	7.645111524	yes	yes	no	yes	yes	no	yes																
BA2469R	BA2469D	2530	Waves1+2	yes	yes	yes	yes	Female	Female		HISPANIC	White	6			50	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML without maturation	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML without maturation	51	0	Residual Disease|Post-Chemotherapy	Residual	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	4	"Busulfan, Fludarabine|5+2 (Cytarabine, Idarubicin)|HiDAC|7+3 (Cytarabine, Idarubicin, Bortezomib"	3	Unknown|Induction|Re-induction	Unknown	Standard Chemotherapy	-1	Bone Marrow Transplant	"Busulfan, Fludarabine"	Unknown	-1	Alive	716	Alive	NA	12		NA	NA	NA	17	NA	NA	NA	NA	NA	NA		NA	NA	"46,XX[20]"	NA	NA		16	FALSE	"FLT3 (ITD) Not detected. Not detected for the FLT3 TKD Mutation. Pathogenic alterations are detected in the BCOR, IDH2 and WT1 genes. Positive for CD34, HLADR, CD117, CD13, CD33 and CD43 and negative for CD11B, CD14, CD64, TDT and MPO. (Bone Marrow Immunophenotyping)"	FALSE	TRUE	NA	1.5	FALSE	negative	0	negative				"BCOR (p.E1348Ifs, MAF 32%)|IDH2 (p.R172K, MAF 41%)|WT1 (p.T171Cfs*116, MAF 39%)"	0.547077127	0.323415987	0.543220947	0.277693331	0.910672747	2.242949349	-0.002005601	1.218263965	0.961082823	0.162069554					no		Found	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	TRUE	5.290487594	7.039864526	2.725593384	3.774309834	7.442425211	-2.305703239	2.913586334	yes	yes	no	yes	yes	no	no																
BA2951R	BA2951D	2228	Waves1+2	yes	yes	yes	yes	Female	Female			White	3		GATA2-MECOM	65	TRUE	FALSE	FALSE	TRUE	FALSE	FALSE	n		n	n	n	n	n	n	y	y	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1	65	3	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	0		0		0				NA	NONE	NONE	NONE	NA	Alive	27	Alive	NA	59.4		NA	NA	NA	NA	NA	NA	NA	NA	NA	NA		NA	NA	"47,XX,+X,inv(3)(q21q26.2),-7,+22[2]/48,sl,+21[18]"	NA	NA	evidence of monosomy 7 in 191/200 (95.5 percent) cells scored	NA	NA		NA	NA	NA	NA	NA	negative	0	negative	RUNX1 (p.D198G; 66.7%)			CALR (p.Leu367fs; MAF 24%)|CBL (p.? ; MAF 16.5%)|DNMT3A (p.Ala571Pro; MAF 51.5%)|EZH2 (p.Pro636Ala; MAF 94.7%)|FLT3 (p.Val579Ala; MAF 2.3 %)|PTPN11 (p.Gly60Ser; MAF 49.1%)|RUNX1 (p.Asp198Gly; MAF 63.7%)	0.488012657	1.051271683	0.628293282	0.694007992	0.578749999	2.936382637	0.539598266	1.351671427	0.887573751	0.087676082					no		Found	FALSE	FALSE	TRUE	FALSE	NA	FALSE	FALSE	FALSE	TRUE	FALSE	NA	FALSE	FALSE	1.984753428	1.014003384	0.523162664	4.025719727	4.094742478	-2.169486987	2.718149952	no	no	no	yes	no	no	no																
BA2361R	BA2361D	2444	Waves1+2	yes	yes	yes	yes	Female	Female	White		White	5			55	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	55	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	2	"7+3 (Cytarabine, Idarubicin) plus Enasidenib|Busulfan, Cyclophosphamide"	2	Allogeneic - Sibling|Induction	Complete Response	Standard Chemotherapy	-1	Bone Marrow Transplant	"Busulfan, Cyclophosphamide"	Allogeneic - Sibling	-1	Alive	428	Alive	1	30	0	0	NA	31	4	6.8	NA	10	11	4.3	NA		32.4	9.9	"46,XX,del(5)(q22q35)[2]/46,XX,+8,-16,der(17)t(16;17)(p11.2;p11.2)[14]/46,XX[3]"	NA	NA	Probe: 8 centromere/20q12 | Normal (5p15.2/ 5q31 (EGR1); 7 centromere/ 7q31)	83	TRUE	Negative (CD19) | Negative (CD22) | Positive (CD38) | Negative (CD7) | Negative (CD56) | Negative (CD11b) | Positive (CD13) | Negative (CD14) | Negative (CD15) | Negative (CD33) | Positive (CD34) | Negative (CD45) | Negative (CD64) | Negative (CD117) | Negative (MPO) | Positive (HLA-DR)	TRUE	TRUE	7.2	10.6	FALSE	negative	0	negative				ASXL1 (c.190 0_1922 delAGAGAGGCGGCCACCACTGCCAT; p.R634Rfs; MAF 33%)|IDH2 (c.419G>A; P.R140Q; MAF 46%)	0.784424686	0.518387057	0.845153293	0.752000615	0.994891575	2.627007294	0.186311178	1.474232515	1.11833562	0.459202949					no		Found	TRUE	FALSE	FALSE	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	TRUE	TRUE	4.127725495	6.490027958	5.420214121	5.754917397	6.753097394	2.527421199	6.882321322	yes	yes	yes	yes	yes	yes	yes																
BA2984R	BA2984D	2520	Waves1+2	yes	yes	yes	yes	Male	Male	White	NON-HISPANIC	White	1			81	TRUE	FALSE	TRUE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	81	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	1	Standard Chemotherapy	1	"Vidaza, BI836858 (anti-CD33)"	1	Induction	Complete Response	Standard Chemotherapy	-1	Standard Chemotherapy	"Vidaza, BI836858 (anti-CD33)"	Induction	-1	Dead	581	Dead-Disease	0	80	80	0	7	7.8	0	6.9	0.5	31	42	3.2	1.3	M1	25.1	8.8	"46,XY[19]"	665	85.1	Normal	16	FALSE	"dim CD13, CD33, CD38, CD58, dim CD64, CD71, dim CD117 and CD123-positive"	TRUE	TRUE	7.2	33.81	TRUE	negative	0	positive				CSF3R ( p.T640N; MAF: 14%)|EZH2 (p.G709D; MAF: 17%)|EZH2 (p.R684C; MAF: 4%)|IDH2 (p.R140Q; MAF: 46%)|KDM6A (Splice site-Intron 5 3' end mutation; MAF:3%)|NPM1 (p.W288fs*12; MAF: 39%)	0.380753751	0.549860604	0.369604105	0.319741545	0.862998607	2.722522427	0.120951156	1.182840037	0.849803247	-0.225748029					no		Found	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	2.195311478	1.459629216	0.10465675	3.420105908	4.830238718	-3.647851047	3.510084808	no	no	no	no	no	no	no																
BA2414R	BA2414D	2307	Waves1+2	yes	yes	yes	yes	Male	Male	White		White	5			50	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	y	Hodgkin Lymphoma	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	50	0	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	2	"GCLAC (GCSF, Clofarabine & Cytarabine)|Fludarabine, Cyclophosphamide, Thiotepa, TBI"	2	Induction|Double Umbilical Cord Blood Transplant (DUCBT)	Complete Response	Standard Chemotherapy	-1	Bone Marrow Transplant	"Fludarabine, Cyclophosphamide, Thiotepa, TBI"	Double Umbilical Cord Blood Transplant (DUCBT)	-1	Dead	201	Dead-Unknown	0	75	82	2	NA	4	0	8	NA	39	45	3.7	NA		20.1	6.5	"46,XY,add(1)(p11),del(5)(q15q33),del(7)(q22q36),der(11)t(1;11)(p31;p12-14)[20] "	NA	NA	Loss of 5q31 sequences for 99% of total cells | Loss of 7q31 sequences for 96% of total cells	12	TRUE	"Positive: CD38, CD56, CD13, CD34, CD45, CD117, HLA-DR | Partially positive: CD7, CD11b, CD33, CD64 | Negative: CD19, CD22, Cyt CD79a, Cyt CD3, CD14, CD15, MPO, TdT"	TRUE	TRUE	6.3	119.6	TRUE	positive	0.818181818	negative				BCOR (C.3067T>C; p.F1023L)|FLT3-ITD|NOTCH1 (c.7625G>A; p.S2542N)	0.456768825	0.953256423	0.633342142	0.925156084	0.828389431	2.850066934	0.427452461	1.377094501	0.937781313	0.11837596					no		Found	FALSE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	TRUE	TRUE	FALSE	FALSE	1.578373928	3.157635869	2.109065935	1.435245391	4.94485332	-2.590271627	4.398469402	no	no	no	no	no	no	no																
BA2999R	BA2999D	2117	Waves1+2	yes	yes	yes	yes	Male	Male	White	NON-HISPANIC	White	1			53	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	"Acute myeloid leukaemia, NOS"	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	"Acute myeloid leukaemia, NOS"	54	0	Post-Chemotherapy|Residual Disease	Residual	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Targeted Therapy - Other	7	"AG-120|7+3 (Cytarabine, Idarubicin)|Azacitidine|MGD006 (CD123 x CD3) |MEC (Cytarabine, Etoposide, Mitoxantrone)|Decitabine|Incyte trial (azacitidine and JAK 1 inhibitor)"	5	Salvage|Induction|Experimental|Re-induction|Maintenance	Refractory	Standard Chemotherapy	6	Standard Chemotherapy	Incyte trial (azacitidine and JAK 1 inhibitor)	Salvage	-1	Dead	543	Dead-Disease	0	75	90	0	0	22.1	6.2	1.8	0	19	33	1.8	0.84		25.5	8.1	"46,XY,t(4;12)(q12;p13)[10]/46,XY[10] "	706	91.4	"42/100 (42%) interphase cells scored were positive for  ETV6 rearrangement. ÊMetaphase FISH showed part of the ETV6 signal (red) on  the long arm of chromosome 4. ÊBased on the breakpoint, ETV6/CHIC2 fusion  is predicted, consistent with AML"	25	TRUE	"partial CD7, CD13, CD33, CD38, CD34, CD58, CD117, CD123,  HLA-DR positive "	TRUE	TRUE	6.6	118	TRUE	negative	0	negative	RUNX1 (p.R166*; 41.5%)			DNMT3A (p.R882H; MAF 49%)|IDH1 (p.R132S; MAF 48%)|RUNX1 (p.R166*; MAF 50%)|SRSF2 (p.P95H; MAF 50%)	0.450582941	0.89377932	0.728383417	0.726608706	0.69821371	2.856947236	0.676310679	1.305505977	0.940032619	0.048630448		yes			yes		Found	TRUE	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	4.423363574	4.771018257	1.207948541	1.825110857	5.613299821	-1.316820856	3.655457998	yes	yes	no	no	no	no	no																
BA2644R	BA2644D	2280	Waves1+2	no	no	no	no	Male	Male	White		White	3			63	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Intermediate	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	63	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	n	y	y	n	2	Standard Chemotherapy|Bone Marrow Transplant	3	"Busulfan, Fludarabine|7+3 (Cytarabine, Idarubicin) plus Crenolanib|IDAC"	3	Consolidation|Induction|Allogeneic - Child	Complete Response	Standard Chemotherapy	-1	Bone Marrow Transplant	"Busulfan, Fludarabine"	Allogeneic - Child	-1	Alive	306	Alive	NA	26.3	12	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA		NA	NA	"46,XY[11]  "	NA	NA	Normal	69	TRUE		NA	NA	NA	9.28	FALSE	negative	0	negative				BCOR (p.Tyr354*; MAF 72.2%)|DNMT3A (p.Phe755Ser; MAF 38.6%)|DNMT3A (p.Thr835Met; MAF 47%)|IDH1 (p.Arg132Cys; MAF 2.9%)	0.808981464	0.725569798	0.839167609	1.043769671	0.759806089	2.789519856	0.269522147	1.472838516	0.912208648	0.212897274					no		Found	TRUE	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	TRUE	TRUE	3.761083856	4.623216308	2.599429395	6.609010906	6.779521012	-2.203211143	4.410920735	yes	yes	no	yes	yes	no	no																
BA2011R	BA2011D	2280	Waves1+2	yes	yes	yes	yes	Male	Male	White		White	3			63	TRUE	FALSE	TRUE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Intermediate	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	63	1	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	3	"Busulfan, Fludarabine|7+3 (Cytarabine, Idarubicin) plus Crenolanib|IDAC"	3	Consolidation|Induction|Allogeneic - Child	Complete Response	Standard Chemotherapy	-1	Bone Marrow Transplant	"Busulfan, Fludarabine"	Allogeneic - Child	-1	Alive	306	Alive	NA	26.3		NA	NA	NA	NA	NA	NA	NA	NA	NA	NA		NA	NA	"46,XY[11] "	NA	NA	Normal	NA	NA		NA	NA	NA	NA	NA	negative	0	negative				BCOR (p.Tyr354*; MAF 72.2%)|DNMT3A (p.Phe755Ser; MAF 38.6%)|DNMT3A (p.Thr835Met; MAF 47%)|IDH1 (p.Arg132Cys; MAF 2.9%)	0.9403176	0.717501539	0.863267986	1.051813971	0.674795524	2.706030241	0.35892798	1.523336027	0.781940072	0.191069211					no		Found	TRUE	FALSE	TRUE	FALSE	NA	FALSE	FALSE	FALSE	FALSE	FALSE	NA	TRUE	TRUE	4.626425024	5.047682741	4.220970819	6.325461091	6.814535931	-0.926284489	3.79421628	yes	yes	yes	yes	yes	yes	no																
BA2217R	BA2217D	2538	Waves1+2	yes	yes	yes	yes	Male	Male	White	NON-HISPANIC	White	1	bi		47	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated CEBPA	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated CEBPA	47	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	2	"7+3 (Cytarabine, Idarubicin)|HiDAC"	2	Consolidation|Induction	Complete Response	Standard Chemotherapy	7	Standard Chemotherapy	HiDAC	Consolidation	116	Alive	214	Alive	0	83	82	3.4	0	23.1	3.4	0	1.6	23	11	3.5	0.95	M1	31.1	10.2	"46,XY[20]"	290	88.9		24	FALSE	"CD7, CD13, CD33, CD34, CD38, partial CD56,  CD58, dim CD64, CD117, CD123, HLA-DR, and cMPO "	TRUE	TRUE	6.5	18.71	FALSE	negative	0	negative				"CEBPA (p.I68fs; MAF 50%)|CEBPA (p.K313_V314insK; MAF 50%)|EZH2 (p.S519P; MAF 51%)|NRAS (p.G13D, MAF 3%)|WT1 (p.M392fs*10; MAF 13%)|WT1 (p.R458*; MAF 23%)"	0.22591986	0.691567443	0.144050231	0.677374641	0.494164527	2.898522553	0.004108678	0.895147794	0.896882878	-0.09213504					no		Found	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	3.59566377	2.561914578	0.341831953	2.770346183	2.648493357	-3.699774364	2.7956563	yes	no	no	no	no	no	no																
BA2500R	BA2500D	2120	Waves1+2	yes	yes	yes	yes	Female	Female	White	NON-HISPANIC	White	1		PML-RARA	59	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	59	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	1	"ATRA, Arsenic Trioxide, Idarubicin"	1	Induction	Complete Response	Standard Chemotherapy	-1	Standard Chemotherapy	"ATRA, Arsenic Trioxide, Idarubicin"	Induction	-1	Alive	28	Alive	0.9	90	90	1.7	44	8.6	0	6	1.5	110	255	2.4	0.86	M3	19.8	6.7	"46,XX,t(15;17)(q22;q21)[20]"	NA	88.4	86/100 cells (86%) had the 1r/1g/2f dual fusion signal pattern consistent  with PML/RARA fusion and with t(15;17) as seen on metaphase analysis. 	30	FALSE	"CD13, CD33, CD58, CD64, CD117, CD123, MPO"	FALSE	TRUE	5.4	47.35	TRUE	negative	0	negative				ASXL1 (p.M1050V; MAF 51%)|FLT3-ITD (MAF 46%)	0.465599745	0.401661365	0.423579438	0.349411757	0.943427999	2.632320633	-0.171003651	1.338747113	1.173130376	0.015645511					no		Found	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	0.658225584	1.755411239	5.458930499	3.515474683	6.954112232	-2.048875085	6.41081514	no	no	yes	no	yes	no	yes																
BA3108R	BA3108D	2673	Waves3+4	yes	yes	yes	no	Female	Female	White	NON-HISPANIC		1			72	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	72	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	n	y	y	n	2	Standard Chemotherapy|Targeted Therapy - Other	4	"Vidaza, BI836858 (anti-CD33)|Azacitidine|Enasidenib|Incyte trial (azacitidine and JAK 1 inhibitor)"	3	Salvage|Induction|Maintenance	Refractory	Standard Chemotherapy	185	Targeted Therapy - Other	Enasidenib	Salvage	28	Alive	1640	Alive	0	47	0	0	0.9	74.3	0	13.3	0	15	8	2.9	0.51	M2	29.1	9.4	"48,XX,+8,+8,add(9)(q22)[1]/50,idem,+15,+18[5]/46,XX[14] (Six of twenty metaphase cells analyzed comprised two related hyperdiploid clones.)"	85	101.7	Results were consistent with tetrasomy 8 (RUNX1T1/CEP8) and trisomy 15 (PML) in approximately 50% of cells scored. ÊAll other probe results were within normal limits with no evidence for rearrangements or deletions. 	57	TRUE	"CD13, CD33, CD34, CD38, moderate-dim  CD45, and CD117+ "	FALSE	TRUE	5.7	1.62	FALSE	negative	0	negative				IDH2 (p.R140Q; MAF 43%)|U2AF1 (p.Q157P; MAF 17%)	0.362520326	0.812422903	0.313992167	0.467039555	0.453938147	2.979276179	0.244044703	1.026143859	0.842027866	0.123188908			yes		yes	yes	Found	TRUE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	2.061925636	3.742671226	0.792123208	6.354451923	5.200819479	-0.651755834	2.126420627	no	yes	no	yes	no	yes	no																
BA2590R	BA2590D	2131	Both	no	no	no	no	Male	Male			HispNative	5			55	TRUE	FALSE	TRUE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Intermediate	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	55	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	3	Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Kinase Inhibitor(s)	3	"Midostaurin|Fludarabine, Cyclophosphamide, Thiotepa, TBI|7+3 (Cytarabine, Idarubicin) plus Enasidenib"	3	Induction|Double Umbilical Cord Blood Transplant (DUCBT)|Maintenance	Complete Response	Standard Chemotherapy	-1	Targeted Therapy - Kinase Inhibitor(s)	Midostaurin	Maintenance	44	Dead	282	Dead-Disease	0	88.5	64	0	NA	25	4	7	NA	34	36	3.3	NA		31.3	10.9	"46,XY[19]"	NA	NA	Normal	54	TRUE	"Negative (CD19, CD22, Cyt CD3, CD7, CD56, CD11b, CD13, CD14, CD34, CD64, CD117, TdT) | Positive (CD38, Cyt CD79a, CD15, CD33, MPO) | Dim (CD45, HLA-DR)"	TRUE	TRUE	7.4	24.9	TRUE	positive	1	positive				FLT3 (c.1811_1812insl8; p.E604_P605insYDLKWE; MAF 32%)|IDH1 (c.395G>A; p.R132H; 44%)|NPM1 (c.863_864insTCTG; p.W288fs; MAF 42%)|SRSF2 (c.284_307del; p.P95_R102del; MAF 45%)	0.418640065	0.591126459	0.390646526	0.536814504	0.939691103	2.762955357	0.145285531	1.254249702	0.871978697	-0.150100992		yes			yes		Found	TRUE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	TRUE	TRUE	FALSE	FALSE	0.463015517	1.323460801	0.502611742	3.938851014	4.472838845	-0.976484324	0.203542587	no	no	no	yes	no	no	no																
BA3195R	BA3195D	2827	Waves3+4	yes	yes	yes	yes	Male	Male				5			77	TRUE	FALSE	FALSE	TRUE	FALSE	FALSE	n		n	n	n	n	y	y	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	77	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	2	Targeted Therapy - Kinase Inhibitor(s)|Targeted Therapy - Other	4	"Venetoclax, Idasanutlin|anti-CD123, Decitabine|Enasidenib|cd47mAb"	3	Salvage|Induction|Experimental	Refractory	Targeted Therapy - Kinase Inhibitor(s)	-1	Targeted Therapy - Kinase Inhibitor(s)	Enasidenib	Salvage	-1	Alive	322	Alive	0	90	92	0	NA	4	1	3	NA	17	22	3.8	NA		24.7	7.4	"46,XY[19]"	NA	NA	Normal	72	TRUE	"Positive (CD38, CD15, CD34, MPO, HLA-DR) | Negative (CD19, CD22, Cyt CD79a, Cyt CD3, CD7, CD56, CD11b, CD13, CD14, CD33, CD64, TdT) | Dim Positive (CD45, CD117)"	TRUE	TRUE	6.4	224.2	TRUE	negative	0	negative	RUNX1 (p.L98Pfs*40; 52.3%)|RUNX1 (p.N434Kfs*166; 32.4%)			DNMT3A (c.2644C>T; p.R882C; MAF 47%)|IDH2 (c.419G>A; p.R140Q; MAF 48%)|JAK2 (c.1849G>T; p.V617F; MAF 50%)|RUNX1 (c.1289_1290insTGCC; p.P430fs; MAF 17%)|RUNX1 (c.1301 1302insA; p.N434å£s; MAF 21%)|RUNX1 (c.292_293insC; p.L98fs; MAF 45%)|SRSF2 (c.284C>A; p.P95H; MAF 48%)	0.468908223	0.935663188	0.532088046	0.599307783	0.506428889	2.955137989	0.577498345	1.296906305	0.826985705	-0.094795565		yes			yes	yes	Found	TRUE	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	FALSE	TRUE	FALSE	TRUE	FALSE	TRUE	0.94047208	3.083073131	0.732935263	4.360158605	5.201166098	-0.058990543	2.378403438	no	no	no	yes	no	yes	no																
BA2516R	BA2516D	2500	Both	no	no	no	no	Male	Male	White	NON-HISPANIC	White	1			70	TRUE	FALSE	FALSE	TRUE	FALSE	FALSE	n		y	n	n	n	n	n	y	y	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	"Acute myeloid leukaemia, NOS"	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	"Acute myeloid leukaemia, NOS"	70	0	Post-Chemotherapy|Residual Disease	Residual	Peripheral Blood	y	y	y	y	y	y	2	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	4	"Imatinib|Cytarabine|MEC (Cytarabine, Etoposide, Mitoxantrone)|Decitabine"	4	Salvage|Induction|Experimental|Re-induction	Refractory	Standard Chemotherapy	61	Standard Chemotherapy	"MEC (Cytarabine, Etoposide, Mitoxantrone)"	Salvage	-1	Dead	362	Dead-Disease	0		15	0	16.2	16.2	8.1	6.3	4.5	20	45	4.6	1.5		31.5	9.8	"46,XY[20]"	851	92.6	Normal	14	FALSE		NA	NA	7.6	92.55	TRUE	negative	0	negative		ASXL1 (p.E635Dfs*22; 42.9%)		BCOR (p.S1024; MAF 5%)|NRAS (p.G13D; MAF 34%)|PTPN11 (p.G60V; MAF 3%)|SRSF2 (p.P95H; MAF 40%)	0.5061283	0.684887767	0.611793635	0.832187724	0.929111005	2.869491493	0.271239399	1.385890731	1.161779147	0.281650252		yes			yes		Found	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	1.514564435	3.997914584	3.719189331	2.963491679	7.10458055	-2.16506181	6.792868793	no	yes	yes	no	yes	no	yes																
BA2971R	BA2971D	2086	Both	no	no	no	no	Male	Male	White	NON-HISPANIC	White	6			57	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	n		y	n	n	n	n	n	y	y	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	"Acute myeloid leukaemia, NOS"	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	"Acute myeloid leukaemia, NOS"	57	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	3	"Busulfan, Fludarabine, Thymoglobulin (Bu/Flu/ATG)|HiDAC|3+7 (Cytarabine, Daunorubicin)"	3	Consolidation|Induction|Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	7	Bone Marrow Transplant	"Busulfan, Fludarabine, Thymoglobulin (Bu/Flu/ATG)"	Allogeneic - Matched Unrelated Donor	13	Alive	307	Alive	NA	20		NA	NA	NA	3	NA	NA	NA	NA	NA	NA		NA	NA	"46,XY[20]"	NA	NA		49	TRUE	"THESE ARE POSITIVE FOR CD34, CD117, HLADR, CD13, AND CD33. (Bone Marrow Immunophenotyping)"	FALSE	TRUE	NA	19.3	FALSE	negative	0	negative	RUNX1 (p.D198N; 47.6%)|RUNX1 (p.P113L; 42.7%)			DNMT3A (c.2644C>T; p.R882C MAF 47%)|JAK2 (c.1849G>T; p.V617F MAF 91%)|RUNX1 (c.338C>T; p.P113L  MAF 42% c.592G>A; p.D198N MAF 46%)|SETBP1 (c.883G>A; p.V1295M MAF 47%)|SRSF2 (c.284C>A; p.P95H MAF 47%)	0.951022061	0.790946522	0.907408112	0.853950029	0.831156914	2.862142863	0.546747241	1.511442253	0.912086667	0.357741874		yes			yes		Found	FALSE	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	TRUE	TRUE	6.067617302	8.232437589	5.896032759	7.304115114	7.437298899	-0.949108598	4.794166584	yes	yes	yes	yes	yes	yes	yes																
BA3217R	BA3217D	2624	Waves3+4	yes	yes	yes	yes	Male	Male	White			5			60	TRUE	FALSE	TRUE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	"Acute myeloid leukaemia, NOS"	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	"Acute myeloid leukaemia, NOS"	60	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	2	"Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)"	2	Allogeneic - Sibling|Induction	Complete Response	Standard Chemotherapy	-1	Bone Marrow Transplant	"Fludarabine, Melphalan"	Allogeneic - Sibling	-1	Alive	293	Alive	NA	95	70	NA	NA	27	1	2	NA	37	32	3.2	NA		29.2	9.9	"46,XY[20]"	NA	NA	Normal	48	TRUE	"Positive (CD38, CD33, CD34, MPO, HLA-DR) | Negative (CD19, CD22, Cyt CD79a, Cyt CD3, CD7, CD56, CD13, CD14, CD15, CD117, TdT) | Dim (CD11b, CD45, CD64)"	TRUE	TRUE	6	25.5	TRUE	positive	0.960784314	negative				"FLT3-ITD (ITD, c.1769_1770ins42; p.Y589_F590insl4 (MAF 38%))|IDH2 (c.419G>A; p.R140Q (MAF 48%))|STAG2 (c.3034delC; p.R1012fs (MAF 92%))"	0.374116822	0.817697707	0.180958547	0.843479771	0.635011952	2.874156708	0.122388469	1.125130698	0.825592246	-0.268169119					no		Found	TRUE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	TRUE	TRUE	FALSE	TRUE	1.177475595	0.893117073	1.357423296	3.091012395	3.966753841	-3.80664195	0.798083757	no	no	no	no	no	no	no																
BA3411R	BA3411D	2615	Waves3+4	yes	yes	yes	yes	Female	Female	White	NON-HISPANIC		1			48	TRUE	FALSE	FALSE	TRUE	FALSE	FALSE	n		y	n	y	y	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	48	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	2	"7+3 (Cytarabine, Idarubicin)|HiDAC"	2	Consolidation|Induction	Complete Response	Standard Chemotherapy	5	Standard Chemotherapy	HiDAC	Consolidation	-1	Alive	351	Alive	0	25	7	0	2.6	47	9.6	36.5	0	NA	NA	NA	NA	M4	19.5	6.7	"47,XX,+8,del(8)(q11.2q22)[20]"	NA	89.4	"CEP 8: Ê73/100 cells (73%) had three signals, consistent with the extra chromosome 8 in the metaphase karyotype"	21	TRUE	"CD13, CD33, CD34, CD38, CD56, CD58,Êvariable CD64, CD71, CD117, dim CD123, HLA-DR, MPO  (Myeloid Blasts) | CD11b, CD13, CD15, CD33, CD56, CD64, HLA-DR (Abnormal Monocytes)"	TRUE	TRUE	NA	4.8	FALSE	negative	0	negative		ASXL1 (p.L823*; 45.9%)		ASXL1 (p.L823; MAF 47%)	0.63895811	0.591846939	0.747378002	0.765039467	1.026749615	2.649721282	0.031702579	1.386816981	1.117021856	0.399412895					no		Found	FALSE	FALSE	FALSE	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	TRUE	FALSE	1.638400218	7.289891995	4.648394391	3.206719524	6.386940213	-1.674034464	7.81832288	no	yes	yes	no	yes	no	yes																
BA3133R	BA3133D	2747	Waves3+4	yes	yes	yes	yes	Male	Male	White	NON-HISPANIC		1			61	TRUE	FALSE	FALSE	TRUE	FALSE	FALSE	y	Skin cancer	y	n	y	y	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	61	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	1	Vidaza	1	Induction	Unknown	Standard Chemotherapy	-1	Standard Chemotherapy	Vidaza	Induction	-1	Dead	51	Dead-Disease	0	25	26	0	11.5	9.7	7.1	43.4	0.1	23	33	3.6	0.8	M2	22	7	"45,XY,del(5)(q13q33),-7,add(8)(q24.3),add(9)(q34),add(10)(q23),del(17)(p13)  ,add(18)(q23)[3]/47-49,sl,+2-4mar[cp12]/44,sl,-2,add(3)(p21),t(6;11)(p22;q1  4),-add(8)(q24.3),add(8)(p22),-9,add(9)(q33),-10,-13,add(21)(q21),+2mar[8] "	855	116.4	"TP53 (17p13.1):  83% of cells were missing a signal for TP53, consistent with the 17p deletion seen on metaphase analysis.  | RUNX1 (21q22):  15.5% of cells were missing a signal for RUNX1. ÊNo  evidence for RUNX1/RUNX1T1 fusion.  | MECOM (3q26.2): Ê33% of cells had six (6) signals for MECOM. On available  metaphases, the extra MECOM signals hybridized to the small marker  chromosomes. ÊNo evidence for MECOM/RPN1 fusion. "	166	TRUE	"CD13, CD33, CD34, CD38, CD58, CD71, CD117,  CD123, HLA-DR + "	TRUE	TRUE	6.7	19.22	FALSE	negative	0	negative	RUNX1 (p.X170_splice; 26.1%)		TP53 (p.Q167*; 91.3%)	BCOR (p.Q1658H; MAF 100%)|RUNX1 (Splice Site; MAF 17%)|SF3B1 (p.K666M; MAF 47%)|SRSF2 (p.R180G; MAF 54%)|TP53 (p.Q167; MAF 65%)	0.639499904	0.935720552	0.673976685	0.623079165	0.856002413	2.895357289	0.442218353	1.292825912	0.978412799	0.349015568	yes	yes			yes	yes	Found	FALSE	FALSE	FALSE	TRUE	TRUE	FALSE	FALSE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	3.696690741	4.308377901	3.097641081	3.261219191	5.735529047	-0.015069307	5.464844015	yes	yes	yes	no	no	yes	yes																
BA3435R	BA3435D	2613	Waves3+4	yes	yes	yes	no	Male	Male	White	NON-HISPANIC		1			79	TRUE	FALSE	TRUE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML without maturation	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML without maturation	79	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	n	y	y	n	1	Standard Chemotherapy	2	"Decitabine|Azacitidine, BI 836858 (anti-CD33)"	2	Salvage|Induction	Refractory	Standard Chemotherapy	50	Standard Chemotherapy	Decitabine	Salvage	37	Dead	135	Dead-Disease	0	85	49	0	0	42.4	0.8	6.8	0.1	20	20	3.6	1.6	M1	26.7	9	"47,XY,+8[18]/46,XY[2] "	NA	89	"CEP8 and RUNX1T1 (8q21.3): ~90% of cells had an extra signal for chromosome 8 probes, consistent with trisomy 8, as seen on metaphase analysis."	97	TRUE	"partial CD13, partial CD33, CD34, CD117, CD123, partial HLA-DR, and partial MPO"	FALSE	TRUE	7.3	20.17	FALSE	positive	0.111111111	negative	RUNX1 (p.T246Hfs*15; 25.0%)	ASXL1 (p.G646Wfs*12; 30.2%)		FLT3-ITD (MAF 16%)|IDH1 (p.R132C; MAF 46%)|JAK2 (p.V617F; MAF 12%)|RUNX1 (p.T246fs*15; MAF 50%)|U2AF1 (p.Q157P; MAF 48%)	0.436583729	0.925458054	0.426038199	0.652207326	0.383797095	2.997059289	0.506564567	1.017194543	0.614170573	-0.111284617			yes		yes		Found	TRUE	FALSE	FALSE	FALSE	TRUE	FALSE	TRUE	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	1.068948967	2.367694063	3.572854403	4.165183053	5.957254663	-2.264986433	-0.644074447	no	no	yes	yes	no	no	no																
BA3261R	BA3261D	2633	Waves3+4	yes	yes	yes	yes	Male	Female	White	NON-HISPANIC		1	bi		61	TRUE	FALSE	TRUE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated CEBPA	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated CEBPA	61	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	4	"FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine|FLAG (Fludarabine, High-dose Cytarabine, G-CSF)|Busulfan, Cyclophosphamide"	3	Consolidation|Induction|Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	5	Bone Marrow Transplant	"Busulfan, Cyclophosphamide"	Allogeneic - Matched Unrelated Donor	-1	Dead	289	Dead-Treatment	0	40	25	0	0	27	0	46	0	30	14	3.9	0.84	M2	22.8	8.1	"45,X,-Y,del(11)(q12)[20]"	NA	98.3	"95/100 cells (95%) had a single signal, consistent with the deleted 11q in the metaphase karyotype. There was no evidence for MLL rearrangement."	35	TRUE	"CD7, partial CD13, dim CD33, CD34, CD28, CD58, CD71, CD117, HLA-DR and MPO "	TRUE	TRUE	6.9	4.17	FALSE	negative	0	negative		ASXL1 (p.A752Lfs*20; 43.9%)		"ASXL1 (p.A752fs*20; MAF 46%)|CEBPA (D105Vfs*64; MAF 45%)|CEBPA (H236Rfs*78; MAF 35%)|EP300 (p.R1627W ; MAF 46%)|IDH2 (p.R140Q, MAF 50%)|KMT2D (p.P647Q; MAF 43%)"	0.425837943	0.543185709	0.665089112	0.631444281	0.840035414	2.872820647	0.037002373	1.22002075	1.063831853	0.333845827					no		Found	TRUE	FALSE	FALSE	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	3.834328217	6.279172432	3.756625678	3.758389918	5.944312861	-0.103804888	6.897101925	yes	yes	yes	no	no	yes	yes																
BA3277R	BA3277D	2818	Waves3+4	yes	yes	yes	yes	Male	Male	White	NON-HISPANIC		5			65	TRUE	FALSE	TRUE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	65	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	1	"Venetoclax (ABT-199), Azacitidine"	1	Induction	Complete Response	Standard Chemotherapy	-1	Standard Chemotherapy	"Venetoclax (ABT-199), Azacitidine"	Induction	-1	Alive	211	Alive	0	66.5	37	2	NA	24	6	31	NA	23	25	2.6	NA	M4	26.3	8.1	"46,XY[20] "	NA	NA	Normal	101	TRUE	"positive (CD38 dim, CD33 dim, CD45 dim, CD117 var, MPO var) | negative (CD10, CD19, CD20, CD22, CD23, Surf Kappa, Surf Lambda, FMC7, CD3, CD5, CD7, CD56, CD13, CD14, CD15, CD34) | PP (CD11b VAR, CD64 VAR, HLA-DR VAR)"	TRUE	TRUE	6	8.6	FALSE	negative	0	positive				IDH2 (c. 419G>A; p.R140Q; MAF 47%)|NPM1 (C.863_864insTCTG; p.W288fs; MAF 34%)|SRSF2 (c. 284C>A; p.P95H; MAF 47%)	0.592861167	0.584386778	0.679918263	0.720898073	1.076677974	2.937969322	0.257528083	1.416781967	0.956562554	0.190344004		yes			yes		Found	TRUE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	TRUE	1.370676648	4.428116689	2.048335989	4.657239738	5.360004718	0.402949581	4.281019838	no	yes	no	yes	no	yes	no																
BA3210R	BA3210D	2644	Waves3+4	yes	yes	yes	yes	Female	Female	White			2			74	TRUE	FALSE	FALSE	TRUE	FALSE	FALSE	n		y	n	y	y	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	75	0	Residual Disease|Post-Chemotherapy	Residual	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	1	"3+7 (Cytarabine, Daunorubicin)"	1	Induction	Refractory	Standard Chemotherapy	-1	Standard Chemotherapy	"3+7 (Cytarabine, Daunorubicin)"	Induction	-1	Alive	305	Alive	NA	65	30	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA		NA	NA	"47,XX,+8,del(9)(q13q22),t(12;22)(p13;q13)[12]/46,XX[8]"	NA	NA		NA	NA		NA	NA	NA	NA	NA	negative	0	negative	RUNX1 (p.L429Pfs*171; 82.9%)	ASXL1 (p.G646Wfs*12; 36.4%)		BCORL1 (K632fs*33)|CSF3R (T6181)|ETV6 (MN1-ETV6 fusion)|IDH2 (R140Q)|IDH2 (p.Arg140Gln)|PHF6|PTPN11 (E69K)|RUNX1 (L429fs*171)	0.894167102	0.600623166	0.833838304	0.721524589	0.908093576	2.514929755	0.442202827	1.496018843	1.066338393	0.24862827					no		Found	TRUE	FALSE	FALSE	FALSE	NA	FALSE	TRUE	FALSE	TRUE	FALSE	NA	TRUE	TRUE	4.218279723	5.681928757	6.07391847	5.393866082	7.589913929	0.230814198	8.143215126	yes	yes	yes	yes	yes	yes	yes																
BA3157R	BA3157D	2614	Waves3+4	yes	yes	yes	yes	Male	Male	White	NON-HISPANIC		1			60	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	y	Basal Cell Carcinoma	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	60	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	3	"HiDAC|3+7 (Cytarabine, Daunorubicin)|Busulfan, Cyclophosphamide"	3	Allogeneic - Sibling|Consolidation|Induction	Complete Response	Standard Chemotherapy	-1	Bone Marrow Transplant	"Busulfan, Cyclophosphamide"	Allogeneic - Sibling	-1	Alive	1425	Alive	0	87	83	0	0	13.4	0.8	8.3	0.3	125	74	2.3	0.79	M1	26.3	9.2	"46,XY,del(9)(q13q22)[20]"	823	89.5	Normal	146	TRUE	"CD13, CD33, variable CD34, CD38, CD58, CD117,  CD123, HLA-DR, variable MPO"	FALSE	TRUE	6.1	23.32	TRUE	negative	0	positive				NPM1 (p.W288fs*12; MAF 41%)|NRAS (p.G13D; MAF 41%)|SF3B1 (p.T663I; MAF 50%)	0.319917645	0.735912951	0.33359581	0.674079506	0.670615834	3.016753934	0.140980145	1.089625342	0.852768032	0.025363902	yes				yes		Found	FALSE	FALSE	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	1.164885487	-0.152736587	-0.730775878	3.143933558	4.768514002	-2.990147787	1.444850418	no	no	no	no	no	no	no																
BA3374R	BA3374D	2617	Waves3+4	yes	yes	yes	yes	Male	Male	White	NON-HISPANIC		1		KMT2A_re	21	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute monoblastic and monocytic leukaemia 	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute monoblastic and monocytic leukaemia 	21	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Intrathecal	6	"GCLAM (G-CSF, Cladribine, Cytarabine, and Mitoxantrone) |ADE (Cytarabine, Daunorubicin & Etoposide)|HiDAC|Venetoclax (ABT-199), Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)|Cytarabine, Methotrexate"	3	Consolidation|Salvage|Induction	Complete Response	Standard Chemotherapy	4	Standard Chemotherapy	"Venetoclax (ABT-199), Azacitidine"	Salvage	26	Dead	316	Dead-Disease	0	91	90	0	0	27.3	0	2.7	0	70	152	2.2	1.35	M5	19.9	6.8	"47~49,XY,+8[cp13]/46,XY[7]"	2767	96.6	RUNX1T1/CEP8: 140/200 cells (70%) reflect the trisomy 8 in the metaphase karyotype; 20 cells (10%) reflect extra centromere signals only. It is possible the G-banded cell with two small markers reflects a small clone containing extra copiesÊof a derivative chromosome 8. | MLL: 88/100 cells (88%) had a variant. A green signal appears on the short arm of a chromosome 10 with a red/small green signal retained on the chromosome 11q. It is unclear whether the material translocated disrupts MLL.	54	FALSE	"CD4, partial CD11b, CD13, CD33, dim CD22, CD34, variable CD56, variable CD64, CD117, HLA-DR, dim PAX5+"	FALSE	TRUE	5.5	55.69	TRUE	negative	0	negative				KRAS (p.G13R; MAF 37%)|U2AF1 (p.S34F; MAF 39%)	0.424612932	0.460811266	0.522453803	0.923707522	0.92471939	2.41487276	-0.0697028	1.427606367	0.826254166	-0.145139244			yes		yes		Found	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	-2.624636946	-0.078273268	1.940888905	0.821801311	5.279352426	-1.485040412	2.829120724	no	no	no	no	no	no	no																
BA3403R	BA3403D	2617	Waves3+4	no	no	no	no	Male	Male	White	NON-HISPANIC		1		KMT2A_re	21	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute monoblastic and monocytic leukaemia 	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute monoblastic and monocytic leukaemia 	22	99	Relapse|Post-Chemotherapy	Relapse	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Intrathecal	6	"GCLAM (G-CSF, Cladribine, Cytarabine, and Mitoxantrone) |ADE (Cytarabine, Daunorubicin & Etoposide)|HiDAC|Venetoclax (ABT-199), Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)|Cytarabine, Methotrexate"	3	Consolidation|Salvage|Induction	Complete Response	Standard Chemotherapy	4	Standard Chemotherapy	"Venetoclax (ABT-199), Azacitidine"	Salvage	26	Dead	316	Dead-Disease	0	95	95	0	0	4.5	6.3	0	0	31	75	3.1	0.8	M5	30	9.9	"49,XY,+8,+mar1,+mar1[cp13]/49,idem,del(6)(q13q21)[8] "	1612	92.9	"RUNX1T1/CEP8: Ê95/100 cells (95%) had an abnormal 3 red/ 3 aqua signal  pattern, reflecting the trisomy 8 in the metaphase karyotype and previously  observed. There was no evidence for RUNX1T1/RUNX1 fusion. | MLL: Ê93/100 cells (93%) had a variant abnormal 0 red/ 1 green/ 1 yellow  (red/small green)/ 1 yellow (red/green) signal pattern, reflecting MLL rearrangement and previously observed. | MECOM/RPN1: Ê84/100 cells (84%) had an abnormal 5-6 red/ 2 green signal  pattern, reflecting extra copies of MECOM (3q26.2) and gain of 3q.  Metaphase FISH shows the extra signals to be on the two markers. There was  no evidence for MECOM/RPN1 fusion."	42	FALSE	"CD4, CD11b, CD13, variable CD14, CD15, CD33, CD34, variable CD38, CD56, CD58, CD64, variable CD117, and HLA-DR"	FALSE	TRUE	5.8	60.51	TRUE	negative	0	negative				KRAS (p.G13R; MAF 52%)|U2AF1 (p.S34F; MAF 49%)	0.509884017	0.411009234	0.55296664	0.896468244	0.888320146	2.364804618	-0.084058215	1.467981338	0.812007607	-0.167700584			yes		yes		Found	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	-1.163931911	-1.780799809	2.483864615	0.810049122	5.530220226	-3.018968201	1.476380914	no	no	no	no	no	no	no																
BA3222R	BA3222D	2617	Waves3+4	no	no	no	no	Male	Male	White	NON-HISPANIC		1		KMT2A_re	21	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute monoblastic and monocytic leukaemia 	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute monoblastic and monocytic leukaemia 	22	267	Post-Chemotherapy|Residual Disease	Residual	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Intrathecal	6	"GCLAM (G-CSF, Cladribine, Cytarabine, and Mitoxantrone) |ADE (Cytarabine, Daunorubicin & Etoposide)|HiDAC|Venetoclax (ABT-199), Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)|Cytarabine, Methotrexate"	3	Consolidation|Salvage|Induction	Complete Response	Standard Chemotherapy	4	Standard Chemotherapy	"Venetoclax (ABT-199), Azacitidine"	Salvage	26	Dead	316	Dead-Disease	0	43	0	1.7	NA	13.3	13.3	70	0	41	26	3.5	0.9	M5	25.4	8.5	"49,XY,del(4)(q21),add(6)(q27),-17,add(19)(p13.3),+mar1X2,+mar2,+mar3 [cp13]/49,XY,add(4)(q21),-6,+8,+mar1X2,+mar4[cp6]/46,XY[1] "	229	85.2	"51% had an abnormal signal pattern, reflecting the trisomy 8 in the metaphase karyotype and previously observed.  There was no evidence for RUNX1T1/RUNX1 fusion.  | 61% had a variant abnormal signal pattern, reflecting MLL rearrangement and previously observed.  | 72% had an abnormal signal pattern, reflecting extra copies of MECOM (3q26.2) and gain of 3q, previously observed.  Metaphase FISH shows the extra signals to be on  two markers.  There was no evidence for MECOM/RPN1 fusion. "	57	TRUE	"dim CD4, CD13, CD33, CD34, dim CD56, CD64, HLA-DR+"	FALSE	TRUE	5.7	0.6	FALSE	negative	0	negative				KRAS (p.G13R; MAF 24%)|U2AF1 (p.S34F; MAF 24%)	0.350878692	0.441496256	0.388270143	0.855259985	0.896519821	2.424254341	-0.128806475	1.322394462	0.900489573	0.224490183			yes		yes		Found	FALSE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	-0.175707025	2.796856029	2.308021862	0.667672635	4.755882325	-1.825294369	3.63957788	no	no	no	no	no	no	no																
BA3167R	BA3167D	2704	Waves3+4	yes	yes	yes	yes	Male	Male	White	NON-HISPANIC		2		MLLT3-KMT2A	38	TRUE	FALSE	TRUE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with t(9;11)(p22;q23); MLLT3-MLL	Intermediate	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with t(9;11)(p22;q23); MLLT3-MLL	38	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	2	"7+3 (Cytarabine, Idarubicin)|HiDAC"	2	Consolidation|Induction	Complete Response	Standard Chemotherapy	-1	Standard Chemotherapy	HiDAC	Consolidation	-1	Alive	162	Alive	NA	94	55	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA		NA	NA	"46,XY,t(9;11)(p22;q23),inv(9)(p11q12)"	NA	NA		NA	NA		NA	NA	NA	25.29	TRUE	negative	0	negative				BCOR (D1006fs*16)|FLT3-D835|MLL (MLL-MLLT3 (AF9) Fusion)	0.600983839	0.534813155	0.647113524	0.864600128	0.733188441	2.682711118	0.299599035	1.432993003	0.515269611	-0.147556106					no		Found	FALSE	FALSE	FALSE	FALSE	NA	FALSE	FALSE	FALSE	FALSE	FALSE	TRUE	TRUE	TRUE	1.047571678	4.022025266	4.753808985	4.510389059	5.519901753	-3.467916029	-0.979592395	no	yes	yes	yes	no	no	no																
BA3232R	BA3232D	2714	Waves3+4	yes	yes	yes	yes	Female	Female	White	NON-HISPANIC		1			36	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	36	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	4	Standard Chemotherapy|Bone Marrow Transplant|Intrathecal|Targeted Therapy - Other	6	"Azacitidine, Sorafenib|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|SY-1425 (Tamibarotene) plus Daratumumab|7+3 (Cytarabine, Idarubicin) plus Midostaurin|Busulfan, Cyclophosphamide|Cytarabine, Methotrexate"	5	Allogeneic - Sibling|Induction|Experimental|Re-induction|Maintenance	Complete Response	Standard Chemotherapy	-1	Targeted Therapy - Other	SY-1425 (Tamibarotene) plus Daratumumab	Experimental	28	Dead	370	Dead-Disease	0	30	40	0	9.6	13.9	0.9	36.5	0.1	14	25	3.5	0.77	M4	13.3	4.6	"46,XX[20]"	NA	100	Normal	58	TRUE	"dim CD7, partial CD11b, variable CD13, CD33, CD64,  CD117, dim CD123, dim HLA-DR and partial MPO positive"	TRUE	TRUE	6.6	59.05	TRUE	positive	0.265822785	positive				BCOR (p.V89D; MAF 54%)|DNMT3A (p.R882H; MAF 51%)|FLT3-ITD (MAF 15%)|NPM1 (p.W288fs*12; MAF 48%)|NRAS (p.G12S; MAF 20%)	0.503060802	0.801399353	0.762391574	0.533711871	0.940745761	2.930617502	0.015060817	1.357979973	0.982091928	0.200821192					no		Found	FALSE	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	TRUE	TRUE	FALSE	FALSE	2.057901585	4.138984655	1.133368614	2.658017302	6.136398279	0.871276132	7.309488343	no	yes	no	no	yes	yes	yes																
BA3436R	BA3436D	2755	Waves3+4	yes	yes	yes	yes	Female	Female	White	NON-HISPANIC		1	mono		23	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	23	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	5	"7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG (Fludarabine, High-dose Cytarabine, G-CSF)|FLAG-IDA, Gemtuzumab|Busulfan, Cyclophosphamide"	4	Consolidation|Induction|Re-induction|Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	6	Bone Marrow Transplant	"Busulfan, Cyclophosphamide"	Allogeneic - Matched Unrelated Donor	-1	Alive	1510	Alive	0.9	80		0	0	11.6	0	10.7	0.3	17	7	3	0.68	M1	26.7	8.9	"46,XX[8]"	145	90.8	Normal	54	FALSE	"CD13, CD33, partial CD34, CD38, CD58, dim CD71, CD117,  CD123, and cMPO+ "	TRUE	TRUE	6.9	29.58	TRUE	negative	0	positive				CEBPA (p.A199fs*114; MAF 50%)|EZH2 (p.R288*; MAF46%)|GATA2 (p.A372T; MAF 31%)|NPM1 (p.W288fs*12; MAF 50%)	0.223647141	0.755802037	0.269856569	0.259765953	0.680398871	3.001476812	0.220859674	1.015962418	0.796639605	-0.144649996					no		Found	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	4.906047114	1.946720599	-0.143707385	1.362836848	4.808852579	0.18384673	1.586439704	yes	no	no	no	no	yes	no																
BA3406R	BA3406D	2796	Waves3+4	yes	yes	yes	yes	Male	Male				3			33	TRUE	FALSE	TRUE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	"Acute myeloid leukaemia, NOS"	Intermediate	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	"Acute myeloid leukaemia, NOS"	33	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	1	Standard Chemotherapy	1	"7+3 (Cytarabine, Idarubicin)"	1	Induction	UNKNOWN	Standard Chemotherapy	6	Standard Chemotherapy	"7+3 (Cytarabine, Idarubicin)"	Induction	6	Alive	30	Alive	NA	69	28	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA		NA	NA	"46, XY[20]"	NA	NA	Normal	70	TRUE		NA	NA	NA	4.52	FALSE	positive	0.492537313	negative				BCOR (p.G1n1626; MAF 62.2%)|FLT3-ITD (p.Glu598_Tyr599ins9)|WT1 (p.Arg370fs; MAF 27.7%)	0.524426436	0.951091214	0.463355705	1.007576048	0.766762577	2.922644824	0.497707968	1.273171385	0.898471273	-0.030946349					no		Found	FALSE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	2.026778569	3.507187124	3.845655809	5.070932999	6.791584377	-0.807899034	3.464121446	no	yes	yes	yes	yes	yes	no																
BA3308R	BA3308D	2772	Waves3+4	yes	yes	yes	yes	Male	Male	White	NON-HISPANIC		1			78	TRUE	FALSE	FALSE	TRUE	FALSE	FALSE	n		n	n	n	n	n	n	y	y	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	78	0	Post-Chemotherapy|Residual Disease	Residual	Bone Marrow Aspirate	y	y	y	y	y	y	2	Supportive/Palliative Care|Targeted Therapy - Kinase Inhibitor(s)	4	AG-221|Imatinib|Midostaurin|Interferon	3	Salvage|Maintenance|Supportive/Palliative Care			NA	Targeted Therapy - Kinase Inhibitor(s)	AG-221	Salvage	191	Dead	319	Dead-Disease	NA			NA	NA	NA	NA	NA	NA	NA	NA	NA	NA		NA	NA	"47,XY,del(6)(q13),+8[8]/47,idem,-8,+13[2]/46,XY,del(13)(q14q22),del(20)(q11.2)[6]/46,XY[4] "	NA	NA	"RUNX1T1: Ê22/200 cells (11%) had a 3 red/ 2 green signal  pattern, reflecting an extra RUNX1T1 (8q21.3) signal, consistent with the  trisomy 8 clone observed in the metaphase karyotype | RUNX1: 18/200 cells (9%) had a 2  red/ 3 green signal pattern, reflecting an extra RUNX1 (21q22) signal. ÊThe  extra chromosome 21 material was not apparent in the G-banded karyotype.  There was no evidence for RUNX1T1/RUNX1 fusion. | CEP8:  29/200 (14.5%) cells  scored with the CEP 8 probe had three signals, consistent with trisomy 8.  | D20S108/20p subtel: Ê6/200 cells (3%) had a 1 red/ 2 green signal pattern,  consistent with the deleted 20q in the metaphase karyotype. "	NA	NA		NA	NA	NA	NA	NA	negative	0	negative	RUNX1 (p.R162S; 84.5%)	ASXL1 (p.G646Wfs*12; 34.3%)	TP53 (p.X187_splice; 9.3%)	IDH2 (p.R140Q; MAF 45%)|KRAS (p.Q61R; MAF 5%)|NOTCH1 (p.P2412L; MAF 57%)|RUNX1 (p.R162S; MAF 74%)|SRSF2 (p.P95H; MAF 54%)|TP53 (Splice site; MAF 9%)	0.394652128	0.840255933	0.404447446	0.68888479	0.541561883	2.855246735	0.379267254	1.137282003	0.785936204	0.023908514		yes			yes	yes	Found	TRUE	FALSE	FALSE	FALSE	NA	FALSE	TRUE	TRUE	TRUE	FALSE	NA	FALSE	FALSE	1.242680414	2.195311478	0.581773503	4.111448431	4.940687389	-2.221671142	2.265641923	no	no	no	yes	no	no	no																
BA3186R	BA3186D	2743	Waves3+4	yes	yes	yes	yes	Male	Male	White	NON-HISPANIC		1			68	TRUE	TRUE	FALSE	TRUE	FALSE	FALSE	n		y	n	n	n	n	n	y	y	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	70	0	Relapse|Post-Chemotherapy|Post-Transplant	Relapse	Peripheral Blood	y	y	y	y	y	y	3	Standard Chemotherapy|Bone Marrow Transplant|Supportive/Palliative Care	3	"Fludarabine, Melphalan|Azacitidine|MiDAC"	3	Symptom Control|Supportive/Palliative Care|Allogeneic - Matched Unrelated Donor			NA	Bone Marrow Transplant	"Fludarabine, Melphalan"	Allogeneic - Matched Unrelated Donor	-1	Dead	980	Dead-Disease	0	79	56	0	0	14.6	4.5	8.2	2.6	31	58	2.9	0.69		33.5	11.8	"45,XY,add(3)(p22),-7,t(8;22)(q11.2;q11.2),add(11)(q23),-13,-15,-16,  der(17)t(7;17)(q11.2;p11.2),+3mar[cp3]/44~46,sl+der(8)t(8;21)(q11.2;q11.2),  -18[cp15]/44,sl,-add(3)(p22),+10,+13,+15,-18,-3mar[2] "	3293	92.5	"MLL: Ê97/100 cells (97%) had the variant abnormal 0 red/ 1 green/1 yellow  signal pattern, reflecting MLL (11q23) rearrangement and previously  observed.  | TP53/CEP 17: Ê99/100 cells (99%) had a 1 red/ 2 green signal pattern,  reflecting TP53 deletion, previously observed and consistent with the  derivative 17 in the metaphase karyotype. | RUNX1T1/RUNX1: Ê93/100 cells (93%) had a 2-3 red/ 3-4 green signal pattern,  reflecting an extra copies of RUNX1T1 and RUNX1. ÊThere was no evidence for  RUNX1T1/RUNX1 fusion.  | CBFB: Ê96/100 cells (96%) had a single intact signal, reflecting CBFB  (16q22) loss and consistent with the monosomy 16 in the metaphase  karyotype.  | D7S486/ CEP 7: Ê99/100 cells (99%) had a 2 red/ 1 green signal pattern,  indicating loss of a chromosome 7 centromere signal with 7q material  attached to the derivative 17 in the metaphase karyotype.  | CEP 8: Ê66/100 cells (66%) had three signals, consistent with the clone  having an extra copy of the derivative 8. "	28	FALSE	"dim CD4, dim CD7, dim CD33, CD34, dim CD56, CD58, dim  CD123, CD117 and HLA-DR positive"	TRUE	TRUE	NA	49.48	TRUE	negative	0	negative			TP53 (p.R248W; 71.9%)	JAK2 (p.V617F; MAF 88%)|SF3B1 (p.G740V; MAF 41%)|TET2 (p.E692fs*8; MAF 40%)|TP53 (p.R248W; MAF 78%)	0.524183573	0.954001664	0.452554752	0.426530504	0.424494824	2.587095088	0.494574863	1.106706906	0.563628633	0.047956412	yes				yes	yes	Found	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	TRUE	FALSE	FALSE	7.458669758	3.139900593	6.882992955	2.202007581	5.176998147	1.694555777	0.878502133	yes	no	yes	no	no	yes	no																
BA3334R	BA3334D	2640	Waves3+4	yes	yes	yes	yes	Female	Female	White			2			76	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	n		n	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	"Acute myeloid leukaemia, NOS"	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	"Acute myeloid leukaemia, NOS"	76	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Targeted Therapy - Other	1	Entospletinib	1	Experimental			NA	Targeted Therapy - Other	Entospletinib	Experimental	-1	Alive	47	Alive	NA			NA	NA	NA	NA	NA	NA	NA	NA	NA	NA		NA	NA		NA	NA	Normal	NA	NA		NA	NA	NA	NA	NA	negative	0	negative		ASXL1 (p.C687Yfs*30; 45.2%)		ASXL1|FLT3 (N841K)|SRSF2|STAG2	0.85210863	0.537046202	0.79314869	0.960795668	0.95084466	2.541722437	0.18365092	1.499875405	1.09084802	0.205952689		yes			yes		Found	FALSE	FALSE	FALSE	FALSE	NA	FALSE	TRUE	FALSE	FALSE	FALSE	NA	TRUE	TRUE	3.934276996	6.840394913	5.402952286	3.903889208	6.363758413	-1.340913836	7.071808265	yes	yes	yes	yes	yes	no	yes																
BA3447R	BA3447D	2669	Waves3+4	yes	yes	yes	no	Male	Male	White			7			67	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	n		n	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML without maturation	Intermediate	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML without maturation	67	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	n	y	y	n	0		0		0				NA	NONE	NONE	NONE	NA	Dead	249	Dead-Disease	NA	82		NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	M1	NA	NA	46XY	NA	NA		NA	NA	"positive for CD13, CD33, CD34, CD38, CD117, HLA-DR, cytoplasmic myeloperoxidase (subset), and TdT (subset)"	FALSE	TRUE	NA	NA	NA	negative	0	negative				FLT3-ITD|NRAS|U2AF1	0.567110476	0.561238929	0.643544202	0.859569347	0.876645932	2.76135185	0.151616662	1.409222198	1.044218317	-0.134089179			yes		yes		Found	FALSE	FALSE	FALSE	FALSE	NA	FALSE	FALSE	FALSE	FALSE	FALSE	NA	FALSE	TRUE	-0.041105053	0.4136809	-1.064561294	0.943216526	5.615495263	-2.32040487	2.262756705	no	no	no	no	no	no	no																
BA3116R	BA3116D	2810	Waves3+4	yes	yes	yes	no	Female	Female	White			5			65	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	65	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	n	y	y	n	1	Standard Chemotherapy	1	"Azacitidine, BI 836858 (anti-CD33)"	1	Induction	Complete Response	Standard Chemotherapy	-1	Standard Chemotherapy	"Azacitidine, BI 836858 (anti-CD33)"	Induction	-1	Alive	83	Alive	NA	40		NA	NA	NA	NA	NA	NA	NA	NA	NA	NA		NA	NA		NA	NA		NA	NA		NA	NA	NA	NA	NA	negative	0	negative				ASXL1|TET2	0.779815266	0.443409233	0.904549071	0.894653263	0.957415729	2.770748172	0.058264547	1.533343517	1.070050144	0.206376532					no		Found	FALSE	TRUE	FALSE	FALSE	NA	FALSE	TRUE	FALSE	FALSE	FALSE	NA	TRUE	TRUE	3.948480229	4.789631377	5.488344205	3.411402903	6.104973667	0.706893141	5.825802632	yes	yes	yes	no	yes	yes	yes																
BA3280R	BA3280D	2648	Waves3+4	yes	yes	yes	no	Male	Male	White			5	N/A		51	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	51	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	n	y	y	n	1	Standard Chemotherapy	1	"7+3 (Cytarabine, Idarubicin)"	1	Induction	Complete Response	Standard Chemotherapy	-1	Standard Chemotherapy	"7+3 (Cytarabine, Idarubicin)"	Induction	-1	Alive	82	Alive	NA	80	85	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA		NA	NA	"46,XY[20]"	NA	NA		NA	NA	"positive for CD117, CD13, CD33, and HLA-DR. Roughly half of the blasts were positive for CD34, roughly half of the blasts showed aberrant dim expression of CD7, and roughly half of the cells showed aberrant dim expression of CD19."	TRUE	TRUE	NA	NA	NA	positive	0.136363636	positive				ASXL1|CEBPA|FLT3-ITD|NPM1|NRAS|PTPN11|STAG2	0.402182799	0.875982142	0.339131996	0.467469909	0.694602342	2.876108849	0.301256265	1.019160344	0.810460139	-0.123790297					no		Found	FALSE	FALSE	FALSE	FALSE	NA	FALSE	TRUE	FALSE	FALSE	TRUE	NA	FALSE	TRUE	1.177475595	3.042413784	0.23878428	3.972999486	5.596625022	0.725196498	0.643937104	no	no	no	yes	no	yes	no																
BA3185R	BA3185D	2769	Waves3+4	yes	yes	yes	yes	Male	Male	White			5			75	TRUE	FALSE	TRUE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	"Acute myeloid leukaemia, NOS"	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	"Acute myeloid leukaemia, NOS"	75	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	2	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	2	"Entospletinib, Azacitidine|Entospletinib"	2	Induction|Re-induction	Refractory	Targeted Therapy - Kinase Inhibitor(s)	-1	Standard Chemotherapy	"Entospletinib, Azacitidine"	Re-induction	-1	Alive	75	Alive	NA	90		NA	NA	NA	NA	NA	NA	NA	NA	NA	NA		NA	NA	"47,XY,+13[20]/47,XY,+8[1]"	NA	NA	Low level gain of chromosome 8 sequences (trisomy). Loss of 21q22 sequences (monosomy)	NA	NA	"CD13, CD33, HLA-DR, and CD34"	FALSE	TRUE	NA	NA	NA	negative	0	negative	RUNX1 (p.H105Afs*33; 41.2%)|RUNX1 (p.T104R; 53.3%)	ASXL1 (p.G646Wfs*12; 33.3%)		ASXL1|RUNX1|SRSF2|TET2	0.590274613	0.805420942	0.441698371	0.954344306	0.358433121	2.775580891	0.441245221	1.309710552	0.578952018	-0.194322273		yes			yes		Found	FALSE	TRUE	FALSE	FALSE	NA	FALSE	TRUE	FALSE	TRUE	FALSE	NA	FALSE	TRUE	4.867454474	3.299070264	3.734565851	4.390354398	5.97158629	-2.701609364	-2.03573425	yes	no	yes	yes	no	no	no																
BA3333R	BA3333D	2746	Waves3+4	yes	yes	yes	yes	Male	Male	White			5			NA	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	y	Prostate Cancer	n	n	y	y	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	NA	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	0		0		0				NA	NONE	NONE	NONE	NA	Dead	2	Dead-Disease	NA	93		NA	NA	NA	NA	NA	NA	NA	NA	NA	NA		NA	NA	"46,XY[20]"	NA	NA	Normal	NA	NA		NA	NA	NA	NA	NA	negative	0	positive				FLT3-TKD (I836del; VAF 8%)|GATA2 (T358A;16%)|NPM1 (W288Cfs*12; VAF 46%)|SRSF2 (P95L; VAF 41%)|TET2 (A1344E; VAF 52%)|TET2 (R1440Tfs*38; VAF 47%)	0.404754753	0.640154002	0.563664227	0.467050884	0.823832038	2.965145543	0.26524242	1.289022733	0.779558387	-0.146603485		yes			yes		Found	FALSE	TRUE	FALSE	FALSE	NA	FALSE	FALSE	FALSE	FALSE	FALSE	NA	FALSE	FALSE	2.907121591	2.949393646	0.253940584	2.671935251	4.851961831	-0.112757807	-0.43050765	yes	no	no	no	no	yes	no																
BA3381R	BA3381D	2754	Waves3+4	yes	yes	yes	yes	Male	Male	Black	NON-HISPANIC		1			51	TRUE	FALSE	TRUE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	51	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	5	"HiDAC + Midostaurin|Fludarabine, TBI|Azacitidine|7+3 (Cytarabine, Idarubicin) plus Midostaurin|Decitabine, Venetoclax"	5	Consolidation|Induction|Allogeneic - Child|Maintenance|Re-induction	Complete Response	Standard Chemotherapy	6	Standard Chemotherapy	"Decitabine, Venetoclax"	Re-induction	-1	Dead	486	Dead-Treatment	4.3	14		0.9	6.1	7	25.2	52.2	0.6	19	34	3.4	1.36	M4	19.7	6.3	"46,XY[20]"	1116	106.5	Normal	17	TRUE	"CD13, CD33, CD34, CD38, CD58, dim CD71, CD117, dim CD123  and HLA-DR+ "	TRUE	TRUE	7.5	80.58	TRUE	negative	0	negative	RUNX1 (p.F259Sfs*338; 18.3%)	ASXL1 (p.G646Wfs*12; 32.0%)		"ASXL1 (p.S1236A; MAF 51% )|CBL (p.R420Q, MAF 3%)|CBL (p.Y368_C372delinsP; MAF 9%)|DNMT3A (p.E616*; MAF 50%)|FLT3 (p.D835V; MAF 37%)|FLT3-ITD (Allelic Ratio = .03)|SF3B1 (p.K666N; MAF 47%)"	0.733384298	0.698947778	0.84315155	1.010119734	0.996023342	2.758319674	0.110959624	1.494007588	1.051569482	0.475977729	yes				yes	yes	Found	FALSE	FALSE	TRUE	TRUE	TRUE	FALSE	TRUE	FALSE	TRUE	FALSE	TRUE	TRUE	FALSE	4.619298469	6.472289491	5.268871336	3.638674576	7.21378005	-0.83073183	7.539743542	yes	yes	yes	no	yes	yes	yes																
BA3290R	BA3290D	2753	Waves3+4	yes	yes	yes	yes	Male	Male	White	NON-HISPANIC		1			66	TRUE	FALSE	FALSE	TRUE	FALSE	FALSE	n		y	n	n	n	n	n	y	y	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with maturation	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with maturation	67	0	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	3	"7+3 (Cytarabine, Idarubicin)|Azacitidine|Decitabine"	2	Induction|Supportive/Palliative Care	Refractory	Standard Chemotherapy	6	Standard Chemotherapy	"7+3 (Cytarabine, Idarubicin)"	Induction	6	Dead	232	Dead-Disease	0.9	17	22	7.1	8	38	7.1	22.1	0.3	43	30	2.9	1.04	M2	25	8.3	"46,XY,del(12)(p11.2)[9]/46,XY[11]"	287	94.7	Normal	16	TRUE	"dim partial CD7, CD13, CD33, CD34, dim CD38, CD58,  CD117, dim CD123, HLA-DR and partial TdT+"	TRUE	TRUE	5.6	6.21	FALSE	negative	0	negative	RUNX1 (p.D198N; MAF 6%)	ASXL1 (p.G646Wfs*12; 36.6%)		RUNX1 (p.D198N; MAF 6%)|SF3B1 (p.K666N; MAF 45%)|SRSF2 (p.P95H; MAF 46%)	0.560996116	0.633929502	0.710075269	0.647432929	0.937247068	2.703052917	0.151088908	1.382781409	1.028649281	0.44241266	yes	yes			yes		Found	FALSE	FALSE	FALSE	TRUE	TRUE	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	2.3905136	7.884946951	5.091442436	3.284332729	7.153278187	0.683432199	7.829887696	no	yes	yes	no	yes	yes	yes																
BA3207R	BA3207D	2641	Waves3+4	yes	yes	yes	yes	Male	Male	White	NON-HISPANIC		1			65	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	y	Melanoma	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myelomonocytic leukaemia	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myelomonocytic leukaemia	65	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Leukapheresis	y	y	y	y	y	y	2	Standard Chemotherapy|Intrathecal	2	"7+3 (Cytarabine, Idarubicin)|Methotrexate"	1	Induction	Complete Response	Standard Chemotherapy	-1	Intrathecal	Methotrexate	Induction	6	Dead	21	Dead-Disease	0	90	96	0	0	3.6	92.8	0.9	0.4	15	60	2.2	6.73	M4	19.7	6.6	"46,XY[20]"	2285	90.4	Normal	18	TRUE	"CD11b, variable CD14, CD15, CD33, CD38, variable CD56,  CD58, CD64, CD123, HLA-DR, variable MPO"	FALSE	TRUE	5.9	89.55	TRUE	negative	0	negative	RUNX1 (p.F396Vfs*204; 55.4%)	ASXL1 (p.G646Wfs*12; 35.0%)		IDH1 (p.R132H; MAF 46%)|MLL (Partial tandem duplication )|NRAS (p.Q61R; MAF 45%)|RUNX1 (p.F396fs*204; MAF 46%)|SRSF2 (p.P95L; MAF 28%)	0.689534804	0.326634337	0.88579484	0.789433183	0.663018538	2.351973447	0.074005854	1.528511029	0.71871729	0.054494488		yes			yes		Found	TRUE	FALSE	FALSE	FALSE	TRUE	FALSE	TRUE	FALSE	TRUE	FALSE	TRUE	TRUE	FALSE	1.503978465	2.273772977	3.060581114	3.738666444	6.860253168	-1.833195787	6.134616331	no	no	yes	no	yes	no	yes																
BA3305R	BA3305D	2634	Waves3+4	yes	yes	yes	yes	Male	Male	White			5			84	TRUE	FALSE	TRUE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	"Acute myeloid leukaemia, NOS"	Intermediate	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	"Acute myeloid leukaemia, NOS"	84	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	1	"Venetoclax (ABT-199), Azacitidine"	1	Induction	Complete Response	Standard Chemotherapy	344	Standard Chemotherapy	"Venetoclax (ABT-199), Azacitidine"	Induction	344	Dead	394	Dead-Disease	NA	90		NA	NA	NA	NA	NA	NA	NA	NA	NA	NA		NA	NA	"47,XY,+8[12]/47,XY,+15[8]/46,XY[5]"	NA	NA	Gain of 8q22 and 15q22 sequences	NA	NA		NA	NA	NA	NA	NA	negative	0	negative				IDH2 (R140Q; VAF 51%)|NRAS (Q61K; VAF 27%)|SMC1A (E687*; VAF 64%)|SMC1A (R807H; VAF 13%)|SRSF2 (P95R; VAF 38%)	0.60347693	0.698360263	0.694209118	0.58517556	0.892705091	2.693241572	0.289385066	1.444544961	1.017971319	0.211817057		yes			yes		Found	TRUE	FALSE	FALSE	FALSE	NA	FALSE	FALSE	FALSE	FALSE	FALSE	NA	TRUE	TRUE	1.317843449	4.90219466	1.371851629	4.16243646	5.892800706	-1.189469267	6.276035046	no	yes	no	yes	no	no	yes																
BA3434R	BA3434D	2651	Waves3+4	yes	yes	yes	yes	Female	Female	White	NON-HISPANIC		1			78	TRUE	FALSE	FALSE	TRUE	FALSE	FALSE	n		y	n	y	y	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	78	0	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	3	CPX-351 (Liposomal Cytarabine + Daunorubicin)|Lenalidomide|Azacitidine	2	Experimental|Supportive/Palliative Care			NA	Standard Chemotherapy	CPX-351 (Liposomal Cytarabine + Daunorubicin)	Experimental	0	Dead	79	Dead-Disease	NA	35	23	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	M2	NA	NA	"46,XX,del(9)(q22q22)[20] "	NA	NA	"With the TP53 probe set, 7/200 cells (3.5%) were missing a TP53  signal, within normal limits, but also this patient's previous abnormal  pattern. Ê"	NA	NA	"CD13, CD33, CD34, CD38, CD58, CD117, HLA-DR, partial  MPO "	FALSE	TRUE	NA	NA	NA	negative	0	negative	RUNX1 (p.T196Dfs*17; 40.6%)|RUNX1 (p.X20_splice; 49.2%)			"DNMT3A (p.A644fs*7; MAF 37%)|ETV6 (p.L205fs*12; MAF 30%)|IKZF1 (p.N159S; MAF 35%)|NRAS (p.Q61H; MAF 31%)|RUNX1 (c.58+2T>C, Donor-splice-site mutation in intron 1; MAF 46%)|RUNX1 (p.T196fs*17; MAF 46%)|SF3B1 (p.K700E; MAF 51%)"	0.660168901	0.889974099	0.766524762	0.763771252	0.826362774	2.894122594	0.497210839	1.41550737	1.021490769	0.367471991	yes				yes	yes	Found	FALSE	FALSE	TRUE	TRUE	NA	FALSE	FALSE	FALSE	TRUE	FALSE	NA	TRUE	TRUE	5.330282684	6.42812419	2.09051066	6.055736452	5.753781149	-0.678720436	6.039384133	yes	yes	no	yes	no	yes	yes																
BA3329R	BA3329D	2715	Waves3+4	yes	yes	yes	yes	Male	Male		HISPANIC		5	mono		77	TRUE	FALSE	FALSE	TRUE	FALSE	FALSE	n		y	n	y	y	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Intermediate	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	77	0	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	1	Standard Chemotherapy	2	"Venetoclax (ABT-199), Azacitidine|Azacitidine"	2	Induction|Maintenance	Refractory	Standard Chemotherapy	36	Standard Chemotherapy	"Venetoclax (ABT-199), Azacitidine"	Induction	36	Dead	113	Dead-Disease	NA	22		NA	NA	NA	NA	NA	NA	NA	NA	NA	NA		NA	NA	"46,XY,inv(4)(p14q21)[9]/47,sl,+8[2]/46,XY[10]Ê"	NA	NA	Gain of chromosome 8 (trisomy)	NA	NA		NA	NA	NA	NA	NA	negative	0	negative				CEBPA (P189dup; VAF 30%)|ETV6 (N228S; VAF 52%)|SRSF2 (P95R; VAF 18%)|STAG2 (VAF 34%)|TET2 (Q745*; VAF 23%)	0.613331374	0.616743227	0.705039085	0.59370198	0.298245857	2.750875853	0.142529252	1.237891949	0.484606314	0.08647744		yes			yes	yes	Found	FALSE	TRUE	FALSE	FALSE	NA	FALSE	FALSE	FALSE	FALSE	FALSE	NA	TRUE	TRUE	3.303259475	3.696205542	2.71568991	4.251887854	4.835825507	-0.579262827	1.62461307	yes	yes	no	yes	no	yes	no																
BA3183R	BA3183D	2798	Waves3+4	yes	yes	yes	yes	Male	Male	White	NON-HISPANIC		1			64	TRUE	FALSE	FALSE	TRUE	FALSE	FALSE	n		y	n	n	n	y	y	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	64	0	Post-Chemotherapy|Residual Disease	Residual	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	5	"Fludarabine, Melphalan|5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|Azacitidine|Decitabine"	4	Consolidation|Induction|Supportive/Palliative Care|Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	5	Bone Marrow Transplant	"Fludarabine, Melphalan"	Allogeneic - Matched Unrelated Donor	-1	Dead	337	Dead-Treatment	0	51	65	0.9	NA	12.3	3.5	15.8	0.1	20	13	2.6	1.2		24.4	8.2	"46,XY[20]"	NA	103	Normal	46	TRUE	"CD13, CD33, CD38, CD58, CD117, CD123, partial MPO+"	FALSE	TRUE	6.5	15.38	FALSE	negative	0	positive				"ATM (p.H1136R; MAF 45%)|DNMT3A (p.R882H; MAF 46%)|IDH1 (p.R132H; MAF 27%)|IDH2 (p.D314V (Low allele frequency, subclonal), MAF 2%)|IDH2 (p.R140Q; MAF 18%)|KRAS (p.G12A; MAF 3%)|NPM1 (p.W288fs*12; MAF 49%)|U2AF1 (p.D208E; MAF 46%)"	0.383597965	0.667504321	0.606944699	0.328676923	0.996330846	2.908200176	0.171985367	1.293389715	0.9460843	0.052122085			yes		yes		Found	TRUE	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	0.872750258	1.397328316	-0.334928321	2.422475967	5.908410754	-0.49525152	5.319397189	no	no	no	no	no	yes	yes																
BA3311R	BA3311D	2720	Waves3+4	yes	yes	yes	yes	Male	Male	White	NON-HISPANIC		1			74	TRUE	FALSE	FALSE	TRUE	FALSE	FALSE	y	Prostate Cancer	y	y	y	y	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	Intermediate	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	74	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	1	Standard Chemotherapy	1	Azacitidine	1	Induction	Unknown	Standard Chemotherapy	6	Standard Chemotherapy	Azacitidine	Induction	6	Dead	24	Dead-Disease	NA	21	8	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	M2	NA	NA	"48,XY,+11,+13[17]/46,XY[3]"	NA	NA	"MLL (11q23):  161/200 cells (80.5%) had three intact signals for MLL, consistent with the trisomy 11 seen on metaphase analysis. "	NA	NA	"CD13, CD33, CD34, variable CD38, partial CD64, CD117, dim CD123, HLA-DR, partial TdT. "	FALSE	TRUE	NA	NA	NA	negative	0	negative				CBLB (p.V581M; MAF 52%)|DNMT3A (p.V877fs*4; MAF 40%)|MLL (Partial tandem duplication (exon 9/exon 3) )|NRAS (p.G12D; MAF 14%)|U2AF1 (p.S34F; MAF 43%)|WT1 (p.R353fs*15; MAF 26%)|WT1 (p.S364*; MAF 25%)	0.822026286	0.725319386	0.907459661	0.780950896	0.83609206	2.74786677	0.226057115	1.511572119	0.861427128	0.243643038			yes		yes		Found	FALSE	FALSE	TRUE	FALSE	NA	FALSE	FALSE	FALSE	FALSE	FALSE	NA	TRUE	FALSE	6.518633362	7.086715234	4.125761549	4.502099476	8.040607806	-0.286763973	6.330027942	yes	yes	yes	yes	yes	yes	yes																
BA3175R	BA3175D	2783	Waves3+4	yes	yes	yes	yes	Male	Male	White	NON-HISPANIC		1			62	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	63	248	Post-Chemotherapy|Residual Disease	Residual	Peripheral Blood	y	y	y	y	y	y	2	Standard Chemotherapy|Targeted Therapy - Other	5	"Decitabine, anti-PD1, anti-TIM3|7+3 (Cytarabine, Idarubicin)|JNJ-40346527 (CSF1R inhibitor)|Mitoxantrone|FLAG, Midostaurin"	3	Salvage|Induction|Re-induction	Refractory	Standard Chemotherapy	6	Standard Chemotherapy	Mitoxantrone	Salvage	0	Dead	373	Dead-Disease	0.9	25		0	NA	6.8	58.1	16.2	0.1	55	53	3.5	1		27.2	9.5	"46,XY,t(1;3)(p36;q21)[2]/46,sl,-1,+der(1)t(1;3)(p36;q21)[15]/46,sl,add(3)(q12)[2]/46,sl,-1,+t(1;3)(p36;q21),-3[1]"	NA	83.4	"MECOM/RPN1: Ê171/200 cells (85.5%) had a 2 red/ 3 green signal pattern,  reflecting an extra RPN1 (3q21.3) signal, consistent with RPN1 disruption  due to the 1;3 translocation observed in the metaphase karyotype. ÊThere  was no evidence for MECOM/RPN1 fusion. "	20	FALSE	"CD7, CD13, CD33, CD34, CD117, and HLA-DR positive"	TRUE	TRUE	7.1	39.59	TRUE	positive	0.234567901	negative	RUNX1 (p.D198N; 44.9%)			"BCL2 (p.A32G; VAF 48%)|FLT3-ITD (p.N609delinsIIPCPEYDLKWEFPREN; VAF 19%, allelic ratio 0.24)|GATA2 (p.S201fs*1; VAF 13%)|NPM1 (p.H30Q; VAF 3%)|NRAS (p.G12D; VAF 72%)|RUNX1 (p.D198N; VAF 44%)|WT1 (p.R380fs*5; VAF 45%)|WT1 (p.V371fs*14; VAF 22%)|ZRSR2 (p.P350R; VAF 5%)"	0.703729223	0.770618907	0.816047234	0.986041109	0.79281754	2.72370376	0.209783682	1.537929824	0.962747161	0.175724859				yes	yes	yes	Found	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	TRUE	TRUE	TRUE	TRUE	FALSE	1.667792673	3.694364627	-1.132160519	4.092741897	6.813948945	-2.713314441	5.768788583	no	yes	no	yes	yes	no	yes																
BA3199R	BA3199D	2724	Waves3+4	yes	yes	yes	yes	Male	Male	White			5	mono		69	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	y	Prostate Cancer	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	"Acute myeloid leukaemia, NOS"	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	"Acute myeloid leukaemia, NOS"	69	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	1	Standard Chemotherapy	1	"7+3 (Cytarabine, Idarubicin)"	1	Induction	Refractory	Standard Chemotherapy	7	Standard Chemotherapy	"7+3 (Cytarabine, Idarubicin)"	Induction	7	Dead	156	Dead-Disease	NA	94		NA	NA	NA	NA	NA	NA	NA	NA	NA	NA		NA	NA	"46,XY[19]Ê"	NA	NA	Normal	NA	NA		NA	NA	NA	NA	NA	negative	0	negative	RUNX1 (p.X269_splice; 48.1%)	ASXL1 (p.K618_A619ins*; 43.5%)		ASXL1 (A619*; VAF 47%)|CEBPA (H24Afs*84; VAF 44%)|CEBPA (R165Afs*153; VAF 48%)|RUNX1 (VAF 45%)|SRSF2 (P95H; VAF 53%)|TET2 (S1486*; VAF 48%)	0.389294875	0.805611612	0.639711581	0.768236175	0.614526335	3.006854985	0.38162718	1.326598117	0.832366034	0.065791674		yes			yes		Found	FALSE	TRUE	FALSE	FALSE	NA	FALSE	TRUE	FALSE	TRUE	FALSE	NA	FALSE	FALSE	2.294287283	2.634397104	1.316669546	0.117009636	3.854717163	-1.141186731	3.29390664	no	no	no	no	no	no	no																
BA3326R	BA3326D	2797	Waves3+4	yes	yes	yes	yes	Male	Male	White			5			63	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	y	Prostate Cancer	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	63	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	1	"Venetoclax (ABT-199), Azacitidine"	1	Induction	Refractory	Standard Chemotherapy	29	Standard Chemotherapy	"Venetoclax (ABT-199), Azacitidine"	Induction	29	Dead	52	Dead-Disease	NA	59		NA	NA	NA	NA	NA	NA	NA	NA	NA	NA		NA	NA	"47,XY,+6[4]/49,sl,+6,+22[2]/49,sl,+4,+8,i(8)(q10)x2[5]/47,XY,+r[2]/46,XY[7]"	NA	NA	"Gain of 8q22, 8 centromere and 16q22 sequences"	NA	NA		NA	NA	NA	NA	NA	negative	0	negative		ASXL1 (p.G646Wfs*12; 36.6%)		ASXL1 (G64Wfs*12; VAF 39%)|NRAS (Q61K; VAF 33%)|TET2 (Q892*; VAF 49%)	0.680858	0.239311752	0.758360256	0.860254209	1.046757925	2.295204341	-0.154046102	1.558706001	0.937753962	0.228673926					no		Found	FALSE	TRUE	FALSE	FALSE	NA	FALSE	TRUE	FALSE	FALSE	FALSE	NA	TRUE	FALSE	4.843555783	4.666461236	2.524098871	2.554574235	5.830943608	0.399544051	6.650696125	yes	yes	no	no	no	yes	yes																
BA3260R	BA3260D	2806	Waves3+4	no	no	no	no	Male	Male	White			5			72	TRUE	FALSE	FALSE	FALSE	TRUE	FALSE	n		n	n	y	y	n	n	n	n	MYELODYSPLASTIC SYNDROMES	Refractory cytopenia with multilineage dysplasia	NonAML	MYELODYSPLASTIC SYNDROMES	Refractory cytopenia with multilineage dysplasia	72	0			Bone Marrow Aspirate	y	y	y	y	y	y	0		0		0				NA	NONE	NONE	NONE	NA	Dead	308	Dead-Disease	NA	2		NA	NA	NA	NA	NA	NA	NA	NA	NA	NA		NA	NA	"46,XY[20]"	NA	NA	Normal	NA	NA		NA	NA	NA	NA	NA	negative	0	negative		ASXL1 (p.G646Wfs*12; 36.2%)		ASXL1 (G646Wfs*12; VAF 41%)|BRAF (G469A; VAF 50%)|ETV6 (VAF 48%)|KRAS (Y64N; VAF 10%)|SRSF2 (P95H; VAF 45%)	0.90648429	0.304989449	0.872892007	0.827128016	0.869575771	2.31707962	0.044435064	1.474567895	1.065885434	0.403633878		yes			yes		Found	FALSE	FALSE	FALSE	FALSE	NA	FALSE	TRUE	FALSE	FALSE	FALSE	NA	TRUE	TRUE	4.985486885	9.222877206	7.782535318	3.471966761	7.130443928	1.479667395	9.144815023	yes	yes	yes	no	yes	yes	yes																
BA3446R	BA3446D	2739	Waves3+4	no	no	no	no	Female	Female	White	NON-HISPANIC		1			66	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	67	366	Relapse|Post-Chemotherapy	Relapse	Peripheral Blood	y	y	y	y	y	y	3	Standard Chemotherapy|Bone Marrow Transplant|Intrathecal	5	"Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|MiDAC|HiDAC, Mitoxantrone, CPI-613|Methotrexate"	4	Consolidation|Induction|Re-induction|Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	6	Bone Marrow Transplant	"Fludarabine, Melphalan"	Allogeneic - Matched Unrelated Donor	-1	Alive	1130	Alive	0	26		0	NA	7.9	21.1	22.8	0.1	35	39	2.7	0.66	M5	33.8	10.6	"46,XX,del(14)(q21q31)[20] "	775	90.1	Normal	14	FALSE	"Myeloid blasts: CD13, CD33, CD38, CD117, HLA-DR. | Blasts with monocytic features: CD11b, dim CD13, CD15, CD33, CD38, CD64, HLA-DR  "	FALSE	TRUE	5.7	39.23	TRUE	negative	0	positive				BCOR (p.E1093K; VAF 48%)|DNMT3A (p.N797D; VAF 46%)|FAT4 (p.D1836N; VAF 41%)|IDH2 (p.R140Q; VAF 47%)|KMT2D (p.P647T; VAF 67%)|NPM1 (p.W288fs*12; VAF 43%)|NRAS (p.Q61P; VAF 46%)|RBBP6 (p.P1416A; VAF 51%)	0.641676721	0.573101465	0.820378916	0.83993722	1.055202219	2.641188425	0.047860354	1.507122532	0.863903984	0.10380132					no		Found	TRUE	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	TRUE	TRUE	FALSE	0.962688765	3.40936163	0.986902066	2.294287283	6.606345231	-0.534916744	6.172970101	no	no	no	no	yes	yes	yes																
BA3234R	BA3234D	2688	Waves3+4	yes	yes	yes	yes	Male	Male	White	NON-HISPANIC		1			75	TRUE	FALSE	TRUE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	75	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	1	Azacitidine	1	Induction	UNKNOWN	Standard Chemotherapy	8	Standard Chemotherapy	Azacitidine	Induction	8	Dead	91	Dead-Disease	0	80		0	NA	4.4	77.4	11.3	0.1	52	29	2.4	2.78	M5	31.4	10.1	"46,XY[20]"	747	99.1	Normal	39	TRUE	"Monocytic population (about 80%) : dim CD4, dim CD9, CD11b, partial CD13,  partial CD14, CD15, subset CD16, CD33, CD38, CD56, CD64, and HLA-DR. | Myeloid blasts phenotype (8%): CD33, CD56, CD117, HLA-DR, and MPO"	FALSE	TRUE	5.9	84.29	TRUE	negative	0	positive				NPM1 (p.W288fs*12; VAF 24%)|SRSF2 (p.P95R; VAF 48%)|TET2 (p.R506*; VAF 95%)	0.768492021	0.27771488	0.928556882	1.015789181	1.007846617	2.404989987	-0.002254831	1.564384711	0.796558473	0.129983851		yes			yes		Found	FALSE	TRUE	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	TRUE	TRUE	TRUE	2.261333777	4.308013345	3.732390207	1.685176012	7.065966362	-0.722823053	2.736165519	no	yes	yes	no	yes	yes	no																
BA3087R	BA3087D	2693	Waves3+4	yes	yes	yes	yes	Male	Male	White	NON-HISPANIC		1			31	TRUE	FALSE	TRUE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML without maturation	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML without maturation	31	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	4	"Fludarabine, Melphalan|5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|Azacitidine"	4	Induction|Re-induction|Maintenance|Allogeneic - Matched Unrelated Donor	Refractory	Standard Chemotherapy	6	Bone Marrow Transplant	"Fludarabine, Melphalan"	Allogeneic - Matched Unrelated Donor	-1	Alive	1073	Alive	0	90		0.9	NA	26.1	1.7	0.9	0.9	13	10	3.8	0.97	M1	24.8	8.6	"46,XY,del(5)(q13q33),t(10;11)(p13;q21)[15]/46,XY[5] "	165	98	"93% of cells were missing a signal for both 5q probes (EGR1, 5q31; and 5q33) but had two signals for 5p, consistent with 5q deletion. "	196	TRUE	"partial CD7, CD13, CD33, CD34, dim CD38, CD56, CD117, HLA-DR, partial MPO, and dim TDT."	TRUE	TRUE	7.1	17.92	FALSE	negative	0	negative		ASXL1 (p.D821Efs*15; 26.7%)|ASXL1 (p.D821Wfs*6; 20.1%)		ASXL1 (p.D821fs*12; VAF 28%)|CREBBP (p.N970fs*21; VAF 8%)|JAK1 (p.T114A; VAF 49%)|KMT2D (p.R598H; VAF 49%)|WT1 (p.S165fs*35; VAF 45%)	0.24810203	0.758810077	0.035979467	0.675212846	0.632779905	2.813053007	0.288435036	0.781966146	0.64222449	-0.181762774					no		Found	FALSE	FALSE	FALSE	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	2.583142494	1.744206884	0.680294621	2.393236193	4.934705374	-2.713314441	1.317843449	no	no	no	no	no	no	no																
BA3302R	BA3302D	2805	Waves3+4	yes	yes	yes	yes	Male	Male	White	NON-HISPANIC		1			65	TRUE	FALSE	TRUE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	65	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	3	Standard Chemotherapy|Targeted Therapy - Other|Targeted Therapy - Kinase Inhibitor(s)	5	"7+3 (Cytarabine, Idarubicin)|SY-1425 (Tamibarotene) plus Daratumumab|Pexidartinib|Azacitidine, BI 836858 (anti-CD33)|Ruxolitinib, Venetoclax"	2	Induction|Experimental|Re-Induction	Refractory	Standard Chemotherapy	6	Targeted Therapy - Kinase Inhibitor(s)	"Ruxolitinib, Venetoclax"	Experimental	69	Dead	541	Dead-Disease	1.7	80	80	0	NA	12.9	1.7	7.8	1.4	41	47	3.5	1.4	M1	26.9	8.5	"46,XY[20] "	1042	95.4	Normal	29	FALSE	"partial CD10, CD13, CD33, CD34, subset CD79a, CD117, HLA-DR, partial MPO, and TDT+"	TRUE	TRUE	6.3	32.75	TRUE	negative	0	negative	RUNX1 (p.D198N; 47.7%)			CBL (p.V363_Q365del; VAF 31%)|RUNX1 (p.D198N; VAF 50%)|SF3B1 (p.K666N; VAF 51%)	0.346201051	0.899526658	0.477263849	0.586498115	0.66377441	2.994557772	0.399384783	1.21990355	0.902830912	0.071823599	yes				yes	yes	Found	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	1.844439662	1.572277307	1.399473865	1.474388626	4.205974553	-3.689319128	5.239657954	no	no	no	no	no	no	yes																
BA3242R	BA3242D	2805	Waves3+4	no	no	no	no	Male	Male	White	NON-HISPANIC		1			65	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	66	316	Residual Disease|Post-Chemotherapy	Residual	Bone Marrow Aspirate	y	y	y	y	y	y	3	Standard Chemotherapy|Targeted Therapy - Other|Targeted Therapy - Kinase Inhibitor(s)	5	"7+3 (Cytarabine, Idarubicin)|SY-1425 (Tamibarotene) plus Daratumumab|Pexidartinib|Azacitidine, BI 836858 (anti-CD33)|Ruxolitinib, Venetoclax"	2	Induction|Experimental	Refractory	Standard Chemotherapy	6	Targeted Therapy - Kinase Inhibitor(s)	"Ruxolitinib, Venetoclax"	Experimental	69	Dead	541	Dead-Disease	0.3	46	23	0.3	NA	43.8	21.3	21.7	3.9	12	22	3.9	0.94	M1	23.8	7.8	"46,XY[20]"	530	105.3	Normal	14	FALSE	"partial CD10, CD34, CD13, CD117, and HLA-DR"	FALSE	FALSE	5.8	10.24	FALSE	negative	0	negative	RUNX1 (p.D198N; 47.3%)			ATG2B (p.L1989V; VAF 51%)|CBL (p.V363_Q365del; VAF 34%)|FLT3-ITD (Allelic Ratio: ~0.013)|MED12 (p.N1049T; VAF 97%)|RTEL1 (p.S925Y; VAF 50%)|RUNX1 (p.D198N; VAF 47%)|SF3B1 (p.K666N; VAF 47%)|SH2B3 (p.S488Y; VAF 49%)	0.552726339	0.742181772	0.772699603	0.581484732	0.91087749	2.803692009	0.237056133	1.348531798	1.130381255	0.398164858	yes				yes	yes	Found	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	4.595808654	6.361822386	2.885208585	2.029156318	6.666754375	0.041398241	7.56094852	yes	yes	yes	no	yes	yes	yes																
BA3268R	BA3268D	2773	Waves3+4	yes	yes	yes	yes	Female	Female	White	NON-HISPANIC		1			73	TRUE	FALSE	TRUE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	73	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Targeted Therapy - Other	2	"Azacitidine, Ivosidenib|Ivosidenib"	2	Induction|Maintenance	Complete Response	Standard Chemotherapy	324	Targeted Therapy - Other	Ivosidenib	Maintenance	-1	Alive	1028	Alive	0	92	90	0	NA	17.7	1	0	9.6	23	39	2.7	0.85	M1	25.5	8.3	"46,X,-X,add(5)(q23),del(7)(q22),add(11)(p13),add(21)(q22),+mar1[9]/47,sl,add(3)(q28),+5,-add(5)(q23),+mar2[3]/46,XX[1] "	615	97.3	"D7S486/ CEP 7:  93/100 cells (90%) had a 1 red/ 2 green signal pattern, consistent with the deleted 7q observed in the metaphase karyotype.  | RUNX1T1/RUNX1:  10/200 cells (5%) had a 2 red/ 3 green signal pattern, suggesting low level presence of an extra copy of RUNX1 (21q22).  There was no evidence for RUNX1T1/RUNX1 fusion.  | EGR-1/ D5S23, D5S721: While this probe set showed a normal numeric signal pattern in interphase cells, metaphase FISH showed an EGR-1 (5q) signal on the add(11p) and a 5q33 signal on the add(21q).  (The G-banded chromosomes were not of adequate band length/morphology to establish specific breakpoints.  Therefore, it is possible that some or all of the apparently missing 5q material is actually accounted for on other chromosomes.  This probe set will not be useful for monitoring the abnormal 5q.)"	48	TRUE	"CD7, dim CD13, CD33, CD34, CD38, CD117, partial HLA-DR, and partial MPO"	TRUE	TRUE	5.8	11.49	FALSE	negative	0	negative				DNMT3A (Splice site; VAF 46%)|IDH1 (p.R132S; VAF 44%)|STAG2 (p.F437fs*11; VAf 48%)	0.351967255	0.94027651	0.214264972	0.48898427	0.472723349	2.821432643	0.336388691	0.923963492	0.649336741	0.051391795					no		Found	TRUE	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	0.152257105	1.706039969	3.444616701	4.23854264	3.974234977	-5.203063766	-2.837666896	no	no	yes	yes	no	no	no																
BA3229R	BA3229D	2619	Waves3+4	yes	yes	yes	yes	Male	Male	White	NON-HISPANIC		1			56	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	n		y	n	n	n	y	y	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	56	0	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	2	Standard Chemotherapy|Targeted Therapy - Other	5	"HAM (Cytarabine, Mitoxantrone)|Azacitidine|Vyxeos (Daunorubicin, Cytarabine - liposomal)|MBG453 (TIM-3 inhibitor)|Decitabine, Ruxolitinib"	4	Salvage|Induction|Maintenance|Re-induction	Refractory	Standard Chemotherapy	5	Standard Chemotherapy	"Decitabine, Ruxolitinib"	Salvage	-1	Dead	164	Dead-Disease	2.5		35	2.5	NA	3.4	12.6	41.2	0.9	17	27	3.3	1.31		29.1	8.7	"49,XY,+10,+13,+21[6]/51,idem,+9,+15[14]"	363	105.8	"Chromosome 9:  With all chromosome 9 probes (ABL, ASS and NUP214) ~20% of cells had three signals, consistent with trisomy 9.  | PML (15q24): 17% of cells had three signals, consistent with trisomy 15.  | RUNX1 (21q22):  69% of cells had three signals, consistent with trisomy 21. "	112	FALSE	"partial CD11b, CD13, partial CD25, CD33, CD34, CD38, partial CD56, CD117 and HLA-DR positive"	FALSE	TRUE	7.2	85.46	TRUE	negative	0	negative	RUNX1 (p.S322*; 49.8%)	ASXL1 (p.G646Wfs*12; 37.6%)		ASXL1 (p.G646fs*12; VAF 36%)|BRAF (p.G469R; VAF 36%)|CREBBP (p.F1703fs*33; VAF 12%)|CSF3R (p.T618I; VAF 5%)|EZH2 (p.F672L; VAF 73%)|FLT3 (p.V491L; VAF 53%)|NRAS (p.G12D; VAF 10%)|RUNX1 (p.G199E; VAF 7%)|RUNX1 (p.S322*; VAF 52%)	0.751656692	0.780168054	0.878558293	0.833653099	0.939586927	2.834797982	0.434944621	1.447468435	1.021760062	0.373223981					no		Found	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	TRUE	FALSE	TRUE	FALSE	TRUE	TRUE	FALSE	5.103157571	6.310689736	4.999926136	1.950096804	6.71095851	-1.192589773	6.510045959	yes	yes	yes	no	yes	no	yes																
BA3312R	BA3312D	2703	Waves3+4	yes	yes	yes	yes	Male	Male	White	NON-HISPANIC		1	bi		43	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated CEBPA	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated CEBPA	43	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	2	"7+3 (Cytarabine, Idarubicin)|HiDAC"	2	Consolidation|Induction	Complete Response	Standard Chemotherapy	6	Standard Chemotherapy	HiDAC	Consolidation	132	Dead	472	Dead-Disease	0	70	68	1.7	NA	14.8	5.2	9.6	0.1	25	24	2.9	0.84	M2	16.5	5.5	"46,XY,t(2;12)(p13;q13)[20]"	1024	102.5	Normal	21	FALSE	"CD13, CD33, variable CD34, CD117, and HLA-DR positive (CD7, dim CD15, and MPO expression was noted on the prior flow cytometric analysis and was not tested in the current assay)"	TRUE	TRUE	7	79.15	TRUE	negative	0	negative				CEBPA (p.G36fs*122; VAF 45%)|CEBPA (p.Q311_Q312linsRKAKQRNVETQ; VAF 45%)|DNMT3A (p.R19P; VAF 48%)|EZH2 (p.K30fs*17 (loss of function); VAF 65%)|GATA2 (p.R362Q; VAF 47%)|NRAS (p.G13D; VAF 43%)	0.461881012	0.55292168	0.652006091	0.698030383	0.916631676	2.765652664	-0.106939544	1.395973975	1.115466106	0.190121665					no		Found	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	2.66937549	4.388170118	1.046216879	2.083415254	5.022017225	-0.470048586	8.184160358	no	yes	no	no	no	yes	yes																
BA3119R	BA3119D	2778	Waves3+4	yes	yes	yes	yes	Female	Female	White	NON-HISPANIC		1			61	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	61	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	2	"7+3 (Cytarabine, Idarubicin)|MiDAC"	2	Consolidation|Induction	Complete Response	Standard Chemotherapy	6	Standard Chemotherapy	MiDAC	Consolidation	101	Alive	784	Alive	0.8	90	65	0	NA	30.2	3.1	6.2	5.3	21	13	3.4	0.5	M1	31.3	10.8	"46,XX[20] "	NA	95.7	Normal	104	TRUE	"CD33, CD38, CD117, MPO positive"	FALSE	TRUE	7.7	4.68	FALSE	negative	0	positive				ASXL1 (p.L1395V; VAF 50%)|IDH1 (p.R132H; VAF 45%)|KMT2D (p.R3167W; VAF 48%)|NPM1 (p.W288fs*12; VAF 48%)	0.154983267	0.631772097	0.154986728	0.453052496	0.803180858	3.033542593	0.231374347	1.014376666	0.828571496	-0.136330079					no		Found	TRUE	FALSE	FALSE	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	1.923986914	1.637454821	-1.173606791	3.678995048	3.865404352	-2.52260439	-1.030400299	no	no	no	no	no	no	no																
BA3208R	BA3208D	2620	Waves3+4	yes	yes	yes	yes	Female	Female	White	NON-HISPANIC		1			70	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	n		y	n	n	n	n	n	y	y	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML without maturation	Intermediate	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML without maturation	70	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	1	"Ruxolitinib, Vyxeos (Daunorubicin, Cytarabine - liposomal)"	1	Induction	Refractory	Standard Chemotherapy	43	Standard Chemotherapy	"Ruxolitinib, Vyxeos (Daunorubicin, Cytarabine - liposomal)"	Induction	43	Dead	84	Dead-Disease	0	85	78	0.9	NA	19.3	0	0	1.2	30	34	3.5	0.81	M1	28.1	9.5	"46,XX[18]"	623	110.6	Normal	57	FALSE	"variable CD11b, CD13, CD33, CD34, variable CD38, dim variable cCD79a, CD117, HLA-DR, cMPO, and cTdT positive"	TRUE	TRUE	6.7	27.26	TRUE	negative	0	negative				"DNMT3A (p.R882H; VAF 47%)|FLT3-ITD (allelic ratio 0.03; VAF 3%)|KMT2A (PTD, exon 9/3 break)|TET2 (p.H578fs*2; VAF 36%)|TET2 (p.Y1345fs*14; VAF 27%)|WT1 (p.D367_V374delinsWS; VAF 3%)|WT1 (p.R370fs*6; VAF 5%)|WT1 (p.R380fs*5; VAF 2%)|WT1 (p.R380fs*5; VAF 47%)|WT1 (p.T377fs*73; VAF 23%)|ZRSR2 (p.R452C; VAF 48%)"	0.427384487	0.757012808	0.332304625	0.777749177	0.645359716	2.973571797	0.322369153	1.220327657	0.906627716	-0.16048329				yes	yes		Found	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	-0.68144834	0.91026955	1.950937219	2.842422378	5.292721338	-2.996770219	0.843813627	no	no	no	no	no	no	no																
BA3310R	BA3310D	2716	Waves3+4	yes	yes	yes	yes	Male	Male	White	NON-HISPANIC		1			82	TRUE	FALSE	TRUE	FALSE	FALSE	FALSE	n		n	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	82	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	0		0		0				NA	NONE	NONE	NONE	NA	Dead	17	Dead-Disease	0	90	70	0	NA	1.7	0	16.7	0.2	11	38	1.9	0.7	M1	25.7	7.8	"46,XY[20]"	421	88.6	Normal	23	TRUE	"dim CD13, CD33, CD117 and MPO"	FALSE	TRUE	6.4	44.35	TRUE	negative	0	positive				CBL (p.G838V; VAF 48%)|CREBBP (p.N1615S; VAF 48%)|FLT3 (p.D839G; VAF 6%)|FLT3 (p.N676K; VAF 2%)|FLT3-ITD (Allelic ratio 0.01)|IDH2 (p.R140Q; VAF 46%)|KIT (p.D816V; VAF 4%)|KMT2D (p.F4579S; VAF 49%)|NPM1 (p.W288fs*12; VAF 46%)|SRSF2 (p.P95_R102del; VAF 45%)	0.299014644	0.682476064	0.532977443	0.297824158	0.826269483	2.886950052	0.299238594	1.140359367	0.815376992	0.032335028		yes			yes		Found	TRUE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	2.583768981	4.769951631	0.483801055	2.236016563	4.343078332	-1.296592903	2.455968127	no	yes	no	no	no	no	no																
BA3211R	BA3211D	2697	Waves3+4	yes	yes	yes	yes	Male	Male	White	NON-HISPANIC		1			69	TRUE	FALSE	FALSE	TRUE	FALSE	FALSE	n		y	n	y	y	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	69	0	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Targeted Therapy - Other	4	"Gilteritinib (ASP2215)|Azacitidine|RVD (Bortezomib, Dexamethasone, Lenalidomide)|7+3 (Cytarabine, Daunorubicin) plus Gemtuzumab Ozogamicin plus Midostaurin"	3	Salvage|Induction|Maintenance	Refractory	Standard Chemotherapy	6	Targeted Therapy - Other	Gilteritinib (ASP2215)	Salvage	-1	Dead	76	Dead-Disease	0	90	78	0	NA	35	31	7	0	12	8	2	0.87	M0	21.6	7.4	"46,XY,del(20)(q11.2)[cp20]"	198	87.8	"CEP 3:  16/100 cells (16%) had three signals, reflecting trisomy 3. "	15	TRUE	"CD43+ and dim CD45+ with dim CD13, dim CD33, dim CD38, partial CD11b, variable HLA-DR, and partial, dim CD117"	FALSE	TRUE	4.9	5.79	FALSE	positive	0.176470588	negative	RUNX1 (p.R346Pfs*254; 37.7%)|RUNX1 (p.X269_splice; 43.5%)			FLT3-ITD (allelic ratio 0.84; VAF 45.7%)|KMT2A (PTD (exon 11/exon 3))|RUNX1 (splice site; VAF 43%)|U2AF1 (p.S34F; VAF 44%)	0.499890382	0.763924331	0.496385045	0.716457391	0.745319317	2.757111195	0.329994437	1.314158155	0.811292076	-0.044704153			yes		yes	yes	Found	FALSE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	4.847741882	2.761737646	5.311447479	4.883287719	6.622989664	-2.325231175	4.024941179	yes	no	yes	yes	yes	no	no																
BA3130R	BA3130D	2610	Waves3+4	yes	yes	yes	yes	Male	Male	White	NON-HISPANIC		1			61	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	n		y	n	n	n	y	y	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Intermediate	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	61	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	3	"Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|HiDAC"	3	Allogeneic - Sibling|Consolidation|Induction	Complete Response	Standard Chemotherapy	-1	Bone Marrow Transplant	"Fludarabine, Melphalan"	Allogeneic - Sibling	-1	Dead	110	Dead-Treatment	0	20	20	0	NA	20.5	55.4	15.2	0.1	160	228	2.1	2.11	M2	22.3	7.6	"48,XY,+7,+mar[4]/46,XY[16] "	NA	99.1	"Chromosome 7: 44% of cells had three signals for both chromosome 7 probes, consistent with trisomy 7"	23	TRUE	"CD4, dim CD7, CD11b, CD13, variable CD14, CD16, dim CD33, dim CD 38, dim CD56, CD64."	TRUE	TRUE	4.6	69.09	TRUE	negative	0	negative				BRAF (p.V600E; VAF 36%)|TET2 (p.A1355V; VAF 48%)|TET2 (p.Q803*; VAF 44%)|ZRSR2 (Splice site; VAF 92%)	0.941099468	0.147195601	0.931367405	0.755879756	0.82577979	2.166976125	-0.091306635	1.538426639	0.964742053	0.21667926				yes	yes	yes	Found	FALSE	TRUE	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	TRUE	TRUE	FALSE	3.232408718	4.236648699	4.116634861	4.756222067	6.917333013	4.0684852	7.270225477	yes	yes	yes	yes	yes	yes	yes																
BA3123R	BA3123D	2611	Waves3+4	yes	yes	yes	no	Male	Male	White	NON-HISPANIC		1			69	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	y	Prostate Cancer	y	y	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	69	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	n	y	y	n	2	Standard Chemotherapy|Bone Marrow Transplant	4	"Busulfan, Fludarabine|Venetoclax (ABT-199), Azacitidine|7+3 (Cytarabine, Daunorubicin) plus Glasdegib/placebo|MiDAC plus Glasdegib/placebo"	4	Consolidation|Salvage|Induction|Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	6	Standard Chemotherapy	"Venetoclax (ABT-199), Azacitidine"	Salvage	149	Dead	468	Dead-Disease	0	60		0	NA	24.3	2.9	11.4	0	31	22	4.2	0.55	M2	33.3	10.9	"46,XY[20]"	256	109.2		21	FALSE	"variable CD5, CD7, CD11b (partial), CD13, CD33 (dim), CD34, CD38 (dim), CD117, and HLA-DR"	TRUE	TRUE	7.1	9.32	FALSE	negative	0	negative		ASXL1 (p.T514Nfs*15; 34.3%)		ASXL1 (p.T514fs*15; VAF 37%)|BLM (p.N936D; VAF 50%)|CSF3R (p.R311C; VAF 50%)|KMT2A (p.D2911N; VAF 50%)|MSH2 (p.V437M; VAF 41%)|PCLO (p.D2885N; VAF 47%)|PRPF40B (p.P751S; VAF 51%)|SRSF2 (p.P95H; VAF 37%)|TCF3 (p.H344R; VAF 49%)|TET2 (p.Q1030*; VAF 43%)|TET2 (p.R1359L; VAF 40%)	0.557342261	0.925256216	0.573494532	0.848418143	0.582722161	2.840945286	0.548263564	1.301522211	0.759346891	0.094861257		yes			yes		Found	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	3.864126404	3.836991222	1.941731631	4.952979609	5.290149278	-0.991836124	1.677635095	yes	yes	no	yes	no	no	no																